

(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 097 709 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
09.05.2001 Bulletin 2001/19

(51) Int Cl.7: A61K 31/426, A61K 31/435,
A61K 31/44, A61K 31/445,
A61K 31/47, A61K 31/495,
A61K 31/505, A61K 31/52,
A61P 3/00

(21) Application number: 00309441.4

(22) Date of filing: 26.10.2000

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 29.10.1999 US 162340 P

(71) Applicant: Pfizer Products Inc.
Groton, Connecticut 06340 (US)

(72) Inventors:
• Chen, Yuhpyng Liang
Groton, Connecticut 06340 (US)
• Hamanaka, Ernest Seiichi
Groton, Connecticut 06340 (US)

(74) Representative: McMunn, Watson Palmer et al
Pfizer Limited
Patents Department
Ramsgate Road
Sandwich, Kent CT13 9NJ (GB)

(54) Use of corticotropin releasing factor antagonists for treating syndrome X

(57) The present invention relates to compositions and methods of achieving a therapeutic effect including, the treatment or prevention of syndrome X in an animal,

preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist alone or together with a glucocorticoid receptor antagonist.

EP 1 097 709 A2

Description**BACKGROUND OF THE INVENTION**

- 5 [0001] The present invention relates to compositions and methods of achieving a therapeutic effect, including the treatment or prevention of Syndrome X, in an animal, preferably a mammal, including a human subject, and a companion animal, using a corticotropin releasing factor (CRF) antagonist alone or together with a glucocorticoid receptor (GR) antagonist.
- 10 [0002] Syndrome X, also known as metabolic syndrome, plurimetabolic syndrome or insulin resistance syndrome, encompasses a complex of disturbances of carbohydrate and fat metabolism characterized by obesity, dyslipoproteinemia (low HDL and high LDL, VLDL and triglycerides), hyperinsulinemia, insulin resistance, glucose intolerance and hypertension (Atherosclerosis X, F.P. Woodford, J. Davignon, A. Sniderman (Eds.), Elsevier Science BV, Amsterdam (1995): 520-524.). Syndrome X is associated with an elevated risk for cardiovascular disease.
- 15 [0003] There are striking similarities between Cushing's disease and Syndrome X, both being characterized by visceral obesity, hypertension, insulin resistance, glucose intolerance and hyperlipidemia (Endocrine Research, 22(4), 701-708 (1996)). Cushing's disease is caused by hypersecretion of cortisol, the most important human glucocorticoid, by the adrenal cortex. Cortisol is known to cause visceral fat accumulation and insulin resistance (Pennington Cent. Nutr. Ser. (1996), 5 (Molecular and Genetic Aspects of Obesity), 340-352; Nutrition, 13:795-803 (1997); and Prog. Obes. Res., 7:505-510 (1996)). Cortisol promotes hepatic gluconeogenesis and glycogen deposition and increases 20 blood glucose levels. Cortisol also increases the sensitivity of adipose tissue to lipolytic hormones, elevating fatty acid levels and thereby stimulating triglyceride synthesis and VLDL (very low density lipoprotein) secretion. The VLDL is converted to VLDL remnants or LDL (low density lipoprotein) which are largely taken up by the liver via the LDL receptors, resulting in down-regulation of the LDL receptor and consequently hypertriglyceridemia and hyper-apobetalipoproteinemia. Abnormalities of glucocorticoid secretion and sensitivity in men have been shown to be associated 25 with hypertension and insulin resistance (Endocrine Research, 22(4), 701-708 (1996); and Hypertension, 1998;31: 891-895). Hypersecretion of cortisol is the result of excessive secretion of ACTH (adrenocorticotrophic hormone). Administration of ACTH has been shown to increase blood pressure in animals (J. Hypertension, 16:593-600 (1998)). The secretion of ACTH is controlled by the releasing hormone, corticotropin releasing factor (CRF or CRH). Thus, a CRF (CRH) antagonist, by decreasing ACTH secretion, will ameliorate the hypersecretion of glucocorticoids and thereby be of therapeutic benefit in the treatment of Syndrome X.
- 30 [0004] In addition, the levels of glucocorticoids present in the body are primarily, but not solely, determined by the concentration of CRF, so the use of a combination of a CRF antagonist and a GR antagonist will be of greater therapeutic benefit in the treatment of Syndrome X than the use of a CRF antagonist alone.
- 35 [0005] International Patent Application Publication No. WO 97/25042, published 17 July 1997, discloses methods for the treatment and/or prophylaxis of Syndrome X by the administration of an agonist of PPAR α and PPAR γ , or a pharmaceutically acceptable derivative thereof, to a human or non-human animal in need of such treatment.
- 40 [0006] International Patent Application Publication No. WO 99/17761, published 15 April 1999, discloses the use of nordihydroguaiaretic acid to treat or ameliorate the characteristic manifestations of Syndrome X in a non-diabetic animal with normal serum glucose levels.
- 45 [0007] CRF antagonists are disclosed in U.S. Patents 4,605,642 and 5,063,245. They are also disclosed in International patent publications WO 95/33750; WO 95/34563; WO 94/13661; WO 94/13644; WO 94/13643; WO 94/13676; WO 94/13677; WO 95/33727; WO 98/05661; WO 98/08847; WO 98/08846; and European patent publications EP 778277 and EP 773023. CRF antagonists are also disclosed in the following patent publications: EP 576350; EP 659747; EP 812831; WO 95/10506; WO 96/35689; WO 96/39400; WO 97/00868; WO 97/14684; WO 97/29109; WO 97/29110; WO 97/35539; WO 97/35580; WO 97/35846; WO 97/44038; WO 97/45421; WO 98/03510; WO 98/08821; WO 98/11075; WO 98/15543; WO 98/21200; WO 98/27066; WO 98/29397; WO 98/29413; WO 98/42699; WO 98/35967; WO 98/42706; WO 98/45295; WO 98/47874; WO 98/47903; WO 98/51312; WO 99/01454; WO 99/01439; WO 99/10350; WO 99/12908; WO 99/00373; WO 99/38868; WO 99/51597; WO 99/51599; WO 99/40089; WO 99/51598; and WO 99/51600. They are also disclosed in United States Patents 5,109,111; 5,132,111; 5,245,009; 5,464,847; 5,493,006; 5,510,458; 5,644,057; 5,663,292; 5,668,145; 5,705,646; 5,712,303; and 5,723,608. An overview of the patent literature on CRF antagonists is provided in T.E. Christos and A. Arvanitis, Exp. Opin. Ther. Patents (1998) 8(2):143-152.
- 50 [0008] The importance of CRF antagonists is set out in the literature, e.g., P. Black, Scientific American: "Science & Medicine," 1995, 2:16-25; T. Lovenberg, et al., Current Pharmaceutical Design, 1995, 1: 305-316; D.T. Chalmers et al., Trends in Pharmacological Sciences, April 1996, pages 166-172; and United States Patent 5,063,245. An outline of the activities possessed by CRF antagonists is found in M. J. Owens et al., 1991, Pharm. Rev., 43:425-473. CRF antagonists are described in the art as being effective in the treatment of stress-related illnesses, mood disorders such as depression, major depressive disorder, single episode depression, recurrent depression, child abuse induced de-

- pression, postpartum depression, dysthemia, bipolar disorders, and cyclothymia; chronic fatigue syndrome; eating disorders such as anorexia and bulimia nervosa; generalized anxiety disorder; panic disorder; phobias; obsessive-compulsive disorder; post-traumatic stress disorder; pain perception such as fibromyalgia; headache; gastrointestinal diseases; hemorrhagic stress; ulcers; stress-induced psychotic episodes; fever; diarrhea; post-operative ileus; colonic hypersensitivity; irritable bowel syndrome; Crohn's disease; spastic colon; inflammatory disorders such as rheumatoid arthritis and osteoarthritis; pain; asthma; psoriasis; allergies; osteoporosis; premature birth; hypertension, congestive heart failure; sleep disorders; neurodegenerative diseases such as Alzheimer's disease, senile dementia of the Alzheimer's type, multiinfarct dementia, Parkinson's disease, and Huntington's disease; head trauma; ischemic neuronal damage; excitotoxic neuronal damage; epilepsy; stroke; spinal cord trauma; psychosocial dwarfism; euthyroid sick syndrome; syndrome of inappropriate antidiuretic hormone; obesity; chemical dependencies and addictions; drug and alcohol withdrawal symptoms; infertility; cancer; muscular spasms; urinary incontinence; hypoglycemia and immune dysfunctions including stress induced immune dysfunctions, immune suppression and human immunodeficiency virus infections; and stress-induced infections in humans and animals.
- [0009] GR antagonists are disclosed in the following references: International patent application PCT/IB00/00366, filed 27 March 2000, and assigned to the assignee hereof; International patent publications WO 99/41256 and WO 99/41257; U.S. Patent 5,696,127; European patent publication 188396; European patent publication 683172; International patent publication WO 98/26783; International patent publication WO 98/27986; International patent publication WO 98/31702; European patent publication 903146; and International patent publications WO 99/41256 and WO 99/41257.
- [0010] GR modulators (e.g., agonists, partial agonists, antagonists and partial antagonists) can be used in the treatment of diseases associated with an excess or a deficiency of glucocorticoids in the body. As such, they may be used to treat the following: obesity, diabetes, cardiovascular disease, hypertension, Syndrome X, depression, anxiety, glaucoma, human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS), neurodegeneration (for example, Alzheimer's and Parkinson's), cognition enhancement, Cushing's Syndrome, Addison's Disease, osteoporosis, frailty, inflammatory diseases (such as osteoarthritis, rheumatoid arthritis, asthma and rhinitis), tests of adrenal function, viral infection, immunodeficiency, immunomodulation, autoimmune diseases, allergies, wound healing, compulsive behavior, multi-drug resistance, addiction, psychosis, anorexia, cachexia, post-traumatic stress syndrome, post-surgical bone fracture, medical catabolism and prevention of muscle frailty.
- [0011] All of the hereinabove and below cited U.S. patents, U.S. and PCT international patent applications, published European patent applications and published PCT international patent applications are incorporated herein by reference in their entirety.

SUMMARY OF THE INVENTION

- [0012] The present invention provides methods of treating or preventing Syndrome X in an animal which comprises administering to said animal an amount of a corticotropin releasing factor antagonist. More particularly, the present invention provides these methods wherein a therapeutically effective amount of a corticotropin releasing factor antagonist is administered. More particularly, the present invention provides these methods wherein the corticotropin releasing factor antagonist is a compound of a particular generic formula as described below.
- [0013] Also, the present invention provides methods of treating or preventing Syndrome X in an animal which comprises administering to said animal an amount of a corticotropin releasing factor antagonist and an amount of a glucocorticoid receptor antagonist; wherein the amount of the corticotropin releasing factor antagonist and the amount of the glucocorticoid receptor antagonist result in a therapeutic effect. More particularly, the present invention provides these methods wherein the corticotrophin releasing factor antagonist is a compound of a particular generic formula as described below. More particularly, the present invention provides these methods wherein the glucocorticoid receptor antagonist is a compound of formula IA wherein the variables are as defined below.
- [0014] Also, the present invention provides pharmaceutical compositions for treating or preventing Syndrome X which comprises an amount of a corticotropin releasing factor antagonist and a pharmaceutically acceptable vehicle, carrier or diluent. More particularly, the present invention provides these compositions which comprise a therapeutically effective amount of a corticotropin releasing factor antagonist. More particularly, the present invention provides these compositions wherein the corticotropin releasing factor is a compound of a particular generic formula as described below.
- [0015] Also, the present invention provides pharmaceutical compositions for treating or preventing Syndrome X which comprises an amount of a corticotropin releasing factor antagonist, an amount of a glucocorticoid receptor antagonist and a pharmaceutically acceptable vehicle, carrier or diluent; wherein the amount of the corticotropin releasing factor antagonist and the amount of the glucocorticoid receptor antagonist result in a therapeutic effect. More particularly, the present invention provides these compositions wherein the corticotrophin releasing factor antagonist is a compound of a particular generic formula as described below. More particularly, the present invention provides these compositions

wherein the glucocorticoid receptor antagonist is a compound of formula IA wherein the variables are as defined below.

[0016] Also, the present invention provides kits which comprise an amount of a corticotropin releasing factor antagonist and a pharmaceutically acceptable vehicle, carrier or diluent in a first unit dosage form; an amount of a glucocorticoid receptor antagonist and a pharmaceutically acceptable vehicle, carrier or diluent in a second unit dosage form; and a container for containing said first and second dosage forms; wherein the amount of the corticotropin releasing factor antagonist and the amount of the glucocorticoid receptor antagonist result in a therapeutic effect. More particularly, the present invention provides these kits wherein the corticotrophin releasing factor antagonist is a compound of a particular generic formula as described below. More particularly, the present invention provides these kits wherein the glucocorticoid receptor antagonist is a compound of formula IA wherein the variables are as defined below.

5 [0017] The present invention relates to compositions and methods useful in achieving therapeutic effects, such as the treatment or prevention of Syndrome X, which compositions preferably comprise a corticotropin releasing factor (CRF) antagonist alone or in combination with a glucocorticoid receptor (GR) antagonist, and a pharmaceutically acceptable carrier, vehicle or diluent, and which methods preferably comprise administering to an animal, preferably a mammal including a human subject or a companion mammal in need of such treatment, a CRF antagonist and a GR antagonist.

10 [0018] The terms "treating" and "treatment," as used herein, unless otherwise indicated, include, *inter alia*, palliative and curative treatment of any disorder enumerated within the methods of the present invention.

15 [0019] The terms "preventing," "prevention" and "prophylaxis," as used herein, unless otherwise indicated, include the inhibition or preclusion of the development of any disorder enumerated within the methods of the present invention.

20 DETAILED DESCRIPTION OF THE INVENTION

[0020] Syndrome X is the syndrome characterized by an initial insulin resistant state, generating hyperinsulinaemia, dyslipidaemia and impaired glucose tolerance, which can progress to non-insulin dependent diabetes mellitus (Type II diabetes), characterized by hyperglycaemia and which then further progresses to diabetic complications.

25 [0021] CRF antagonists alone or together with GR antagonists are effective for the treatment and/or prophylaxis of Syndrome X and the resulting complications thereof. These compounds are therefore considered to be useful for the treatment and/or prophylaxis of any combination of the following list of disorders associated with Syndrome X and the resulting complications thereof, including, for example, insulin resistance, diabetes, more particularly non-insulin dependent diabetes mellitus (Type II diabetes), and the complications associated with diabetes, dyslipidaemia, hyperinsulinaemia, hyperglycaemia, atherosclerosis, hypertension, cardiovascular disease and obesity. This list is for purposes of illustration only and is not intended to limit the scope of the present invention.

30 [0022] The complications associated with diabetes include, for example, cardiovascular disease, especially atherosclerosis, retinopathy, neuropathy and renal disease including diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis and end stage renal disease.

35 [0023] The term corticotropin releasing factor (CRF) antagonist refers to a compound having the ability to inhibit or reverse the deleterious effects of the presence of CRF. It is well known that CRF profoundly stimulates the pituitary-adrenalcortical axis and, in dysfunctional states, initiates behavioral, physiological and endocrine responses that are essentially identical to those observed when animals, including humans and companion animals, are subjected to a stressful environment. Therefore, CRF antagonists are known to have utility, *inter alia*, in the amelioration of certain stress-induced conditions including memory loss, mood alteration, depression, hypertension and the like.

40 [0024] Any CRF antagonist can be used to practice the present invention, including those that are described in U. S. Patents 4,605,642 and 5,063,245; International patent publications WO 95/33750; WO 95/34563; WO 94/13661; WO 94/13644; WO 94/13643; WO 94/13676; WO 94/13677; WO 95/33727; WO 98/05661; WO 98/08847; and WO 45. 98/08846; and European patent publications EP 778277; and EP 773023. They also include those of the following patent publications: EP 576350; EP 659747; EP 812831; WO 95/10506; WO 96/35689; WO 96/39400; WO 97/00868; WO 97/14684; WO 97/29109; WO 97/29110; WO 97/35539; WO 97/35580; WO 97/35846; WO 97/44038; WO 97/45421; WO 98/03510; WO 98/08821; WO 98/11075; WO 98/15543; WO 98/21200; WO 98/27066; WO 98/29397; WO 98/29413; WO 98/42699; WO 98/35967; WO 98/42706; WO 98/45295; WO 98/47874; WO 98/47903; WO 98/51312; WO 99/01454; WO 99/01439; WO 99/10350; WO 99/12908; WO 99/00373; WO 99/38868; WO 99/51597; WO 99/51599; WO 99/40089; WO 99/51598; and WO 99/51600. They are also disclosed in United States Patents 5,109,111; 5,132,111; 5,245,009; 5,464,847; 5,493,006; 5,510,458; 5,644,057; 5,663,292; 5,668,145; 5,705,646; 5,712,303; and 5,723,608. Additional information relating to preparing certain of these compounds is provided in WO 96/39388, which describes the production of certain intermediates. As noted above, the texts of all of these publications are incorporated by reference herein in their entireties.


55 [0025] Following are listed particular examples of CRF antagonists that may be used in practicing the invention. It is understood that in the generic formulae employed below, the variables employed, e.g., "A", "B", "R₁", "R₂", etc. have the meanings attributed to them only in the particular Roman numeral section in which they are found. Thus, the

meaning attributed, for example, to "R¹" is different for the structures in section I and the structures of the other sections.

I. For example, the CRF antagonist may be of the following formula, described in WO 94/13677:

5

10



15

and the pharmaceutically acceptable acid addition salts thereof, wherein A is NR₁R₂, CR₁R₂R₁₁, or C (=CR₁R₁₂)R₂, NHCR₁R₂R₁₁, OCR₁R₂R₁₁, SCR₁R₂R₁₁, NHNR₁R₂, CR₂R₁₁NHR₁, CR₂R₁₁OR₁, CR₂R₁₁SR₁ or C(O)R₂;

20

R₁ is hydrogen, or C₁-C₆ alkyl which may be substituted by one or two substituents R₆ independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, C₁-C₆ alkoxy, O-C(O)-(C₁-C₆ alkyl), O-C(O)-N(C₁-C₄ alkyl)(C₁-C₂ alkyl); amino, NH(C₁-C₄ alkyl), S(C₁-C₆ alkyl), OC(O)NH(C₁-C₄ alkyl), N(C₁-C₂ alkyl)C(O)(C₁-C₄ alkyl), NHC(O)(C₁-C₄ alkyl), COOH, CO(C₁-C₄ alkyl), C(O)NH(C₁-C₄ alkyl), C(O)N(C₁-C₄ alkyl)(C₁-C₂ alkyl), SH, CN, NO₂, SO(C₁-C₄ alkyl); SO₂(C₁-C₄ alkyl), SO₂NH(C₁-C₄ alkyl), SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl), and said C₁-C₆ alkyl may have one or two double or triple bonds;

25

R₂ is C₁-C₁₂ alkyl, aryl or (C₁-C₁₀ alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinolyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, oxazolyl, or benzoxazolyl; 3- to 8-membered cycloalkyl or (C₁-C₆ alkylene) cycloalkyl, wherein said cycloalkyl may have one or two of O, S or N-Z, wherein Z is hydrogen, substituted, independently, for one or two carbons of said cycloalkyl, C₁-C₄ alkyl, benzyl or C₁-C₄ alkanoyl, wherein R² may be substituted independently by from one to three of chloro, fluoro, or C₁-C₄ alkyl, or one of hydroxy, bromo, iodo, C₁-C₆ alkoxy, OC(O)(C₁-C₆ alkyl), O-C-N(C₁-C₄ alkyl)(C₁-C₂ alkyl), S(C₁-C₆ alkyl), NH₂, NH(C₁-C₂ alkyl), N(C₁-C₄ alkyl)C(O)(C₁-C₄ alkyl), NHC(O)(C₁-C₄ alkyl), COOH, C(O)O(C₁-C₄ alkyl), C(O)NH(C₁-C₄ alkyl), C(O)N(C₁-C₄ alkyl)(C₁-C₂ alkyl), SH, CN, NO₂, SO(C₁-C₄ alkyl), SO₂(C₁-C₄ alkyl), SO₂NH(C₁-C₄ alkyl), SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl), and wherein said C₁-C₁₂ alkyl or C₁-C₁₀ alkylene may have one to three double or triple bonds; or

30

NR₁R₂ or CR₁R₂R₁₁ may form a 4- to 8-membered ring optionally having one or two double bonds or one or two of O, S or N-Z wherein Z is hydrogen, C₁-C₄ alkyl, benzyl, or C₁-C₄ alkanoyl;

35

R₃ is hydrogen, C₁-C₆ alkyl, fluoro, chloro, bromo, iodo, hydroxy, amino, O(C₁-C₆ alkyl), NH(C₁-C₆ alkyl), N(C₁-C₄ alkyl)(C₁-C₂ alkyl), SH, S(C₁-C₄ alkyl), SO(C₁-C₄ alkyl), or SO₂(C₁-C₄ alkyl), wherein said C₁-C₄ alkyl and C₁-C₆ alkyl may have one or two double or triple bonds and may be substituted by from 1 to 3 R₇ substituents independently selected from the group consisting of hydroxy, amino, C₁-C₃ alkoxy, dimethylamino, diethylamino, methylamino, ethylamino, NHC(O)CH₃, fluoro, chloro or C₁-C₃ thioalkyl;

40

R₄ is hydrogen, C₁-C₆ alkyl, fluoro, chloro, bromo, iodo, C₁-C₆ alkoxy, amino, NH(C₁-C₆ alkyl), N(C₁-C₆ alkyl)(C₁-C₂ alkyl), SO_n(C₁-C₆ alkyl), wherein n is 0, 1 or 2, cyano, hydroxy, carboxy, or amido, wherein said C₁-C₆ alkyls may be substituted by one to three of hydroxy, amino, carboxy, amido, NHC(O)(C₁-C₄ alkyl), NH(C₁-C₄ alkyl), N(C₁-C₄ alkyl)(C₁-C₂ alkyl), C(O)O(C₁-C₄ alkyl), C₁-C₃ alkoxy, C₁-C₃ thioalkyl, fluoro, bromo, chloro, iodo, cyano or nitro;

45

R₅ is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinolyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, benzoxazolyl, oxazolyl, pyrrolidinyl, thiazolidinyl, piperazinyl, piperidinyl, or tetrazolyl, wherein each one of the above groups may be substituted independently by from one to three of fluoro, chloro, bromo, formyl, C₁-C₆ alkyl, C₁-C₆ alkoxy or trifluoromethyl, or one of hydroxy, iodo, cyano, nitro, amino, cyclopropyl, NH(C₁-C₄ alkyl), N(C₁-C₄ alkyl)(C₁-C₂ alkyl), COO(C₁-C₄ alkyl), CO(C₁-C₄ alkyl), SO₂NH(C₁-C₄ alkyl), SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl), SO₂NH₂, NH₂SO₂(C₁-C₄ alkyl), S(C₁-C₆ alkyl), SO₂(C₁-C₆ alkyl), wherein said C₁-C₄ alkyl and C₁-C₆ alkyl may have one double or triple bond and may be substituted by one or two of fluoro, chloro, hydroxy, amino, methylamino, dimethylamino or acetyl; with the proviso that R₅ is not unsubstituted phenyl;

R₁₁ is hydrogen, hydroxy, fluoro, chloro, COO(C₁-C₂ alkyl), cyano, or CO(C₁-C₂ alkyl); and


R₁₂ is hydrogen or C₁-C₄ alkyl;

- 5 (a) A is not straight chain C₁-C₁₂ alkyl;
 (b) when R₃ is hydrogen, A is benzyl or phenethyl, and R₄ is fluoro, chloro, bromo or iodo, then R₅ is not 5'-deoxy-ribofuranosyl or 5'-amino-5'-deoxyribofuranosyl; and
 (c) when R⁵ is phenyl, said phenyl is substituted by two or three substituents.

II. The invention also relates to use of a CRF antagonist of the following formula, described in WO 94/13676:

10

15



20

and the pharmaceutically acceptable acid addition salts thereof, wherein B is NR₁R₂, CR₁R₂R₁₁, C(=CR₂R₁₂)R₁, NHR₁R₂R₁₁, OCR₁R₂R₁₁, SCR₁R₂R₁₁, NHNR₁R₂, CR₂R₁₁NHR₁, CR₂R₁₁OR₁, CR₂R₁₁SR₁, or C(O)R₂;

25

30

R₁ is hydrogen, or C₁-C₆ alkyl which may be substituted by one or two substituents R₇ independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, C₁-C₈ alkoxy, O-C(=O)-(C₁-C₆ alkyl), O-C(=O)NH(C₁-C₄ alkyl), O-C(=O)-N(C₁-C₄ alkyl)(C₁-C₂ alkyl), amino, NH(C₁-C₄ alkyl), N(C₁-C₂ alkyl)(C₁-C₄ alkyl), S(C₁-C₆ alkyl), N(C₁-C₄ alkyl)C(=O)(C₁-C₄ alkyl), NH(C₁-C₄ alkyl), COOH, C(=O)O(C₁-C₄ alkyl), C(=O)NH(C₁-C₄ alkyl), C(=O)N(C₁-C₄ alkyl)(C₁-C₂ alkyl), SH, CN, NO₂, SO(C₁-C₄ alkyl), SO₂(C₁-C₄ alkyl), SO₂NH(C₁-C₄ alkyl), SO₂O(C₁-C₄ alkyl), and said C₁-C₆ alkyl may contain one or two double or triple bonds;

35

40

R₂ is C₁-C₁₂ alkyl, aryl or (C₁-C₁₀ alkylene)aryl wherein said aryl is phenyl, naphthyl, thiienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, oxazolyl, or benzoxazolyl; 3- to 8-membered cycloalkyl or (C₁-C₆ alkylene) cycloalkyl, wherein said cycloalkyl may contain one or two of O, S or N-Z wherein Z is hydrogen, C₁-C₄ alkyl, benzyl or C₁-C₄ alkanoyl, wherein R₂ may be substituted independently by from one to three of chloro, fluoro, or C₁-C₄ alkyl, or one of hydroxy, bromo, iodo, C₁-C₆ alkoxy, O-C(=O)-(C₁-C₆ alkyl), O-C-N(C₁-C₄ alkyl)(C₁-C₂ alkyl), S(C₁-C₆ alkyl), NH₂, NH(C₁-C₂ alkyl), N(C₁-C₂ alkyl)(C₁-C₄ alkyl), N(C₁-C₄)-C(=O)(C₁-C₄ alkyl), NHC(=O)(C₁-C₄), COOH, C(=O)O(C₁-C₄ alkyl), C(=O)NH(C₁-C₄ alkyl), C(=O)N(C₁-C₄ alkyl)(C₁-C₂ alkyl), SH, CN, NO₂, SO(C₁-C₄ alkyl), SO₂(C₁-C₄ alkyl), SO₂NH(C₁-C₄ alkyl), SO₂O(C₁-C₄ alkyl), and wherein said C₁-C₁₂ alkyl or C₁-C₁₀ alkylene may contain one to three double or triple bonds; or

45

NR₁R₂ or CR₁R₂R₁₁ may form a saturated 3- to 8 membered carbocyclic ring of which the 5- to 8-membered ring contain one or two double bonds or one or two of O, S or N-Z wherein Z is hydrogen, C₁-C₄ alkyl, benzyl or C₁-C₄ alkanoyl;

50

R₃ is hydrogen, C₁-C₆ alkyl, fluoro, chloro, bromo, iodo, hydroxy, amino, O(C₁-C₆ alkyl), NH(C₁-C₆ alkyl), N(C₁-C₄ alkyl)(C₁-C₂ alkyl), SH, S(C₁-C₄ alkyl), SO(C₁-C₄ alkyl), or SO₂(C₁-C₄ alkyl), wherein said C₁-C₄ alkyl and C₁-C₆ alkyl may contain from one or two double or triple bonds and may be substituted by from 1 to 3 substituents R₈ independently selected from the group consisting of hydroxy, amino, C₁-C₃ alkoxy, dimethylamino, diethylamino, methylamino, ethylamino, NHCH₃, fluoro, chloro or C₁-C₃ thioalkyl;

55


R₄ and R₆ are each independently hydrogen, C₁-C₆ alkyl, fluoro, chloro, bromo, iodo, C₁-C₆ alkoxy, amino, NH(C₁-C₆ alkyl), N(C₁-C₆ alkyl)(C₁-C₂ alkyl), SO_n(C₁-C₆ alkyl), wherein n is 0, 1 or 2; cyano, hydroxy, carboxy, or amido, wherein said C₁-C₆ alkyl may be substituted by one to three of hydroxy, amino, carboxy, amido, NHC(=O)(C₁-C₄ alkyl), NH(C₁-C₄ alkyl), N(C₁-C₄ alkyl)(C₁-C₂ alkyl), C(=O)O(C₁-C₄ alkyl), C₁-C₃ alkoxy, C₁-C₃ thioalkyl, fluoro, bromo, chloro, iodo, cyano or nitro;

R₅ is phenyl, naphthyl, thiienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, tri-

azolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, benzoxazolyl, oxazolyl, pyrrolidinyl, thiazolidinyl, morpholinyl, piperidinyl, piperazinyl, tetrazolyl, or 3- to 8-membered cycloalkyl or 9- to 12-membered bicycloalkyl, optionally containing one to three of O, S or N-Z wherein Z is hydrogen, C₁-C₄ alkyl, C₁-C₄ alkanoyl, phenyl or phenylmethyl, wherein each one of the above groups may be substituted independently by from one to four of fluoro, chloro, C₁-C₆ alkyl, C₁-C₆ alkoxy or trifluoromethyl, or one of bromo, iodo, cyano, nitro, amino, NH(C₁-C₄ alkyl), N(C₁-C₄)(C₁-C₂ alkyl), COO(C₁-C₄ alkyl), CO(C₁-C₄ alkyl), SO₂NH(C₁-C₄ alkyl), SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl), SO₂NH₂, NSO₂(C₁-C₄ alkyl), S(C₁-C₆ alkyl), SO₂(C₁-C₆ alkyl), wherein said C₁-C₄ alkyl and C₁-C₆ alkyl may be substituted by one or two of fluoro, chloro, hydroxy, amino, methylamino, dimethylamino or acetyl; with the proviso that R₅ is not unsubstituted phenyl;

10 R₁₁ is hydrogen, hydroxy, fluoro, chloro, COO(C₁-C₂ alkyl), cyano, or CO(C₁-C₂ alkyl); and R₁₂ is hydrogen or C₁-C₄ alkyl; with the proviso that (1) when R₅ is 4-bromophenyl, R₃ is hydrogen, and R₄ and R₆ are methyl, then B is not methylamino or ethyl, and (2) when R₅ is 4-bromophenyl, and R₃, R₄ and R₆ are methyl, then B is not 2-hydroxyethylamino.

15 III. It is also possible to employ a CRF antagonist that has a structure selected from the group shown below, and pharmaceutically acceptable salts and esters thereof, as described in WO 95/33750:



or a pharmaceutically acceptable salt thereof, wherein

30 the dashed lines represent optional double bonds;
 A is CR₇ or N;
 B is NR₁R₂, CR₁R₂R₁₁, C(=CR₂R₁₂)R₁, NHCHR₁R₂, OCHR₁R₂, SCHR₁R₂, CHR₂OR₁₂, CHR₂SR₁₂, C(S)R₂ or C(O)R₂;
 G is oxygen, sulfur, NH, NH₃, hydrogen, methoxy, ethoxy, trifluoromethoxy, methyl, ethyl, thiomethoxy, NH₂, NHCH₃, N(CH₃)₂ or trifluoromethyl;
 35 Y is CH or N;
 Z is NH, O, S, N (C₁-C₂ alkyl), or CR₁₃R₁₄, wherein R₁₃ and R₁₄ are each independently hydrogen, trifluoromethyl, or C₁-C₄ alkyl, or one of R₁₃ and R₁₄ may be cyano, chloro, bromo, iodo, fluoro, hydroxy, O(C₁-C₂ alkyl), amino, NH(C₁-C₂ alkyl), or CR₁₃R₁₄ may be C=O or cyclopropyl;
 40 R₁ is C₁-C₆ alkyl which may be substituted by one or two substituents R₈ independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, C₁-C₄ alkoxy, O-CO-(C₁-C₄ alkyl), O-CO-NH(C₁-C₄ alkyl), O-CO-N(C₁-C₄ alkyl)(C₁-C₂ alkyl), NH(C₁-C₄ alkyl), N(C₁-C₂ alkyl)(C₁-C₄ alkyl), S(C₁-C₄ alkyl), N(C₁-C₄ alkyl)CO(C₁-C₄ alkyl), NHCO(C₁-C₄ alkyl), COO(C₁-C₄ alkyl), CONH(C₁-C₄ alkyl), CON(C₁-C₄ alkyl)(C₁-C₂ alkyl), S(C₁-C₄ alkyl), CN, NO₂, SO(C₁-C₄ alkyl), SO₂(C₁-C₄ alkyl), and said C₁-C₆ alkyl or C₁-C₄ alkyl may contain one double or triple bond;
 45 R₂ is C₁-C₁₂ alkyl, aryl or (C₁-C₄ alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, or benzoxazolyl; 3- to 8-membered cycloalkyl or (C₁-C₆ alkylene)cycloalkyl, wherein said cycloalkyl may contain one or two of O, S or N-R₉ wherein R₉ is hydrogen, or C₁-C₄ alkyl, wherein the above defined R₂ may be substituted independently by from one to three of chloro, fluoro, or C₁-C₄ alkyl, or one of bromo, iodo, C₁-C₆ alkoxy, O-CO-(C₁-C₆ alkyl), O-CO-N(C₁-C₄ alkyl)(C₁-C₂ alkyl), S(C₁-C₆ alkyl), CN, NO₂, SO(C₁-C₄ alkyl), or SO₂(C₁-C₄ alkyl), and wherein said C₁-C₁₂ alkyl or C₁-C₄ alkylene may contain one double or triple bond; or
 50 NR₁R₂ or CR₁R₂R₁₁ may form a saturated 5- to 8-membered carbocyclic ring which may contain one or two double bonds or one or two of O or S;
 55 R₃ is methyl, ethyl, fluoro, chloro, bromo, iodo, cyano, methoxy, OCF₃, methylthio, methylsulfonyl, CH₂OH or CH₂OCH₃;
 R₄ is hydrogen, C₁-C₄ alkyl, fluoro, chloro, bromo, iodo, C₁-C₄ alkoxy, amino, nitro, NH(C₁-C₄ alkyl), N(C₁-C₄

alkyl)(C₁-C₂ alkyl), SO_n(C₁-C₄ alkyl), wherein n is 0, 1 or 2, cyano, hydroxy, CO(C₁-C₄ alkyl), CHO, or COO (C₁-C₄ alkyl), wherein said C₁-C₄ alkyl may contain one or two double or triple bonds and may be substituted by one or two of hydroxy, amino, carboxy, NHCOCH₃, NH(C₁-C₂ alkyl), N(C₁-C₂ alkyl)₂, COO(C₁-C₄ alkyl), CO(C₁-C₄ alkyl), C₁-C₃ alkoxy, C₁-C₃ thioalkyl, fluoro, chloro, cyano or nitro;

5 R₅ is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, furanyl, benzofuranyl, benzothiazolyl, or indolyl, wherein each one of the above groups R₅ is substituted independently by from one to three of fluoro, chloro, C₁-C₆ alkyl, or C₁-C₆ alkoxy, or one of hydroxy, iodo, bromo, formyl, cyano, nitro, trifluoromethyl, amino, NH(C₁-C₄ alkyl), N(C₁-C₆)(C₁-C₂ alkyl), COOH, COO(C₁-C₄ alkyl), CO(C₁-C₄ alkyl), SO₂NH(C₁-C₄ alkyl), SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl), SO₂NH₂, NSO₂(C₁-C₄ alkyl), S(C₁-C₆ alkyl), or SO₂ (C₁-C₆ alkyl), wherein said C₁-C₄ alkyl and C₁-C₆ alkyl may be substituted by one or two of fluoro, hydroxy, amino, methylamino, dimethylamino or acetyl;

10 R₆ is hydrogen, or C₁-C₆ alkyl, wherein said C₁-C₆ alkyl may be substituted by one hydroxy, methoxy, ethoxy or fluoro;

15 R₇ is hydrogen, C₁-C₄ alkyl, fluoro, chloro, bromo, iodo, cyano, hydroxy, O(C₁-C₄ alkyl), C(O)(C₁-C₄ alkyl), or C(O)O(C₁-C₄ alkyl), wherein the C₁-C₄ alkyl groups may be substituted with one hydroxy, chloro or bromo, or one to three fluoro;


R₁₁ is hydrogen, hydroxy, fluoro, or methoxy;

R₁₂ is hydrogen or C₁-C₄ alkyl; and

20 R₁₆ and R₁₇ are each independently hydrogen, hydroxy, methyl, ethyl, methoxy, or ethoxy, except that they are not both methoxy or ethoxy, and CR₄R₆ and CR₁₆R₁₇ each independently may be C=O.

IV. It is also possible to employ a CRF antagonist of the following formula, disclosed in WO 95/34563:

25



30

35

and the pharmaceutically acceptable acid addition salts thereof, wherein

A is N or -CR₆;

40 B is -NR₁R₂, -CR₁R₂R₁₁, -C(=CR₂R₁₂)R₁, -NHCHR₁R₂, -OCHR₁R₂, -SCHR₁R₂, -CHR₂OR₁₂, -CHR₂SR₁₂, -C(S)R₁ or -C(O)R₁;

45 R₁ is C₁-C₆ alkyl which may optionally be substituted with one or two substituents independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, C₁-C₄ alkoxy, -O-CO-(C₁-C₄ alkyl), -O-CO-NH (C₁-C₄ alkyl), -O-CO-N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -NH(C₁-C₄ alkyl), -N(C₁-C₂ alkyl)(C₁-C₄ alkyl), -S(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)CO(C₁-C₄ alkyl), -NHCO(C₁-C₄ alkyl), -COO(C₁-C₄ alkyl), -CONH(C₁-C₄ alkyl), -CON (C₁-C₄ alkyl)(C₁-C₂ alkyl), CN, NO₂, -SO(C₁-C₄ alkyl), -SO₂(C₁-C₄ alkyl), and wherein any of the foregoing C₁-C₄ alkyl and C₁-C₆ alkyl groups may optionally contain one carbon-carbon double or triple bond;

50 R₂ is C₁-C₁₂ alkyl, aryl, -(C₁-C₄ alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, oxazolyl, or benzoxazolyl; or 3- to 8-membered cycloalkyl or -(C₁-C₆ alkylene)cycloalkyl, wherein one or two of the ring carbons of said cycloalkyl having at least 4 ring members and the cycloalkyl moiety of said -(C₁-C₆ alkylene)cycloalkyl having at least 4 ring members may optionally be replaced by an oxygen or sulfur atom or by N-Z wherein Z is hydrogen; or C₁-C₄ alkyl, and wherein each of said groups R₂ may optionally be substituted with from one to three substituents independently selected from chloro, fluoro, and C₁-C₄ alkyl, or by one substituent selected from bromo, iodo, C₁-C₆ alkoxy, -O-CO-(C₁-C₆ alkyl), -S(C₁-C₆ alkyl), -COO(C₁-C₄ alkyl), CN, NO₂, -SO(C₁-C₄ alkyl), and -SO₂(C₁-C₄ alkyl), and wherein said C₁-C₁₂ alkyl and the C₁-C₄ alkylene moiety of said -(C₁-C₄ alkylene)aryl may optionally contain one carbon-carbon double or triple bond; or -NR₁R₂ may form a saturated 5- to 8-membered heterocyclic ring, or -CHR₁R₂ may form a saturated 5- to

8-membered carbocyclic ring, wherein each of these rings may optionally contain one or two carbon-carbon double bonds and wherein one or two of the carbon atoms of each of these rings may optionally be replaced with a sulfur or oxygen atom;

5 R_3 is C_1 - C_4 alkyl, fluoro, chloro, bromo, iodo, $-CH_2OH$, $-CH_2OCH_3$, $-O(C_1$ - C_3 alkyl), $-S(C_1$ - C_3 alkyl), or $-SO_2$ (C_1 - C_3 alkyl), wherein said C_1 - C_3 alkyl may optionally contain one carbon-carbon double or triple bond;

R_4 is hydrogen, C_1 - C_6 alkyl, fluoro, chloro, bromo, iodo, C_1 - C_4 alkoxy, amino, $-NHCH_3$, $-N(CH_3)_2$, $-CH_2OH$, $-CH_2OCH_3$, or $-SO_n(C_1$ - C_4 alkyl), wherein n is 0, 1 or 2, cyano, hydroxy, $-CO(C_1$ - C_4 alkyl), $-CHO$, or $-COO$ (C_1 - C_4 alkyl) wherein the C_1 - C_4 alkyl moieties in the foregoing R_4 groups may optionally contain one carbon-carbon double or triple bond;

10 R_5 is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, pyrimidyl, benzofuranyl, pyrazinyl or benzothiazolyl, wherein each one of said groups R_5 may optionally be substituted with from one to three substituents independently selected from fluoro, chloro, C_1 - C_6 alkyl and C_1 - C_6 alkoxy, or by one substituent selected from iodo, hydroxy, bromo, formyl, cyano, nitro, amino, trifluoromethyl, $-NH(C_1$ - C_4 alkyl), $-N(C_1$ - $C_6)(C_1$ - C_2 alkyl), $-COO$ (C_1 - C_4 alkyl), $-CO(C_1$ - C_4 alkyl), $-COOH$, $-SO_2NH(C_1$ - C_4 alkyl), $-SO_2N(C_1$ - C_4 alkyl)(C_1 - C_2 alkyl), $-SO_2NH_2$, $-NHSO_2(C_1$ - C_4 alkyl), $-S(C_1$ - C_6 alkyl) and $-SO_2(C_1$ - C_6 alkyl), wherein each of said C_1 - C_4 alkyl and C_1 - C_6 alkyl moieties in the foregoing R_5 groups may optionally be substituted with one to three fluorine atoms;

15 R_6 is hydrogen, C_1 - C_4 alkyl, fluoro, chloro, bromo, iodo, $-CH_2OH$, $-CH_2OCH_3$; or C_1 - C_4 alkoxy; R_7 is hydrogen, C_1 - C_4 alkyl, fluoro, chloro, bromo, iodo, $-O(C_1$ - C_4 alkyl), cyano, $-CH_2OH$, $-CH_2O(C_1$ - C_2 alkyl), $-CO(C_1$ - C_2 alkyl), or $-COO(C_1$ - C_2 alkyl);

20 R_{11} is hydrogen, hydroxy, fluoro, or methoxy; and


R_{12} is hydrogen or C_1 - C_4 alkyl;

with the proviso that when A is N, then: (a) B is not unsubstituted alkyl; (b) R_5 is not unsubstituted phenyl or monosubstituted phenyl; and (c) R_3 is not unsubstituted alkyl; or a pharmaceutically acceptable salt of such compound.


25

V. In another embodiment, the CRF antagonist is of the following formula, disclosed in EP 778277:

30




35



40

or

45



50

or a pharmaceutically acceptable salt thereof, wherein

55 the dashed lines represent optional double bonds;

A is nitrogen or CR^7 ;

B is $-NR^1R^2$, $-CR^1R^2R^{10}$, $-C(=CR^2R^{11})R^1$, $-NHCR^1R^2R^{10}$, $-OCR^1R^2R^{10}$, $-SCR^1R^2R^{10}$, $-CR^2R^{10}NHR^1$, $-CR^2R^{10}OR^1$, $-CR^2R^{10}SR^1$ or $-COR^2$;

D is nitrogen and is single bonded to all atoms to which it is attached, or D is carbon and is either double bonded to E in formulas I and II or double bonded to the adjacent carbon atom common to both fused rings in formula III, or D is CH and is single bonded to E in formulas I and II;

E is nitrogen, CH or carbon;

5 F is oxygen, sulfur, CHR^4 or NR^4 when it is single bonded to E and F is nitrogen or CR^4 when it is double bonded to E;

G, when single bonded to E, is hydrogen, C₁-C₄ alkyl, -S(C₁-C₄ alkyl), -O(C₁-C₄ alkyl), NH₂, -NH(C₁-C₄ alkyl) or -N(C₁-C₂ alkyl)(C₁-C₄ alkyl), wherein each of the C₁-C₄ alkyl groups of G may optionally be substituted with one hydroxy, -O(C₁-C₂ alkyl) or fluoro group; G, when double bonded to E, is oxygen, sulfur or NH; and G, when E is nitrogen and double bonded to D or F, is absent;

10 when E is nitrogen and double bonded to D or F, is absent;

R^1 is hydrogen, C_1 - C_6 alkyl optionally substituted with one or two substituents R^8 independently selected from hydroxy, fluoro, chloro, bromo, iodo, C_1 - C_4 alkoxy, CF_3 , $-C(=O)O-(C_1-C_4)alkyl$, $-OC(=O)(C_1-C_4)alkyl$, $-OC(=O)N(C_1-C_4)alkyl(C_1-C_2)alkyl$, $-NHCO(C_1-C_4)alkyl$, $-COOH$, $-COO(C_1-C_4)alkyl$, $-CONH(C_1-C_4)alkyl$, $-CON(C_1-C_4)alkyl(C_1-C_2)alkyl$, $-S(C_1-C_4)alkyl$, $-CN$, $-NO_2$, $-SO(C_1-C_4)alkyl$, $-SO_2(C_1-C_4)alkyl$, $-SO_2NH(C_1-C_4)alkyl$ and $-SO_2N(C_1-C_4)alkyl(C_1-C_2)alkyl$, wherein each of the C_1 - C_4 alkyl groups in the foregoing R^1 groups may optionally contain one or two double or triple bonds;

R^2 is C_1 - C_{12} alkyl which may optionally contain from one to three double or triple bonds, aryl or (C_1 - C_4 alkylene) aryl, wherein said aryl and the aryl moiety of said (C_1 - C_4 alkylene) aryl is selected from phenyl, naphthyl, thiophenyl, benzothiophenyl, pyridyl, quinolyl, pyrazinyl, pyrimidinyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothi-

20

alkylene)(C₃-C₈ cycloalkyl), wherein one or two of the carbon atoms of said cycloalkyl and the 5 to 8 membered cycloalkyl moieties of said (C₁-C₆ alkylene)(C₃-C₈ cycloalkyl) may optionally and independently be replaced by an oxygen or sulfur atom or by NZ² wherein Z² is selected from hydrogen, C₁-C₄ alkyl, benzyl and C₁-C₄ alkanoyl, and wherein each of the foregoing R² groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro, hydroxy and C₁-C₄ alkyl, or with one substituent selected from bromo, iodo, C₁-C₆ alkoxy, -OC(=O)(C₁-C₆ alkyl), -OC(=O)N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -S(C₁-C₆ alkyl), amino, -NH(C₁-C₂ alkyl), -N(C₁-C₂ alkyl)(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)-CO-(C₁-C₄ alkyl), -NHCO(C₁-C₄ alkyl), -COOH, -COO(C₁-C₄ alkyl), -CONH(C₁-C₄ alkyl), -CON(C₁-C₄ alkyl)(C₁-C₂ alkyl), -SH, -CN, -NO₂, -SO₂(C₁-C₆ alkyl), -OC(=O)C₆H₄NR³ and -OC(=O)N(C₁-C₄ alkyl)(C₆H₄NR³), where R³ is selected from hydrogen, C₁-C₄ alkyl, benzyl and C₁-C₄ alkanoyl.

-NR¹R² or CR¹R²R¹⁰ may form a saturated 3 to 8 membered carbocyclic ring which may optionally contain from one to three double bonds and wherein one or two of the ring carbon atoms of such 5 to 8 membered rings may optionally and independently be replaced by an oxygen or sulfur atom or by NZ³ wherein Z³ is hydrogen, C₁-C₄ alkyl, benzyl or C₁-C₄ alkanoyl;

R^3 is hydrogen, C_1 - C_4 alkyl, $-O(C_1$ - C_4 alkyl), chloro, fluoro, bromo, iodo, $-CN$, $-S(C_1$ - C_4 alkyl) or $-SO_2(C_1$ - C_4 alkyl) wherein each of the (C_1 - C_4 alkyl) moieties in the foregoing R^3 groups may optionally be substituted with

35

one substituent R⁹ selected from hydroxy, fluoro and (C₁-C₂ alkoxy);
each R⁴ is, independently, hydrogen, (C₁-C₆ alkyl), fluoro, chloro, bromo, iodo, hydroxy, cyano, amino, nitro,

70

with one or two substituents independently selected from hydroxy, amino, C₁-C₃ alkoxy, dimethylamino, methylamino, ethylamino, -NHC(=O)CH₃, fluoro, chloro, C₁-C₃ thioalkyl, -CN, -COOH, -C(=O)O(C₁-C₄ alkyl), -C(=O)(C₁-C₄ alkyl) and -NO₂;

R^4 is phenyl, napthyl, trienyl, benzotrienyl, pyridyl, quinolyl, pyrazinyl, furanyl, benzofuranyl, benzothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, benzoxazolyl or C_3 - C_8 cycloalkyl wherein one or two of the carbon atoms of said cycloalkyl rings that contain at least 5 ring members may optionally and independently be replaced by an oxygen or sulfur atom or by NZ^4 wherein Z^4 is hydrogen, C_1 - C_4 alkyl or benzyl; and wherein each of the foregoing R^5 groups is substituted with from one to four substituents R^{12} wherein one to three of said substituents may be selected independently from chloro, C_1 - C_6 alkyl and $-O(C_1$ - C_6 alkyl) and

50

one or said substituents may be selected from bromo, iodo, formyl, -CN, -CF₃, -NO₂, -NH₂, -NH(C₁-C₄ alkyl), -N(C₁-C₂ alkyl)(C₁-C₆ alkyl), -C(=O)O(C₁-C₄ alkyl), -C(=O)(C₁-C₄ alkyl), -COOH, -SO₂NH(C₁-C₄ alkyl), -SO₂N(C₁-C₂ alkyl)(C₁-C₄ alkyl), -SO₂NH₂, -NHSO₂(C₁-C₄ alkyl), -S(C₁-C₆ alkyl) and -SO₂(C₁-C₆ alkyl), and wherein each of the C₁-C₄ alkyl and C₁-C₆ alkyl moieties in the foregoing R⁵ groups may optionally be substituted with one or two substituents independently selected from fluoro, hydroxy, amino, methylamino, dimethylamino and acetyl;

R¹ is hydrogen, C₁-C₄ alkyl, halo, cyano, hydroxy, -O(C₁-C₄ alkyl), -C(=O)(C₁-C₄ alkyl), -C(=O)O(C₁-C₄ alkyl), -OCF₃, -CF₃, -CH₂OH, -CH₂O(C₁-C₄ alkyl); R¹⁰ is hydrogen, hydroxy, methoxy or fluoro;

R¹ is hydrogen, hydroxy, methoxy or fluoro.

R¹¹ is hydrogen or C₁-C₄ alkyl; and
 Z is NH, oxygen, sulfur, -N(C₁-C₄ alkyl), -NC(=O)(C₁-C₂ alkyl), NC(=O)O(C₁-C₂ alkyl) or CR¹³R¹⁴ wherein R¹³ and R¹⁴ are independently selected from hydrogen, trifluoromethyl and methyl with the exception that one of R¹³ and R¹⁴ can be cyano;
 5 with the proviso that: (a) in the five membered rings of structures I, II and III, there can not be two double bonds adjacent to each other; and (b) when R⁴ is attached to nitrogen, it is not halo, cyano or nitro; or a pharmaceutically acceptable salt of such compound.


VI. The CRF antagonist can also be of the following formula, disclosed in WO 98/05661:

10

15

20

25



wherein the dashed lines represent optional double bonds;

A is nitrogen or CR⁷;
 B is -NR¹R², -CR¹R²R¹⁰, -C(=CR²R¹¹)R¹, -NHCR¹R²R¹⁰, -OCR¹R²R¹⁰, -SCR¹R²R¹⁰, -CR²R¹⁰NHR¹,
 30 -CR²R¹⁰OR¹, -CR²R¹⁰SR¹ or -COR², and is single bonded to D; or B is -CR¹R², and is double bonded to D and D is carbon;
 D is nitrogen or CR⁴ and is single bonded to all atoms to which it is attached, or D is carbon and is double bonded to E or double bonded to B;
 E is oxygen, nitrogen, sulfur, C=O, C=S, CR⁶R¹², NR⁶ or CR⁶; or E is a two atom spacer, wherein one of the atoms is oxygen, nitrogen, sulfur, C=O, C=S, CR⁶R¹², NR⁶ or CR⁶, and the other is CR⁶R¹² or CR⁹;
 35 K and G are each, independently, C=O, C=S, sulfur, oxygen, CHR⁸ or NR⁸ when single bonded to both adjacent ring atoms, or nitrogen or CR⁸ when it is double bonded to an adjacent ring atom;
 the 6- or 7-membered ring that contains D, E, K and G may contain from one to three double bonds, from zero to two heteroatoms selected from oxygen, nitrogen and sulfur, and from zero to two C=O or C=S groups, wherein the carbon atoms of such groups are part of the ring and the oxygen and sulfur atoms are substituents
 40 on the ring;
 R¹ is C₁-C₆ alkyl optionally substituted with from one or two substituents independently selected from hydroxy, fluoro, chloro, bromo, iodo, C₁-C₄ alkoxy, CF₃, -C(=O)(C₁-C₄ alkyl), -C(=O)-O-(C₁-C₄)alkyl, -OC(=O)(C₁-C₄ alkyl), -OC(=O)N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -NHCO(C₁-C₄ alkyl), -COOH, -COO(C₁-C₄ alkyl), -CONH(C₁-C₄ alkyl), -CON(C₁-C₄ alkyl)(C₁-C₂ alkyl), -S(C₁-C₄ alkyl), -CN, -NO₂, -SO(C₁-C₄ alkyl), -SO₂(C₁-C₄ alkyl), -SO₂NH(C₁-C₄ alkyl) and -SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl), wherein each of the C₁-C₄ alkyl groups in the foregoing R¹ groups may optionally contain one or two double or triple bonds;
 R² is C₁-C₁₂ alkyl which may optionally contain from one to three double or triple bonds, aryl or (C₁-C₄ alkylene)aryl, wherein said aryl and the aryl moiety of said (C₁-C₄ alkylene)aryl is selected from phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidinyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, oxazolyl and benzoxazolyl; C₃-C₈ cycloalkyl or (C₁-C₆ alkylene)(C₃-C₈ cycloalkyl), wherein one or two of the carbon atoms of said cycloalkyl and the 5 to 8 membered cycloalkyl moieties of said (C₁-C₆ alkylene)(C₃-C₈ cycloalkyl) may optionally and independently be replaced by an oxygen or sulfur and wherein each of the foregoing R² groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro, hydroxy and C₁-C₄ alkyl, or with one substituent selected from C₁-C₆ alkoxy, -OC(=O)(C₁-C₆ alkyl), -OC(=O)N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -S(C₁-C₆ alkyl), amino, -NH(C₁-C₂ alkyl), -N(C₁-C₂ alkyl)(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)-CO-(C₁-C₄ alkyl), -NHCO(C₁-C₄ alkyl), -COOH, -COO(C₁-C₄ alkyl), -CONH(C₁-C₄ alkyl), -CON(C₁-C₄ alkyl)(C₁-C₂ alkyl), -SH, -CN, -NO₂, -SO(C₁-C₄ alkyl), -SO₂(C₁-C₄ alkyl), -SO₂NH(C₁-C₄ alkyl) and -SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl);
 55

-NR¹R² or CR¹R²R¹⁰ may form a ring selected from saturated 3 to 8 membered rings, the 5 to 8 membered rings of which may optionally contain one or two double bonds, and wherein one or two of the ring carbon atoms of such 5 to 8 membered rings may optionally and independently be replaced by an oxygen or sulfur atom or by NZ³ wherein Z³ is hydrogen or C₁-C₄ alkyl;

5 R³ is hydrogen, C₁-C₄ alkyl, -O(C₁-C₄ alkyl), chloro, fluoro, bromo, iodo, -S(C₁-C₄ alkyl) or -SO₂(C₁-C₄ alkyl);

R⁴ is hydrogen, C₁-C₂ alkyl, hydroxy or fluoro;

10 each R⁶, R⁸ and R⁹ that is attached to a carbon atom is selected, independently, from hydrogen, C₁-C₂ alkyl, fluoro, chloro, bromo, iodo, hydroxy, hydroxymethyl, formyl, trifluoromethyl, cyano, amino, nitro, -O(C₁-C₂ alkyl), -N(C₁-C₂ alkyl)(C₁-C₂ alkyl), -S(C₁-C₂ alkyl), -CO(C₁-C₂ alkyl), -C(=O)H or -C(=O)O(C₁-C₂ alkyl), wherein each of the C₁-C₂ alkyl moieties in the foregoing R⁶, R⁸, and R⁹ groups may optionally contain one double or triple bond; and each R⁶, R⁸, and R⁹ that is attached to a nitrogen atom is selected, independently, from hydrogen and C₁-C₄ alkyl;

15 R⁵ is substituted phenyl, naphthyl, pyridyl or pyrimidyl, wherein each of the foregoing R⁵ groups is substituted with from two to four substituents R¹⁵, wherein from one to three of said substituents may be selected, independently, from chloro, C₁-C₆ alkyl, -O(C₁-C₆ alkyl) and -(C₁-C₆ alkylene)O(C₁-C₆ alkyl), and wherein one of said substituents may be selected, independently, from bromo, iodo, formyl, cyano, trifluoromethyl, nitro, amino, -NH(C₁-C₄ alkyl), -N(C₁-C₂ alkyl)(C₁-C₆ alkyl), -C(=O)O(C₁-C₄ alkyl), -C(=O)(C₁-C₄ alkyl), -COOH, -SO₂NH(C₁-C₄ alkyl), -SO₂N(C₁-C₂ alkyl)(C₁-C₄ alkyl), -SO₂NH₂, -NHSO₂(C₁-C₄ alkyl), -S(C₁-C₆ alkyl) and -SO₂(C₁-C₆ alkyl), and wherein each of the C₁-C₄ alkyl and C₁-C₆ alkyl moieties in the foregoing R⁵ groups may optionally be substituted with one or two substituents independently selected from fluoro, hydroxy, amino, methylamino, dimethylamino and acetyl;

20 R⁷ is hydrogen, methyl, halo (e.g., chloro, fluoro, iodo or bromo), hydroxy, methoxy, -C(=O)(C₁-C₂ alkyl), -C(=O)O(C₁-C₂ alkyl), trifluoromethoxy, hydroxymethyl, trifluoromethyl or formyl;

R¹⁰ is hydrogen, hydroxy, methoxy or fluoro;

25 R¹¹ is hydrogen or C₁-C₄ alkyl;

R¹² is hydrogen or methyl; and

Z is NH, oxygen, sulfur, -N(C₁-C₄ alkyl), or CR¹³R¹⁴ wherein R¹³ and R¹⁴ are independently selected from hydrogen, and methyl with the exception that one of R¹³ and R¹⁴ may optionally be cyano;


30 with the proviso that: (a) in the six or seven membered rings of structures in formula I, there can not be two double bonds adjacent to each other; and (b) when D is carbon and is double bonded to B, then B is CR¹R²; or a pharmaceutically acceptable salt of such compound.

VII. The CRF antagonist can also be of the following formula, disclosed in WO 98/08847:

35

40

45



or a pharmaceutically acceptable salt thereof, wherein

the dashed lines represent optional double bonds;

50 A is nitrogen or CR⁷;

B is -NR¹R², -CR¹R²R¹⁰, -C(=CR²R¹¹)R¹, -NHCR¹R²R¹⁰, -OCR¹R²R¹⁰, -SCR¹R²R¹⁰, -CR²R¹⁰NHR¹, -CR²R¹⁰OR¹, -CR²R¹⁰SR¹ or -COR²;

J and K are each independently nitrogen or carbon and both J and K are not nitrogens;

D and E are each selected, independently, from nitrogen, CR⁴, C=O, C=S, sulfur, oxygen, CR⁴R⁶ and NR⁸;

55 G is nitrogen or carbon;

the ring containing D, E, G, K, and J in formula I may be a saturated or unsaturated 5-membered ring and may optionally contain one or two double bonds and may optionally contain from one to three heteroatoms in the ring and may optionally have one or two C=O or C=S groups;

R¹ is C₁-C₆ alkyl optionally substituted with one or two substituents independently selected from hydroxy, fluoro, chloro, bromo, iodo, -O-(C₁-C₄ alkyl), CF₃, -C(=O)O-(C₁-C₄ alkyl), -OC(=O)(C₁-C₄ alkyl), -OC(=O)N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -NHCO(C₁-C₄ alkyl), -COOH, -COO(C₁-C₄ alkyl), -CONH(C₁-C₄ alkyl), -CON(C₁-C₄ alkyl)(C₁-C₂ alkyl), -S(C₁-C₄ alkyl), -CN, -NO₂, -SO(C₁-C₄ alkyl), -SO₂(C₁-C₄ alkyl), -SO₂NH(C₁-C₄ alkyl) and -SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl), wherein each of the C₁-C₄ alkyl groups in the foregoing R¹ groups may 5 optionally contain one or two double or triple bonds;

R² is C₁-C₁₂ alkyl which may optionally contain from one to three double or triple bonds, aryl or (C₁-C₄ alkylene) aryl, wherein said aryl and the aryl moiety of said (C₁-C₄ alkylene)aryl is selected from phenyl, naphthyl, thienyl, 10 benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidinyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, oxazolyl and benzoxazolyl; C₃-C₈ cycloalkyl or (C₁-C₆ alkylene)(C₃-C₈ cycloalkyl), wherein one or two of the carbon atoms of said cycloalkyl and the 5 to 8 membered 15 cycloalkyl moieties of said (C₁-C₆ alkylene)(C₃-C₈ cycloalkyl) may optionally and independently be replaced by an oxygen or sulfur atom or by NZ² wherein Z² is selected from hydrogen, C₁-C₄ alkyl, benzyl and C₁-C₄ alkanoyl, and wherein each of the foregoing R² groups may optionally be substituted with from one to three 20 substituents independently selected from chloro, fluoro, hydroxy and C₁-C₄ alkyl, or with one substituent selected from bromo, iodo, C₁-C₆ alkoxy, -OC(=O)(C₁-C₆ alkyl), -OC(=O)N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -S(C₁-C₆ alkyl), amino, -NH(C₁-C₂ alkyl), -N(C₁-C₂ alkyl)(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)-CO-(C₁-C₄ alkyl), -NHCO(C₁-C₄ alkyl), -COOH, -COO(C₁-C₄ alkyl), -CONH(C₁-C₄ alkyl), -CON(C₁-C₄ alkyl)(C₁-C₂ alkyl), -SH, -CN, -NO₂, -SO(C₁-C₄ alkyl), -SO₂(C₁-C₄ alkyl), -SO₂NH(C₁-C₄ alkyl) and -SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl);

25 -NR¹R² or CR¹R²R¹⁰ may form a saturated 3 to 8 membered carbocyclic ring which may optionally contain from one to three double bonds and wherein one or two of the ring carbon atoms of such 5 to 8 membered rings may optionally and independently be replaced by an oxygen or sulfur atom or by NZ³ wherein Z³ is hydrogen, C₁-C₄ alkyl, benzyl or C₁-C₄ alkanoyl;

R³ is hydrogen, C₁-C₄ alkyl, -O(C₁-C₄ alkyl), chloro, fluoro, bromo, iodo, (C₁-C₂ alkylene)-O-(C₁-C₂ alkyl), (C₁-C₂ alkylene)-OH, or -S(C₁-C₄ alkyl);

30 each R⁴ is, independently, hydrogen, (C₁-C₆ alkyl), fluoro, chloro, bromo, iodo, hydroxy, cyano, amino, (C₁-C₂ alkylene)-OH, CF₃, CH₂SCH₃, nitro, -O(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -S(C₁-C₄ alkyl), -CO(C₁-C₄ alkyl), -C(=O)H or -C(=O)O(C₁-C₄ alkyl);

R⁶ is hydrogen, methyl or ethyl;

35 R⁸ is hydrogen or C₁-C₄ alkyl;

R⁵ is phenyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl and wherein each of the foregoing R⁵ groups is substituted with from one to four substituents R¹³ wherein one to three of said substituents may be selected, independently, from fluoro, chloro, C₁-C₆ alkyl and -O(C₁-C₆ alkyl) and one of said substituents may be selected from bromo, 40 iodo, formyl, OH, (C₁-C₄ alkylene)-OH, (C₁-C₄ alkylene)-O-(C₁-C₂ alkyl), -CN, -CF₃, -NO₂, -NH₂, -NH(C₁-C₄ alkyl), -N(C₁-C₂ alkyl)(C₁-C₆ alkyl), -OCO(C₁-C₄ alkyl), (C₁-C₄ alkylene)-O-(C₁-C₄ alkyl), -S(C₁-C₆ alkyl), (C₁-C₄ alkylene)-S-(C₁-C₄ alkyl), -C(=O)O(C₁-C₄ alkyl), -C(=O)(C₁-C₄ alkyl), -COOH, -SO₂NH(C₁-C₄ alkyl), -SO₂N(C₁-C₂ alkyl)(C₁-C₄ alkyl), -SO₂NH₂, -NHSO₂(C₁-C₄ alkyl), -S(C₁-C₆ alkyl) and -SO₂(C₁-C₆ alkyl), and wherein each of the C₁-C₄ alkyl and C₁-C₆ alkyl moieties in the foregoing R⁵ groups may optionally have one or two double bonds;

45 R⁷ is hydrogen, C₁-C₄ alkyl, halo (e.g., chloro, fluoro, iodo or bromo), hydroxy, -O(C₁-C₄ alkyl), -C(=O)(C₁-C₄ alkyl), -C(=O)O(C₁-C₄ alkyl), -OCF₃, -CF₃, -CH₂OH or -CH₂O(C₁-C₂ alkyl);


R¹⁰ is hydrogen, hydroxy, methoxy or fluoro;

50 R¹¹ is hydrogen or C₁-C₄ alkyl; and

with the proviso that: a) when both J and K are carbons and D is CR⁴ and E is nitrogen, then G can not be nitrogen; (b) when both J and K are carbons and D and G are nitrogens, then E can not be CR⁴ or C=O or C=S; (c) when both J and K are carbons and D and E are carbons, then G can not be nitrogen; (d) when G is carbon, it must be double banded to E; and (e) in the ring containing J, K, D, E and G, there can not be two double bonds adjacent to each other;

and the pharmaceutically acceptable salts of such compounds.

VIII. Other useful CRF antagonists are of the following formula, disclosed in WO 98/08846:



wherein the dashed lines represent optional double bonds;

- 15 A is nitrogen or CR⁷;
 B is -NR¹R², -CR¹R²R¹⁰, -C(=CR²R¹¹)R¹, -NHCR¹R²R¹⁰, -OCR¹R²R¹⁰, -SCR¹R²R¹⁰, -CR²R¹⁰NHR¹,
 -CR²R¹⁰OR¹, -CR²R¹⁰SR¹ or -COR²;
 20 G is nitrogen or CR⁴ and is single bonded to all atoms to which it is attached, or G is carbon and is double
 bonded to K;
 K is nitrogen or CR⁶ when double bonded to G or E, or K is oxygen, sulfur, C=O, C=S, CR⁶R¹² or NR⁸ when
 25 single bonded to both adjacent ring atoms, or K is a two atom spacer, wherein one of the two ring atoms of
 the spacer is oxygen, nitrogen, sulfur, C=O, C=S, CR⁶R¹², NR⁶ or CR⁶, and the other is CR⁶R¹² or CR⁹;
 D and E are each, independently, C=O, C=S, sulfur, oxygen, CR⁴R⁶ or NR⁸ when single bonded to both
 30 adjacent ring atoms, or nitrogen or CR⁴ when it is double bonded to an adjacent ring atom;
 the 6- or 7-membered ring that contains D, E, K and G may contain from one to three double bonds, from zero
 to two heteroatoms selected from oxygen, nitrogen and sulfur, and from zero to two C=O or C=S groups,
 35 wherein the carbon atoms of such groups are part of the ring and the oxygen and sulfur atoms are substituents
 on the ring;
 40 R¹ is C₁-C₆ alkyl optionally substituted with from one or two substituents independently selected from hydroxy,
 fluoro, chloro, bromo, iodo, C₁-C₄ alkoxy, CF₃, -C(=O)(C₁-C₄ alkyl), -C(=O)-O-(C₁-C₄)alkyl, -OC(=O)(C₁-C₄
 45 alkyl), -OC(=O)N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -NHCO(C₁-C₄ alkyl), -COOH, -COO(C₁-C₄ alkyl), -CONH(C₁-C₄
 alkyl), -CON(C₁-C₄ alkyl)(C₁-C₂ alkyl), -S(C₁-C₄ alkyl), -CN, -NO₂, -SO(C₁-C₄ alkyl), -SO₂(C₁-C₄ alkyl),
 -SO₂NH(C₁-C₄ alkyl) and -SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl), wherein each of the C₁-C₄ alkyl groups in the
 50 foregoing R¹ groups may optionally contain one or two double or triple bonds;
 R² is C₁-C₁₂ alkyl which may optionally contain from one to three double or triple bonds, aryl or (C₁-C₄ alkylene)
 aryl, wherein said aryl and the aryl moiety of said (C₁-C₄ alkylene)aryl is selected from phenyl, naphthyl, thienyl,
 benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidinyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothi-
 azolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, oxazolyl and benzoxazolyl; C₃-C₈ cycloalkyl or (C₁-C₆
 55 alkylene)(C₃-C₈ cycloalkyl), wherein one or two of the carbon atoms of said cycloalkyl and the 5 to 8 membered
 cycloalkyl moieties of said (C₁-C₆ alkylene)(C₃-C₈ cycloalkyl) may optionally and independently be replaced
 by an oxygen or sulfur atom or by NZ where Z is hydrogen, C₁-C₄ alkyl or benzyl, and wherein each of the
 foregoing R² groups may optionally be substituted with from one to three substituents independently selected
 from chloro, fluoro, hydroxy and C₁-C₄ alkyl, or with one substituent selected from C₁-C₆ alkoxy, -OC(=O)(C₁-
 C₆ alkyl), -OC(=O)N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -S(C₁-C₆ alkyl), amino, -NH(C₁-C₂ alkyl), -N(C₁-C₂ alkyl)(C₁-
 C₄ alkyl), -N(C₁-C₄ alkyl)-CO-(C₁-C₄ alkyl), -NHCO(C₁-C₄ alkyl), -COOH, -COO(C₁-C₄ alkyl), -CONH(C₁-C₄
 alkyl), -CON(C₁-C₄ alkyl)(C₁-C₂ alkyl), -SH, -CN, -NO₂, -SO(C₁-C₄ alkyl), -SO₂(C₁-C₄ alkyl), -SO₂NH(C₁-C₄
 alkyl) and -SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl);
 -NR¹R² or CR¹R²R¹⁰ may form a ring selected from saturated 3 to 8 membered rings, the 5 to 8 membered
 60 rings of which may optionally contain one or two double bonds, and wherein one or two of the ring carbon
 atoms of such 5 to 8 membered rings may optionally and independently be replaced by an oxygen or sulfur
 atom or by NZ² wherein Z² is hydrogen, benzyl or C₁-C₄ alkyl;
 R³ is hydrogen, C₁-C₄ alkyl, -O(C₁-C₄ alkyl), chloro, fluoro, bromo, iodo, -S(C₁-C₄ alkyl) or -SO₂(C₁-C₄ alkyl);
 65 each R⁸, R⁹ and R¹² is selected, independently, from hydrogen and C₁-C₂ alkyl;
 each R⁴ and R⁶ that is attached to a carbon atom is selected, independently, from hydrogen and C₁-C₆ alkyl,
 fluoro, chloro, bromo, iodo, hydroxy, hydroxy (C₁-C₂ alkyl), trifluoromethyl, cyano, amino, nitro, -O(C₁-C₄ alkyl),
 -N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -CH₂SCH₃, -S(C₁-C₄ alkyl), -CO(C₁-C₄ alkyl), -C(=O)H or -C(=O)O(C₁-C₄ alkyl),
 70 wherein each of the C₁-C₂ alkyl moieties in the foregoing R⁴ and R⁶ groups may optionally contain one double

or triple bond; and R⁶, when attached to a nitrogen atom, is selected from hydrogen and C₁-C₄ alkyl; R⁵ is substituted phenyl, naphthyl, pyridyl or pyrimidyl, wherein each of the foregoing R⁵ groups is substituted with from two to four substituents R¹³, wherein up to three of said substituents may be selected, independently, from chloro, C₁-C₆ alkyl, -O(C₁-C₆ alkyl) and -(C₁-C₆ alkylene)O(C₁-C₆ alkyl), and wherein one of said substituents may be selected, independently, from bromo, iodo, formyl, cyano, trifluoromethyl, nitro, amino, -NH(C₁-C₄ alkyl), -N(C₁-C₂ alkyl)(C₁-C₆ alkyl), -C(=O)O(C₁-C₄ alkyl), -C(=O)(C₁-C₄ alkyl), -COOH, -SO₂NH(C₁-C₄ alkyl), -SO₂N(C₁-C₂ alkyl)(C₁-C₄ alkyl), -SO₂NH₂, -NSO₂(C₁-C₄ alkyl), -(C₀-C₁alkylene)-S-(C₁-C₂alkyl), -(C₀-C₁alkylene)-SO-(C₁-C₂alkyl), -(C₀-C₁alkylene)-SO₂-(C₁-C₂alkyl) and -(C₁-C₄alkylene)-OH, and wherein each of the C₁-C₄ alkyl and C₁-C₆ alkyl moieties in the foregoing R⁵ groups may optionally be substituted with one or two substituents independently selected from fluoro, hydroxy, amino, methylamino, dimethylamino and acetyl;

5 R⁷ is hydrogen, methyl, halo (e.g., chloro, fluoro, iodo or bromo), hydroxy, methoxy, -C(=O)(C₁-C₂ alkyl), -C(=O)O(C₁-C₂ alkyl), hydroxymethyl, trifluoromethyl or formyl;


10 R¹⁰ is hydrogen, hydroxy, methoxy or fluoro; and

15 R¹¹ is hydrogen or C₁-C₄ alkyl;

with the proviso that in the ring containing D, E, K and G of formula I, there can not be two double bonds adjacent to each other;

and the pharmaceutically acceptable salt of such compound.

20 IX. The CRF antagonist may also be of the following formula, disclosed in WO 95/10506:



or a pharmaceutically acceptable salt or prodrug thereof, wherein Y is CR^{3a}, N, or CR²⁹;

when Y is CR^{3a} or N:

R¹ is independently selected at each occurrence from the group consisting of C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, halogen, C₁-C₂ haloalkyl, NR⁶R⁷, OR⁸, and S(O)_nR⁸;

40 R³ is C₁-C₄ alkyl, aryl, C₃-C₆ cycloalkyl, C₁-C₂ haloalkyl, halogen, nitro, NR⁶R⁷, OR⁸, S(O)_nR⁸, C(=O)R⁹, C(=O)NR⁶R⁷, C(=S)NR⁶R⁷, -(CHR¹⁶)_kNR⁶R⁷, (CH₂)_kOR⁸, C(=O)NR¹⁰CH(R¹¹)CO₂R¹², C(OH)(R²⁵)(R^{25a}), -(CH₂)_pS(O)_n-alkyl, -(CHR¹⁶)R²⁵, -C(CN)(R²⁵)(R¹⁶) provided that R²⁵ is not -NH- containing rings, -C(=O)R²⁵, -CH(CO₂R¹⁶)₂, NR¹⁰C(=O)CH(R¹¹)NR¹⁰R¹², NR¹⁰CH(R¹¹)CO₂R¹²; substituted C₁-C₄ alkyl, substituted C₂-C₄ alkenyl, substituted C₂-C₄ alkynyl, substituted C₁-C₄ alkoxy, aryl-(substituted C₁-C₄) alkyl, aryl-(substituted C₁-C₄) alkoxy, substituted C₃-C₆ cycloalkyl, amino-(substituted C₁-C₄)alkyl, substituted C₁-C₄ alkylamino, where substitution by R²⁷ can occur on any carbon containing substituent; 2-pyridinyl, imidazolyl, 3-pyridinyl, 4-pyridinyl, 2-methyl-3-pyridinyl, 4-methyl-3-pyridinyl, furanyl, 5-methyl-2-furanyl, 2,5-dimethyl-3-furanyl, 2-thienyl, 3-thienyl, 5-methyl-2-thienyl, 2-pheno-thiazinyl, 4-pyrazinyl, azetidinyl, phenyl, 1H-indazolyl, 2-pyrrolidonyl, 2H,6H-1,5,2-dithiazinyl, 2H-pyrrolyl, 3H-indolyl, 4-piperidonyl, 4aH-carbazolyl, 4H-quinolizinyl, 6H-1,2,5-thiadiazinyl, acridinyl, azocinyl, azepinyl, benzofuranyl, benzothiophenyl, carbazolyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, furazanyl, imidazolidinyl, indolinyl, indolizinyl, indolyl, isobenzofuranyl, isochromanyl, isoindolinyl, isoindolyl, isoquinolinyl, benzimidazolyl, isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxazolidinyl, oxazolyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, quinuclidinyl, β -carbolinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, thianthrenyl, thiazolyl, thiophenyl, triazinyl, xanthenyl; or 1-tetrahydroquinolinyl or 2-tetrahydroisoquinolinyl

either of which can be substituted with 0-3 groups chosen from keto and C₁-C₄ alkyl; J, K, and L are independently selected at each occurrence from the group of N, CH, and CX'; M is CR⁵ or N;

5 V is CR^{1a} or N;

Z is CR² or N;

R^{1a}, R², and R^{3a} are independently selected at each occurrence from the group consisting of hydrogen, halo, halomethyl, C₁-C₃ alkyl, and cyano;

R⁴ is (CH₂)_mOR¹⁶, C₁-C₄ alkyl, allyl, propargyl, (CH₂)_mR¹³, or -(CH₂)_mOC(O)R¹⁶;

10 X is halogen, aryl, heteroaryl, S(O)₂R⁸, SR⁸, halomethyl, -(CH₂)_pOR⁸, cyano, -(CHR¹⁶)_pNR¹⁴R¹⁵, -C(=O)R⁸, C₁-C₆ alkyl, C₄-C₁₀ cycloalkylalkyl, C₁-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₂-C₁₀ alkoxy, aryl-(C₂-C₁₀)-alkyl, C₃-C₆ cycloalkyl, aryl-(C₁-C₁₀)-alkoxy, nitro, thio-(C₁-C₁₀)-alkyl, -C(=NOR¹⁶)-C₁-C₄-alkyl, -C(=NOR¹⁶)H, or -C(=O)NR¹⁴R¹⁵, where substitution by R¹⁸ can occur on any carbon containing substituents;

X' is independently selected at each occurrence from the group consisting of hydrogen, halogen, aryl, heteroaryl, S(O)_nR⁸, halomethyl, -(CHR¹⁶)_pOR⁸, cyano, -(CHR¹⁶)_pNR¹⁴R¹⁵, C(=O)R⁸, C₁-C₆ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₁-C₁₀ alkoxy, aryl-(C₁-C₁₀)-alkyl, C₃-C₆ cycloalkyl, aryl-(C₁-C₁₀)-alkoxy, nitro, thio-(C₁-C₁₀)-alkyl, -C(=NOR¹⁶)-C₁-C₄-alkyl, -C(=NOR¹⁶)H, and -C(=O)NR¹⁴R¹⁵, where substitution by R¹⁶ can occur on any carbon containing substituents;

15 R⁵ is halo, -C(=NOR¹⁶)-C₁-C₄-alkyl, C₁-C₄ alkyl, C₁-C₃ haloalkyl, -(CHR¹⁶)_pOR⁸, -(CHR¹⁶)_pS(O)_nR⁸, -(CHR⁶)_pNR¹⁴R¹⁵, C₃-C₆ cycloalkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, aryl-(C₂-C₁₀)-alkyl, aryl-(C₁-C₁₀)-alkoxy, cyano, C₃-C₆ cycloalkoxy, nitro, amino-(C₂-C₁₀)-alkyl, thio-(C₂-C₁₀)-alkyl, SO_n(R⁸), C(=O)R⁸ -C(=NOR¹⁶)H, or -C(=O)NR¹⁴R¹⁵, where substitution by R¹⁸ can occur on any carbon containing substituents;

R⁶ and R⁷ are independently selected at each occurrence from the group consisting of hydrogen, C₁-C₆ alkyl, C₃-C₁₀ cycloalkyl, C₁-C₆ alkoxy, (C₄-C₁₂)-cycloalkylalkyl, -(CH₂)_kR¹³, (CHR¹⁶)_pOR⁸, -(C₁-C₆ alkyl)-aryl, heteroaryl, -S(O)_z-aryl or -(C₁-C₆ alkyl)-heteroaryl or aryl, wherein the aryl or heteroaryl groups are optionally substituted with 1-3 groups selected from the group consisting of hydrogen, halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, amino, NHC(=O)(C₁-C₆ alkyl), NH(C₁-C₆ alkyl), N(C₁-C₆ alkyl)₂, nitro, carboxy, CO₂(C₁-C₆ alkyl), cyano, and S(O)₂(C₁-C₆ alkyl); or can be taken together to form -(CH₂)_pA(CH₂)_q, optionally substituted with 0-3 R¹⁷; or, when considered with the commonly attached nitrogen, can be taken together to form a heterocycle, said heterocycle being substituted on carbon with 1-3 groups consisting of hydrogen, C₁-C₆ alkyl, hydroxy, or C₁-C₆ alkoxy;

20 30 A is CH₂, O, NR²⁵, C(=O), S(O)_n, N(C(=O)R¹⁷), N(R¹⁹), C(H)(NR¹⁴R¹⁵), C(H)(OR²⁰), C(H)(C(=O)R²¹), or N(S(O)_nR²¹);

R⁸ is independently selected at each occurrence from the group consisting of hydrogen; C₁-C₆ alkyl; -(C₄-C₁₂)-cycloalkylalkyl; (CH₂)_tR²²; C₃-C₁₀ cycloalkyl; -NR⁶R⁷; aryl; heteroaryl; -NR¹⁶(CH₂)_nR⁶R⁷; -(CH₂)_kR²⁵; and (CH₂)_theteroaryl or (CH₂)_taryl, either of which can optionally be substituted with 1-3 groups selected from the group consisting of hydrogen, halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, amino, NHC(=O)(C₁-C₆ alkyl), NH(C₁-C₆ alkyl), N(C₁-C₆ alkyl)₂, nitro, carboxy, CO₂(C₁-C₆ alkyl), cyano, and S(O)₂(C₁-C₆ alkyl);

35 40 R⁹ is independently selected at each occurrence from R¹⁰, hydroxy, C₁-C₄ alkoxy, C₃-C₆ cycloalkyl, C₂-C₄ alkenyl, aryl substituted with 0-3 R¹⁸, and -(C₁-C₆ alkyl)-aryl substituted with 0-3 R¹⁸;

R¹⁰, R¹⁶, R²³, and R²⁴ are independently selected at each occurrence from hydrogen or C₁-C₄ alkyl;

R¹¹ is C₁-C₄ alkyl substituted with 0-3 groups chosen from the following: keto, amino, sulfhydryl, hydroxyl, guanidinyl, p-hydroxyphenyl, imidazolyl, phenyl, indolyl, and indolinyl, or, when taken together with an adjacent R¹⁰, are (CH₂)_t;

45 R¹² is hydrogen or an appropriate amine protecting group for nitrogen or an appropriate carboxylic acid protecting group for carboxyl;

R¹³ is independently selected at each occurrence from the group consisting of CN, OR¹⁹, SR¹⁹, and C₃-C₆ cycloalkyl;

R¹⁴ and R¹⁵ are independently selected at each occurrence from the group consisting of hydrogen, C₄-C₁₀-cycloalkyl-alkyl, and R₁₉;

50 R¹⁷ is independently selected at each occurrence from the group consisting of R¹⁰, C₁-C₄ alkoxy, halo, OR²³, SR²³, NR²³R²⁴, and (C₁-C₆) alkyl (C₁-C₄) alkoxy;

R¹⁸ is independently selected at each occurrence from the group consisting of R¹⁰, hydroxy, halogen, C₁-C₂ haloalkyl, C₁-C₄ alkoxy, C(=O)R²⁴, and cyano;

55 R¹⁹ is independently selected at each occurrence from the group consisting of C₁-C₆ alkyl, C₃-C₆ cycloalkyl, (CH₂)_wR²², and aryl substituted with 0-3 R¹⁸;

R²⁰ is independently selected at each occurrence from the group consisting of R¹⁰, C(=O)R³¹, and C₂-C₄ alkenyl;

R²¹ is independently selected at each occurrence from the group consisting of R¹⁰, C₁-C₄ alkoxy, NR²³R²⁴,

and hydroxyl;

R²² is independently selected at each occurrence from the group consisting of cyano, OR²⁴, SR²⁴, NR²³R²⁴, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, -S(O)_nR³¹, and -C(=O)R²⁵;

R²⁵, which can be optionally substituted with 0-3 R¹⁷, is independently selected at each occurrence from the group consisting of phenyl, pyrazolyl, imidazolyl, 2-methyl-3-pyridinyl, 4-methyl-3-pyridinyl, furanyl, 5-methyl-2-furanyl, 2,5-dimethyl-3-furanyl, 2-thienyl, 3-thienyl, 5-methyl-2-thienyl, 2-pheno-thiazinyl, 4-pyrazinyl, aze-tidinyl, 1H-indazolyl, 2-pyrrolidonyl, 2H,6H-1,5,2-dithiazinyl, 2H-pyrrolyl, 3H-indolyl, 4-piperidonyl, 4aH-carbazolyl, 4H-quinolizinyl, 6H-1,2,5-thiadiazinyl, acridinyl, azocinyl, azepinyl, benzofuranyl, benzothiophenyl, carbazolyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, furazanyl, indolinyl, indolizinyl, indolyl, isobenzofuranyl, isochromanyl, isoindolinyl, isoindolyl, isoquinolinyl benzimidazolyl, isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxazolidinyl, oxazolyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxythiinyl, phenoxyazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazolidinyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, quinuclidinyl, B-carbolinyl, tetrahydrofuran, tetrazolyl, thianthrenyl, thiazolyl, thiophenyl, triazinyl, xanthenyl; and 1-tetrahydroquinolinyl or 2-tetrahydroisoquinolinyl either of which can be substituted with 0-3 groups chosen from keto and C₁-C₄ alkyl;

R^{25a}, which can be optionally substituted with 0-3 R¹⁷, is independently selected at each occurrence from the group consisting of H and R²⁵;

R²⁷ is independently selected at each occurrence from the group consisting of C₁-C₃ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₂-C₄ alkoxy, aryl, nitro, cyano, halogen, aryloxy, and heterocycle optionally linked through O;

R³¹ is independently selected at each occurrence from the group consisting of C₁-C₄ alkyl, C₃-C₇ cycloalkyl, C₄-C₁₀ cycloalkyl-alkyl, and aryl-(C₁-C₄) alkyl;

k, m, and r are independently selected at each occurrence from 1-4;

n is independently selected at each occurrence from 0-2;

p, q, and z are independently selected at each occurrence from 0-3; t and w are independently selected at each occurrence from 1-6, provided that when J is CX' and K and L are both CH, and M is CR⁵, then

(A) when V and Y are N and Z is CH and R¹ and R³ are methyl,

(1) and R⁴ is methyl, then

- (a) R⁵ can not be methyl when X is OH and X' is H;
- (b) R⁵ can not be -NHCH₃, or -N(CH₃)₂ when X and X' are -OCH₃; and
- (c) R⁵ can not be -N(CH₃)₂ when X and X' are -OCH₂CH₃;

(2) and R⁴ is ethyl, then

- (a) R⁵ can not be methylamine when X and X' are -OCH₃;
- (b) R⁵ can not be OH when X is Br and X' is OH; and
- (c) R⁵ can not be -CH₂OH or -CH₂N(CH₃)₂ when X is -SCH₃ and X' is H;

(B) when V and Y are N, Z is CH, R⁴ is ethyl, R⁵ is iso-propyl, X is Br, X' is H, and

(1) R¹ is CH₃, then

(a) R³ can not be OH, piperazin-1-yl, -CH₂-piperidin-1-yl, -CH₂-(N-4-methylpiperazin-1-yl), -C(O)NH-phenyl, -CO₂H, -CH₂O-(4-pyridyl), -C(O)NH₂, 2-indolyl, -CH₂O-(4-carboxyphenyl), -N(CH₂CH₃)(2-bromo-4-isopropylphenyl);

(2) R² is -CH₂CH₂CH₃ then R³ can not be -CH₂CH₂CH₃

(C) when V, Y and Z are N, R⁴ is ethyl, and

(1) R⁵ is iso-propyl, X is bromo, and X' is H, then

- (a) R³ can not be OH or -OCH₂CN when R¹ is CH₃ and
- (b) R³ can not be -N(CH₃)₂ when R¹ is -N(CH₃)₂;

(2) R⁵ is -OCH₃, X is -OCH₃, and X' is H, then R³ and R¹ can not both be chloro;
further provided that when J, K, and L are all CH and M is CR⁵, then

- (D) at least one of V, Y, and Z must be N;
 (E) when V is CR^{1a}, Z and Y can not both be N;
 (F) when Y is CR^{3a}, Z and V can not both be N;
 (G) when Z is CR², V and Y must both be N;
 5 (H) Z can be N only when both V and Y are N or when V is CR^{1a} and Y is CR^{3a};
 (I) when V and Y are N, Z is CR², and R² is H or C₁-C₃ alkyl, and R⁴ is C₁-C₃ alkyl, R³ can not be 2-pyridinyl, indolyl, indolinyl, imidazolyl, 3-pyridinyl, 4-pyridinyl, 2-methyl-3-pyridinyl, 4-methyl-3-pyridinyl, furanyl, 5-methyl-2-furanyl, 2,5-dimethyl-3-furanyl, 2-thienyl, 3-thienyl, 5-methyl-2-thienyl, 2-phenothiazinyl, or 4-pyrazinyl;
 10 (J) when V and Y are N; Z is CR²; R² is H or C₁-C₃ alkyl; R⁴ is C₁-C₄ alkyl, R⁵, X, and/or X' are OH, halo, CF₃, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, amino, carbamoyl, or C₁-C₄ alkanoyl; and R¹ is C₁-C₄ alkyl, then R⁴ can not be -NH(substituted phenyl) or -N(C₁-C₄ alkyl) (substituted phenyl);
- and wherein, when Y is CR²⁹:
 15 J, K, L, M, Z, A, k, m, n, p, q, r, t, w, R³, R¹⁰, R¹¹, R¹², R¹³, R¹⁶, R¹⁸, R¹⁹, R²¹, R²³, R²⁴, R²⁵, and R²⁷ are as defined above and R^{25a}, in addition to being as defined above, can also be C₁-C₄ alkyl, but V is N;
 20 R¹ is C₁-C₂ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₂-C₄ alkoxy, halogen, amino, methylamino, dimethylamino, aminomethyl, or N-methylaminomethyl;
 R² is independently selected at each occurrence from the group consisting of hydrogen, halo, C₁-C₃, alkyl, nitro, amino, and -CO₂R¹⁰;
 25 R⁴ is taken together with R²⁹ to form a 5-membered ring and is -C(R²⁶)= or -N= when R²⁹ is -C(R³⁰)= or -N=, or -CH(R²⁶)- when R²⁹ is -CH(R³⁰)-;
 X is Cl, Br, I, S(O)_nR⁸, OR⁸, halomethyl, -(CHR¹⁶)_pOR⁸, cyano, -(CHR¹⁶)_pNR¹⁴R¹⁵, C(=O)R⁸, C₁-C₆ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₁-C₁₀, alkoxy, aryl-(C₁-C₁₀)-alkyl, C₃-C₆ cycloalkyl, aryl-(C₁-C₁₀)-alkoxy, nitro, thio-(C₁-C₁₀)-alkyl, -C(=NOR¹⁶)-C₁-C₄-alkyl, -C(=NOR¹⁶)H, or C(=O)NR¹⁴R¹⁵ where substitution by R¹⁸ can occur on any carbon containing substituents;
 30 X' is hydrogen, Cl, Br, I, S(O)_nR⁸, -(CHR¹⁶)_pOR⁸, halomethyl, cyano, -(CHR¹⁶)_pNR¹⁴R¹⁵, C(=O)R⁸, C₁-C₆ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₁-C₁₀ alkoxy, aryl-(C₁-C₁₀)-alkyl, C₃-C₆ cycloalkyl, aryl-(C₂-C₁₀)-alkoxy, nitro, thio-(C₂-C₁₀)-alkyl, -C(=NOR¹⁶)-C₁-C₄-alkyl, -C(=NOR¹⁶)H, or C(=O)NR⁸R¹⁵ where substitution by R¹⁸ can occur on any carbon containing substituents;
 R⁵ is halo, -C(=NOR¹⁶)-C₁-C₄-alkyl, C₁-C₆ alkyl, C₁-C₃ haloalkyl, C₁-C₆ alkoxy, (CHR¹⁶)_pOR⁵, (CHR¹⁶)_pS(O)_nR⁸, (CHR¹⁶)_pNR¹⁴R¹⁵, C₃-C₆ cycloalkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, aryl-(C₂-C₁₀)-alkyl, aryl-(C₁-C₁₀)-alkoxy, cyano, C₃-C₆ cycloalkoxy, nitro, amino-(C₁-C₁₀)-alkyl, thio-(C₁-C₁₀)-alkyl, SO_n(R⁸), C(=O)R⁸, -C(=NOR¹⁶)H, or C(=O)NR⁸R¹⁵ where substitution by R¹⁸ can occur on any carbon containing substituents;
 35 R⁶ and R⁷ are independently selected at each occurrence from the group consisting of hydrogen, C₁-C₆ alkyl, C₃-C₁₀ cycloalkyl, -(CH₂)_kR¹³, (C₄-C₁₂)-cycloalkylalkyl, C₁-C₆ alkoxy, -(C₁-C₆ alkyl)-aryl, heteroaryl, aryl, -S(O)_z-aryl or -(C₁-C₆ alkyl)-heteroaryl or aryl wherein the aryl or heteroaryl groups are optionally substituted with 1-3 groups selected from hydrogen, halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, amino, NHC(=O)(C₁-C₆ alkyl), NH(C₁-C₆ alkyl), N(C₁-C₆ alkyl)₂, nitro, carboxy, CO₂(C₁-C₆ alkyl), and cyano; or can be taken together to form -(CH₂)_qA(CH₂)_r, optionally substituted with 0-3 R¹⁷; or, when considered with the commonly attached nitrogen, can be taken together to form a heterocycle, said heterocycle being substituted on carbon with 1-3 groups consisting of hydrogen, C₁-C₆ alkyl, hydroxy, or C₁-C₆ alkoxy;
 40 R⁸ is independently selected at each occurrence from the group consisting of hydrogen, C₁-C₆ alkyl, -(C₄-C₁₂)-cycloalkylalkyl, (CH₂)_tR²², C₃-C₁₀ cycloalkyl, -(C₁-C₆ alkyl)-aryl, heteroaryl, -NR¹⁶, -N(CH₂)_nNR⁶R⁷, -(CH₂)_kR²⁵, -(C₁-C₆ alkyl)-heteroaryl or aryl optionally substituted with 1-3 groups selected from hydrogen, halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, amino, NHC(=O)(C₁-C₆ alkyl), NH(C₁-C₆ alkyl), N(C₁-C₆ alkyl)₂, nitro, carboxy, CO₂(C₁-C₆ alkyl), and cyano;
 45 R⁹ is independently selected at each occurrence from R¹⁰, hydroxy, C₁-C₄ alkoxy, C₃-C₆ cycloalkyl, C₂-C₄ alkenyl, and aryl substituted with 0-3 R¹⁸;
 50 R¹⁴ and R¹⁵ are independently selected at each occurrence from the group consisting of hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, (CH₂)_tR²², and aryl substituted with 0-3 R¹⁸;
 R¹⁷ is independently selected at each occurrence from the group consisting of R¹⁰, C₁-C₄ alkoxy, halo, OR²³, SR²³, and NR²³R²⁴;
 55 R²⁰ is independently selected at each occurrence from the group consisting of R¹⁰ and C(=O)R³¹;
 R²² is independently selected at each occurrence from the group consisting of cyano, OR²⁴, SR²⁴, NR²³R²⁴, C₃-C₆ cycloalkyl, -S(O)_nR³¹, and -C(=O)R²⁵;
 R²⁶ is hydrogen or halogen;
 R²⁸ is C₁-C₂, alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, hydrogen, C₁-C₂ alkoxy, halogen, or C₂-C₄ alkylamino;

R^{29} is taken together with R^4 to form a five membered ring and is: $-\text{CH}(R^{30})-$ when R^4 is $-\text{CH}(R^{28})-$, $-\text{C}(R^{30})=$ or $-\text{N}=\text{}$ when R^4 is $-\text{C}(R^{28})=\text{}$ or $-\text{N}=\text{}$;

R^{30} is hydrogen, cyano, $C_1\text{-}C_2$ alkyl, $C_1\text{-}C_2$ alkoxy, halogen, $C_1\text{-}C_2$ alkenyl, nitro, amido, carboxy, or amino;

5 R^{31} is $C_1\text{-}C_4$ alkyl, $C_3\text{-}C_7$ cycloalkyl, or aryl- $(C_1\text{-}C_4)$ alkyl; provided that when J, K, and L are all CH, M is CR^5 , Z is CH, R^3 is CH_3 , R^{28} is H, R^5 is isopropyl, X is Br, X' is H, and R^1 is CH_3 , then R^{30} can not be H, $-\text{CO}_2\text{H}$, or $-\text{CH}_2\text{NH}_2$; and further provided that when J, K and L are all CH; M is CR^5 ; Z is N; and


- (A) R^{29} is $-\text{C}(R^{30})=$; then one of R^{28} or R^{30} is hydrogen;
 (B) R^{29} is N; then R^3 is not halo, NH_2 , NO_2 , CF_3 , CO_2H , $\text{CO}_2\text{-alkyl}$, alkyl, acyl, alkoxy, OH, or $-(\text{CH}_2)_m\text{Oalkyl}$;
 10 (C) R^{29} is N; then R^{28} is not methyl if X or X' are bromo or methyl and R^5 is nitro; or
 (D) R^{29} is N; and R^1 is CH_3 ; and R^3 is amino; then R^5 is not halogen or methyl.

[0026] Preferred compounds of this group include those wherein:

- 15 i) V is N, R^1 is methyl; and R^3 is aryl, NR^6R^7 , or OR^8 ;
 ii) V is N, R^1 is methyl; R^3 is aryl, NR^6R^7 , or OR^8 ; and R^4 is methyl or ethyl;
 iii) V is N, R^1 is methyl; R^3 is aryl, NR^6R^7 , or OR^8 ; R^4 is methyl or ethyl; and X is $O(C_1\text{-}C_4$ alkyl), Br, or $C_1\text{-}C_4$ alkyl;
 iv) V is N, R^1 is methyl; R^3 is aryl, NR^6R^7 , or OR^8 ; R^4 is methyl, ethyl; X is OMe , Br, or $(C_1\text{-}C_4$ alkyl), M is $C_1\text{-}C_4$ alkyl, Br, Cl, or $O(C_1\text{-}C_4$ alkyl); and
 20 v) V is N, R^1 is methyl; R^3 is aryl, NR^6R^7 , OR^8 ; or R^4 is methyl, ethyl; X is OMe , Br, or $C_1\text{-}C_4$ alkyl, M is $C_1\text{-}C_4$ alkyl, Br, Cl, or $O(C_1\text{-}C_4$ alkyl); and L is CH, or N.

X. The present invention also encompasses use of aminothiazole derivatives of the following formula, disclosed in WO 97/00868:

25




wherein each of R^1 and R^2 is independently a halogen atom; a $C_1\text{-}C_5$ hydroxyalkyl radical; $C_1\text{-}C_5$ alkyl; $C_7\text{-}C_{10}$ aralkyl; $C_1\text{-}C_5$ alkoxy; trifluoromethyl; nitro; a group $-\text{SR}$ where R is hydrogen, a $C_1\text{-}C_5$ alkyl radical or a $C_7\text{-}C_{10}$ aralkyl radical; a group $-\text{S-CO-R}$ where R is a $C_1\text{-}C_5$ alkyl radical or aralkyl in which the aryl portion is $C_6\text{-}C_8$ and the alkyl portion is $C_1\text{-}C_4$; a group $-\text{COOR}'$ where R' is hydrogen or $C_1\text{-}C_5$ alkyl; a group $-\text{CONR}'R''$ where R' and R'' are as defined above for R'; a group $-\text{NR}'R''$ where R' and R'' are as previously defined for R'; a group $-\text{CONRaRb}$ or $-\text{NRaRb}$, where Ra and Rb, taken together with the nitrogen atom to which they are attached, form a 5- to 7-membered heterocyclic ring; or a group $-\text{NHCO-NR}'R''$, where R' and R'' are as defined above for R'; R^3 is hydrogen or as defined for R^1 and R^2 is a hydrogen atom; $C_1\text{-}C_5$ alkyl; halogen; a hydroxymethyl group; or a formyl group; R^5 is $C_1\text{-}C_5$ alkyl; a $C_3\text{-}C_7$ cycloalkyl group; a cycloalkylalkyl group in which the cycloalkyl portion is $C_3\text{-}C_7$ and the alkyl portion is $C_1\text{-}C_5$; or $C_5\text{-}C_6$ alkenyl; n is 0 or 1; R^6 is $C_1\text{-}C_5$ alkyl; alkoxyalkyl in which the alkyl portions are $C_1\text{-}C_5$; $C_3\text{-}C_7$ cycloalkyl; a cycloalkylalkyl group in which the cycloalkyl portion is $C_3\text{-}C_7$ and the alkyl portion is $C_1\text{-}C_5$; a cycloalkyloxyalkyl radical in which the cycloalkyl is $C_3\text{-}C_7$ and the alkyl is $C_1\text{-}C_4$; a hydroxyalkyloxyalkyl radical in which the alkyls are $C_2\text{-}C_{10}$; or an alkoxyalkyloxyalkyl radical in which the alkyls are $C_3\text{-}C_{12}$; and Z is an optionally substituted bi- or tricyclic aromatic or heteroaromatic group; and stereoisomers and/or addition salts thereof.

50 XI. CRF antagonists of the following formula, disclosed in WO 97/29109, may also be employed:

55

5



10

including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein

R¹ is NR⁴R⁵ or OR⁵;

15

R² is C₁-C₆alkyl, C₁-C₆alkyloxy or C₁-C₆alkylthio;

R³ is hydrogen, C₁-C₆alkyl, C₁-C₆alkylsulfonyl, C₁-C₆alkylsulfoxy or C₁-C₆alkylthio;

R⁴ is hydrogen, C₁-C₆alkyl, mono- or di(C₃-C₆cycloalkylmethyl, C₃-C₆cycloalkyl, C₃-C₆alkenyl, hydroxyC₁-C₆alkyl, C₁-C₆alkylcarbonyloxyC₁-C₆alkyl or C₁-C₆alkyloxyC₁-C₆alkyl;

20

R⁵ is C₁-C₈alkyl, mono- or di(C₃-C₆cycloalkyl)methyl, Ar¹CH², C₃-C₆alkenyl, C₁-C₆alkyloxyC₁-C₆alkyl, hydroxyC₁-C₆alkyl, thienylmethyl, furanylmethyl, C₁-C₆alkylthioC₁-C₆alkyl, morpholinyl, mono- or di(C₁-C₆alkyl)aminoC₁-C₆alkyl, di(C₁-C₆alkyl)amino, C₁-C₆alkylcarbonylC₁-C₆alkyl, C₁-C₆alkyl substituted with imidazolyl; or a radical of formula -Alk-O-CO-Ar¹;

or R⁴ and R⁵ taken together with the nitrogen atom to which they are attached may form a pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group, optionally substituted with C₁-C₆alkyl or C₁-C₆alkyloxyC₁-C₆alkyl; and

25

[0027] Ar is phenyl; phenyl substituted with 1, 2 or 3 substituents independently selected from halo, C₁-C₆alkyl, trifluoromethyl, hydroxy, cyano, C₁-C₆alkyloxy, benzyloxy, C₁-C₆alkylthio, nitro, amino and mono- or di(C₁-C₆alkyl)amino; pyridinyl; pyridinyl substituted with 1 ~ 2 or 3 substituents independently selected from halo, C₁-C₆alkyl, trifluoromethyl, hydroxy, cyano, C₁-C₆alkyloxy, benzyloxy, C₁-C₆alkylthio, nitro, amino, mono- or di(C₁-C₆alkyl)amino and piperidinyl; and wherein said substituted phenyl may optionally be further substituted with one or more halogens;

[0028] Ar¹ is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, C₁-C₆alkyl, C₁-C₆alkyloxy, di(C₁-C₆alkyl)aminoC₁-C₆alkyl, trifluoromethyl and C₁-C₆alkyl substituted with morpholinyl; or pyridinyl; and

35

Alk is C₁-C₆alkanediyi;


with the proviso that

5-methyl-3-phenyl-7-(phenylmethoxy)-pyrazolo[1,5-a]pyrimidine and 2,5-dimethyl-7-(methylamino)-3-phenyl-pyrazolo[1,5-a]pyrimidine are not included.

[0029] Preferred compounds of this formula are those wherein R² is methyl; R³ is hydrogen, or C₁-C₆ alkyl; and Ar is substituted phenyl or 3-pyridyl.

XII. CRF antagonists of the following formula, disclosed in WO 97/29110, may also be employed:

45



50

including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein

55

X is S, SO or SO₂;

R¹ is NR⁴R⁵ or OR⁵;

R² is C₁-C₆alkyl, C₁-C₆alkyloxy or C₁-C₆alkylthio;

R³ is hydrogen, C₁-C₆alkyl, C₁-C₆alkylsulfonyl, C₁-C₆alkylsulfoxy or C₁-C₆alkylthio;

R⁴ is hydrogen, C₁-C₆alkyl, mono- or di(C₃-C₆cycloalkyl)methyl, C₃-C₆cycloalkyl, C₃-C₆alkenyl, hydroxyC₁-C₆alkyl, C₁-C₆alkylcarbonyloxyC₁-C₆alkyl or C₁-C₆alkyloxyC₁-C₆alkyl;

R⁵ is C₁-C₆alkyl, mono- or di(C₃-C₆cycloalkyl)methyl, Ar¹CH², C₃-C₆alkenyl, C₁-C₆alkyloxyC₁-C₆alkyl, hydroxyC₁-C₆alkyl, thiethylmethyl, furanylmethyl, C₁-C₆alkylthioC₁-C₆alkyl, morpholinyl, mono- or di(C₁-C₆alkyl)aminoC₁-C₆alkyl, di(C₁-C₆alkyl)amino, C₁-C₆alkylcarbonylC₁-C₆alkyl, C₁-C₆alkyl substituted with imidazolyl; or a radical of formula -Alk-O-CO-Ar I;

or R⁴ and R⁵ taken together with the nitrogen atom to which they are attached may form a pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group, optionally substituted with C₁-C₆alkyl or C₁-C₆alkyloxyC₁-C₆alkyl;

[0030] Ar is phenyl; phenyl substituted with 1, 2 or 3 substituents independently selected from halo, C₁-C₆alkyl, trifluoromethyl, hydroxy, cyano, C₁-C₆alkyloxy, benzyloxy, C₁-C₆alkylthio, nitro, amino and mono- or di(C₁-C₆alkyl)amino; pyridinyl; pyridinyl substituted with 1, 2 or 3 substituents independently selected from halo, C₁-C₆alkyl, trifluoromethyl, hydroxy, cyano, C₁-C₆alkyloxy, benzyloxy, C₁-C₆alkylthio, nitro, amino, mono- or di(C₁-C₆alkyl)amino and piperidinyl; and wherein said substituted phenyl may optionally be further substituted with one or more halogens;

[0031] Ar¹ is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, C₁-C₆alkyl, C₁-C₆alkyloxy, di(C₁-C₆alkyl)aminoC₁-C₆alkyl trifluoromethyl, and C₁-C₆alkyl substituted with morpholinyl; or pyridinyl; and

[0032] Alk is C₁-C₆alkanediyl.

[0033] Preferred compounds of this group include those wherein:



20

- i) R² is methyl;
- ii) R² is methyl; and Ar is substituted phenyl or 3-pyridyl;
- iii) R² is methyl; R³ is methyl; and Ar is substituted phenyl or 3-pyridyl

25

XIII. CRF antagonists of the following formula, disclosed in EP 0773023, may also be employed:

25



or a pharmaceutically acceptable salt thereof, wherein

40

the dashed line represents an optional double bond;

A is -CR₇ or N;

B is -NR₁R₂, -CR₁R₂R₁₁, -C(=CR₁R₁₂)R₂, -NHCR₁₁R₁R₂, -OCR₁₁R₁R₂, -SCR₁₁R₁R₂, -CR₁₁R₂OR₁, -CR₁₁R₂SR₁, -C(S)R₂, -NHNR₁R₂, -CR₂R₁₁NHR₁ or -C(O)R₂;

45

D is N or -CR₁₀ when a double bond connects E and D and E is -CR₄; -CR₁₀ when a double bond connects E and D and E is N; or -CR₈R₉, -CHR₁₀, -C=O, -C=S, -C=NH, or -C=NCH₃ when a single bond connects E and D;

E is -CR₄ or N when a double bond connects E and D, and E is -CR₄R₆ or -NR₆ when a single bond connects E and D;

50

Y is N or -CH;

Z is NH, O, S, -N(C₁-C₂ alkyl), or -CR₁₂R₁₃, wherein R₁₂ and R₁₃ are each, independently, hydrogen, trifluoromethyl, or methyl, or one of R₁₂ and R₁₃ is cyano and the other is hydrogen or methyl;

55

R₁ is hydrogen or C₁-C₆ alkyl which is optionally substituted with up to two substituents independently selected from hydroxy, cyano, nitro, fluoro, chloro, bromo, iodo, CF₃, C₁-C₄ alkoxy, -O-CO-(C₁-C₄ alkyl), -O-CO-NH(C₁-C₄ alkyl), -O-CO-N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -NH(C₁-C₄ alkyl), -N(C₁-C₂ alkyl)(C₁-C₄ alkyl), -S(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)CO(C₁-C₄ alkyl), -NHCO(C₁-C₄ alkyl), -CO₂(C₁-C₄ alkyl), -CONH(C₁-C₄ alkyl), -CON(C₁-C₄ alkyl)(C₁-C₂ alkyl), (C₁-C₄ alkyl)sulfinyl, (C₁-C₄ alkyl)sulfonyl, and (C₁-C₄ alkyl)sulfanyl, and wherein said C₁-C₆ alkyl, C₁-C₄ alkoxy, and C₁-C₄ alkyl moieties in the foregoing R₁ groups optionally contain one

double or triple bond;

R₂ is C₁-C₆ alkyl, heteroaryl, aryl, heteroaryl (C₁-C₄ alkyl), or aryl (C₁-C₄ alkyl), wherein said aryl and the aryl moiety of said (aryl)C₁-C₄ alkyl are selected from the group consisting of phenyl and naphthyl, and said heteroaryl and the heteroaryl moiety of said (heteroaryl)C₁-C₄ alkyl is selected from the group consisting of thienyl, benzothienyl, pyridyl, thiazolyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, and benzoxazolyl; or R² is C₃-C₈ cycloalkyl or (C₃-C₈ cycloalkyl)C₁-C₆ alkyl, wherein one or two of the ring carbons of said cycloalkyl having at least 4 ring members and the cycloalkyl moiety of said (C₃-C₈ cycloalkyl)C₁-C₆ alkyl having at least 4 ring members is optionally replaced by an oxygen or sulfur atom or by -NR₁₄ wherein R₁₄ is hydrogen or C₁-C₄ alkyl; and wherein each of the foregoing R₂ groups is optionally substituted by up to three substituents independently selected from chloro, fluoro, and C₁-C₄ alkyl, or by one substituent selected from bromo, iodo, cyano, nitro, C₁-C₆ alkoxy, -O-CO-(C₁-C₄ alkyl), -O-CO-N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -CO₂(C₁-C₄ alkyl), (C₁-C₄ alkyl)sulfanyl, (C₁-C₄ alkyl)sulfinyl, and (C₁-C₄ alkyl)sulfonyl, and wherein said C₁-C₄ alkyl and C₁-C₆ alkyl moieties of the foregoing R₂ groups optionally contain one carbon-carbon double or triple bond;

or R¹ and R² of said -NR₁R₂ and said -CR₁R₂R₁₁ are taken together to form a saturated or partially saturated 5- to 8-membered ring, wherein said ring optionally contains one or two carbon-carbon double bonds, and wherein one or two of the ring carbons is optionally replaced by a heteroatom selected from O, S, and N;

R₃ is hydrogen, C₁-C₆ alkyl, fluoro, chloro, bromo, iodo, hydroxy, amino, SH, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -CH₂OH, -CH₂OCH₃, -O(C₁-C₄ alkyl), (C₁-C₄ alkyl)sulfanyl, (C₁-C₄ alkyl)sulfonyl, or (C₁-C₄ alkyl)sulfinyl, wherein said C₁-C₆ alkyl and C₁-C₄ alkyl moieties of the foregoing R₃ groups optionally contain one double or triple bond and are optionally substituted by from one to three substituents independently selected from hydroxy, amino, C₁-C₃ alkoxy, -NH(C₁-C₂ alkyl), -N(C₁-C₂ alkyl)₂, -NHCOCH₃, fluoro, chloro, and C₁-C₃ thioalkyl;

R₄ is hydrogen, C₁-C₆ alkyl, fluoro, chloro, bromo, iodo, C₁-C₆ alkoxy, formyl, trifluoromethoxy, -CH₂OCH₃, -CH₂OCH₂CH₃, -CH₂CH₂OCH₃, -CH₂CF₃, CF₃, amino, nitro, -NH(C₁-C₄ alkyl), -N(CH₃)₂, -NHCOCH₃, -NHCONHCH₃, (C₁-C₄ alkyl)sulfanyl, (C₁-C₄ alkyl)sulfinyl, (C₁-C₄ alkyl)sulfonyl, cyano, hydroxy, -CO(C₁-C₄ alkyl), -CHO, or -CO₂(C₁-C₄ alkyl), wherein said C₁-C₆ alkyl, C₁-C₆ alkoxy, and C₁-C₄ alkyl moieties of the foregoing R₄ groups optionally contain one double or triple bond and are optionally substituted with one substituent selected from hydroxy, amino, -NHCOCH₃, -NH(C₁-C₂ alkyl), -N(C₁-C₂ alkyl)₂, -CO₂(C₁-C₄ alkyl), -CO(C₁-C₄ alkyl), C₁-C₃ alkoxy, (C₁-C₃ alkyl)sulfanyl, fluoro, chloro, cyano, and nitro;

R₅ is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzoisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, benzoxazolyl, oxazolyl, pyrrolidinyl, thiazolidinyl, morpholinyl, pyridinyl, tetrazolyl, or a 3- to 8-membered cycloalkyl ring or a 9- to 12-membered bicycloalkyl ring system, wherein said cycloalkyl ring and said bicycloalkyl ring system optionally contain one or two of O, S, or -N-G wherein G is hydrogen, C₁-C₄ alkyl, C₁-C₄ alkanoyl, phenyl, or benzyl, wherein each of the above R₅ groups is optionally substituted by up to three substituents independently selected from fluoro, chloro, C₁-C₆ alkyl, C₁-C₆ alkoxy, and trifluoromethyl, or one substituent selected from bromo, iodo, cyano, nitro, amino, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -CO₂(C₁-C₄ alkyl), -CO(C₁-C₄ alkyl), -SO₂NH(C₁-C₄ alkyl), -SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -SO₂NH₂, -NHSO₂(C₁-C₄ alkyl), -S(C₁-C₄ alkyl), and -SO₂(C₁-C₄ alkyl), wherein said C₁-C₄ alkyl and C₁-C₆ alkyl moieties of the foregoing R₅ groups optionally contain one double or triple bond and are optionally substituted by one or two substituents independently selected from fluoro, chloro, hydroxy, amino, methylamino, dimethylamino, and acetyl;

R₆ is hydrogen or C₁-C₆ alkyl, wherein said C₁-C₆ alkyl is optionally substituted by a single hydroxy, methoxy, ethoxy, or fluoro group;

R₇ is hydrogen, C₁-C₄ alkyl, fluoro, chloro, bromo, iodo, cyano, hydroxy, C₁-C₄ alkoxy, -CO(C₁-C₄ alkyl), -CO₂(C₁-C₄ alkyl), -OCF₃, CF₃, -CH₂OH, -CH₂OCH₃, or -CH₂OCH₂CH₃;

R₈ and R₉ are each, independently, hydrogen, hydroxy, methyl, ethyl, methoxy, or ethoxy; or R₈ and R₉ together form an oxo (=O) group;

R₁₀ is hydrogen, C₁-C₆ alkyl, fluoro, chloro, bromo, iodo, C₁-C₆ alkoxy, formyl, amino, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)(C₁-C₂ alkyl), cyano, carboxy, amido, or -SO_n(C₁-C₄ alkyl) wherein n is 0, 1, or 2, wherein said C₁-C₆ alkyl and C₁-C₄ alkyl moieties of the foregoing R₁₀ groups are optionally substituted by one of hydroxy, trifluoromethyl, amino, carboxy, amido, -NHCO(C₁-C₄ alkyl), -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -CO₂(C₁-C₄ alkyl), C₁-C₃ alkoxy, C₁-C₃ thioalkyl, fluoro, bromo, chloro, iodo, cyano, or nitro; and

R₁₁ is hydrogen, hydroxy, fluoro, or methoxy.

[0034] Specific CRF antagonists useful in the practice of the present invention, include, without limitation, the following compounds:

4-(1-ethyl-propoxy)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-pyridine;
 butyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-ethyl-amine;
 4-(butyl-ethylamino)-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one;
 4-(1-ethylpropoxy)-2,5-dimethyl-6-(2,4,6-trimethylphenoxy)-pyrimidine;
 5 N-butyl-N-ethyl-2,5-dimethyl-NN-(2,4,6-trimethylphenyl)-pyrimidine-4,6-diamine;
 [4-(1-ethyl-propoxy)-3,6-dimethyl-pyridin-2-yl]-2-(2,4,6-trimethylphenyl)-amine;
 10 6-(ethyl-propyl-amino)-2,7-dimethyl-9-(2,4,6-trimethylphenyl)-7,9-dihydro-purin-8-one;
 3-{(4-methyl-benzyl)-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amino}-propan-1-ol;
 15 diethyl-[6-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
 2-{butyl-[6-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amino}-ethanol;
 dibutyl-[6-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
 butyl-ethyl-[6-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
 butyl-ethyl-[6-methyl-3-methylsulfonyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
 20 butyl-cyclopropylmethyl-[6-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
 di-1-propyl-[6-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
 diallyl-[6-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
 butyl-ethyl-[6-chloro-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
 25 butyl-ethyl-[6-methoxy-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
 propyl-ethyl-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
 4-(1-ethyl-propyl)-6-methyl-3-methylsulfanyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidine;
 n-butyl-ethyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;
 di-n-propyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;
 30 ethyl-n-propyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;
 diethyl-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;
 n-butyl-ethyl-[2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;
 35 2-{N-n-butyl-N-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}-ethanol;
 4-(1-ethyl-propyl)-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine;
 n-butyl-ethyl-[2,5-dimethyl-7-(2,4-dimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;
 40 2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidyl-4-yl)-(1-ethyl-propyl)amine;
 butyl-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-ethylamine;
 [3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4,b]pyridin-4-yl]-1-methoxymethylpropyl)-amine;
 45 4-(1-methoxymethylpropoxy)-3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridine;
 (1-ethylpropyl)-[3,5,6-trimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-amine;
 4-(1-ethylpropoxy)-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-b]pyridine;
 4-(1-ethylpropoxy)-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-b]pyridine;
 50 2,5,6-trimethyl-7-(1-propylbutyl)-4-(2,4,6-trimethylphenoxy)-7H-pyrrolo[2,3-d]pyrimidine;
 1-(1-ethylpropyl)-6-methyl-4-(2,4,6-trimethylphenylamino)-1,3-dihydro-imidazo[4,5-c]pyridin-2-one;
 9-(1-ethylpropyl)-2-methyl-6-(2,4,6-trimethylphenylamino)-7,9-dihydro-purin-8-one;
 1-(1-ethylpropyl)-6-methyl-4-(2,4,6-trimethylphenoxy)-1,3-dihydro-imidazo[4,5-c]pyridin-2-one;
 1-(1-ethylpropyl)-6-methyl-4-(2,4,6-trimethylphenoxy)-1H-imidazo[4,5-c]pyridine;
 1-(1-ethylpropyl)-3,6-dimethyl-4-(2,4,6-trimethylphenoxy)-1,3-dihydro-imidazo[4,5-c]pyridin-2-one;
 55 1-(1-ethylpropyl)-3,6-dimethyl-4-(2,4,6-trimethylphenylamino)-1,3-dihydro-imidazo[4,5-c]pyridin-2-one;
 1-(1-ethyl-propyl)-4,7-dimethyl-5-(2,4,6-trimethyl-phenoxy)-1,4-dihydro-2H-pyrido[3,4-b]pyrazin-3-one;
 1-(1-ethyl-propyl)-4,7-dimethyl-5-(2,4,6-trimethyl-phenoxy)-1,2,3,4-tetrahydro-pyrido[3,4-b]pyrazine;
 1-(1-ethyl-propyl)-7-methyl-5-(2,4,6-trimethyl-phenoxy)-1,2,3,4-tetrahydro-pyrido[3,4-b]pyrazine;
 1-(1-ethyl-propyl)-7-methyl-2-oxo-5-(2,4,6-trimethyl-phenoxy)-1,2,3,4-tetra-hydro-[1,6]naphthyridine-3-carboxyl-
 ic acid methyl ester;
 1-(1-ethyl-propyl)-7-methyl-2-oxo-5-(2,4,6-trimethyl-phenoxy)-1,2,3,4-tetra-hydro-[1,6]naphthyridine-3-carboxyl-
 ic acid isopropyl ester;
 1-(1-ethyl-propyl)-7-methyl-5-(2,4,6-trimethyl-phenoxy)-3,4-dihydro-1H-[1,6]naphthyridin-2-one;
 1-(1-ethyl-propyl)-7-methyl-5-(2,4,6-trimethyl-phenoxy)-1,2,3,4-tetrahydro-[1,6]naphthyridine;
 1-(1-ethyl-propyl)-7-methyl-5-(2,4,6-trimethyl-phenoxy)-1,4-dihydro-2H-3-oxa-1,6-diaza-naphthalene;
 1-(1-ethyl-propyl)-4,7-dimethyl-5-(2,4,6-trimethyl-phenoxy)-1,4-dihydro-2H-3-oxa-1,6-diaza-naphthalene;
 1-(1-ethyl-propyl)-3,7-dimethyl-5-(2,4,6-trimethyl-phenoxy)-3,4-dihydro-1H-3-oxa-[1,6]-naphthyridin-2-one;
 1-(1-ethyl-propyl)-3,3,6-trimethyl-4-(2,4,6-trimethyl-phenoxy)-2,3-dihydro-1H-pyrrolo[3,2-c]pyridine;

7-(1-ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a] pyrimidine;
 [2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-1-ethyl-propyl)-amine;
 (1-ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-amine;
 7-(1-ethyl-propoxy)-2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidine;
 5 [2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-ethyl-propyl-amine;
 [6-bromo-5-bromomethyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl]-1-ethyl-propyl)-amine;
 (1-ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl]-amine;
 [6-bromo-5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl]-1-ethyl-propyl)-methyl-amine;
 7-(1-ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridine;
 10 4-(1-ethyl-propoxy)-2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyrimidine;
 (±)-2,5-dimethyl-4-(tetrahydro-furan-3-yloxy)-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo-[3,2-d]pyrimidine;
 2,5-dimethyl-4-(S)-(tetrahydro-furan-3-yloxy)-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo-[3,2-d]pyrimidine;
 2,5-dimethyl-4-(1-propyl-butoxy)-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyrimidine;
 4-sec-butylsulfanyl-2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyrimidine;
 15 4-(butyl-ethyl-amino)-2,6-dimethyl-8-(2,4,6-trimethyl-phenyl)-5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-7-one;
 8-(1-ethyl-propoxy)-6-methyl-4-(2,4,6-trimethyl-phenyl)-3,4-dihydro-1H-pyrido[2,3-b] pyrazin-2-one;
 8-(1-ethyl-propoxy)-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydro-pyrido [2,3-b]pyrazine;
 4-(1-ethyl-propoxy)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline;
 5-(1-ethyl-propoxy)-7-methyl-1-(2,4,6-trimethyl-phenyl)-1,4-dihydro-2H-3-oxa-1,8-diaza-naphthalene;
 20 5-(1-ethyl-propoxy)-7-methyl-1-(2,4,6-trimethyl-phenyl)-1,2-dihydro-3-oxa-1, 8-diaza-naphthalen-4-one;
 8-(1-ethyl-propoxy)-1,6-dimethyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine;
 (1-ethyl-propyl)-[2-methyl-8-(2,4,6-trimethyl-phenyl)-quinolin-4-yl]-amine;
 4-(butyl-ethyl-amino)-2,6-dimethyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-7-one;
 25 4-(butyl-ethyl-amino)-2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,8-dihydro-6H- pyrido[2,3-d]pyrimidin-7-one;
 4-(1-ethyl-propoxy)-2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,8-dihydro-6 H- pyrido[2,3-d]pyrimidin-7-one;
 (butyl-ethyl)-[2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-4-yl]-amine;
 (propyl-ethyl)-[2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-4-yl]-amine;
 (diethyl)-[2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,6,7,8-tetrahydro-pyrido [2,3-d]pyrimidin-4-yl]-amine;
 30 (1-ethyl-propyl)-[2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-4-yl]-amine;
 (1-ethyl-propoxy)-2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,6,7,8-tetrahydro- pyrido[2,3-d]pyrimidine;
 4-(butyl-ethyl-amino)-2-methyl-8-(2,4,6-trimethyl-phenyl)-5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-7-one;
 4-(1-ethyl-propoxy)-2-methyl-8-(2,4,6-trimethyl-phenyl)-5,8-dihydro-6H-pyrido [2,3-d]pyrimidin-7-one;
 35 (butyl-ethyl)-[2-methyl-8-(2,4,6-trimethyl-phenyl)-5,6,7,8-tetrahydro-pyrido[2, 3-d] pyrimidin-4-yl]-amine;
 (propyl-ethyl)-[2-methyl-8-(2,4,6-trimethyl-phenyl)-5,6,7,8-tetrahydro-pyrido-[2,3-d] pyrimidin-4-yl]-amine;
 (diethyl)-[2-methyl-8-(2,4,6-trimethyl-phenyl)-5,6,7,8-tetrahydro-pyrido[2,3-d] pyrimidin-4-yl]-amine;
 (1-ethyl-propyl)-[2-methyl-8-(2,4,6-trimethyl-phenyl)-5,6,7,8-tetrahydro-pyrido[2,3-d] pyrimidin-4-yl]-amine;
 (1-ethyl-propoxy)-2-methyl-8-(2,4,6-trimethyl-phenyl)-5,6,7,8-tetrahydro-pyrido[2,3-d] pyrimidine;
 40 8-(1-ethyl-propoxy)-6-methyl-4-(2,6-dimethyl-4-bromo-phenyl)-3,4-dihydro-1 H-pyrido [2,3-b]pyrazin-2-one;
 8-(1-ethyl-propoxy)-6-methyl-4-(2,6-dimethyl-4-bromo-phenyl)-1,2,3,4-tetrahydro- pyrido[2,3-b]pyrazine;
 4-(1-ethyl-propoxy)-2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-quinoline;
 5-(1-ethyl-propoxy)-7-methyl-1-(2,6-dimethyl-4-bromo-phenyl)-1,4-dihydro-2 H- 3-oxa-1,8-diaza-naphthalene;
 5-(1-ethyl-propoxy)-7-methyl-1-(2,6-dimethyl-4-bromo-phenyl)-1,2-dihydro-3 - oxa-1,8-diaza-naphthalen-4-one;
 45 8-(1-ethyl-propoxy)-1,6-dimethyl-4-(2,6-dimethyl-4-bromo-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine;
 (1-ethyl-propyl)-[2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-quinolin-4-yl]-amine;
 4-(butyl-ethyl-amino)-2,6-dimethyl-8-(2,6-dimethyl-4-chloro-phenyl)-5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-7-one;
 50 8-(1-ethyl-propoxy)-6-methyl-4-(2,6-dimethyl-4-chloro-phenyl)-3,4-dihydro-1 H- pyrido[2,3-b]pyrazin-2-one;
 8-(1-ethyl-propoxy)-6-methyl-4-(2,6-dimethyl-4-chloro-phenyl)-1,2,3,4-tetrahydro- pyrido[2,3-b]pyrazine;
 4-(1-ethyl-propoxy)-2-methyl-8-(2,6-dimethyl-4-chloro-phenyl)-quinoline;
 5-(1-ethyl-propoxy)-7-methyl-1-(2,6-dimethyl-4-chloro-phenyl)-1,4-dihydro-2H-3-oxa-1,8-diaza-naphthalene;
 5-(1-ethyl-propoxy)-7-methyl-1-(2,6-dimethyl-4-chloro-phenyl)-1,2-dihydro-3-oxa-1,8-diaza-naphthalen-4-one;
 55 8-(1-ethyl-propoxy)-1,6-dimethyl-4-(2,6-dimethyl-4-chloro-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine;
 (1-ethyl-propyl)-[2-methyl-8-(2,6-dimethyl-4-chloro-phenyl)-quinolin-4-yl]-amine;
 8-(1-hydroxymethyl-propoxy)-6-methyl-4-(2,4,6-trimethyl-phenyl)-3,4-dihydro - 1 H-pyrido[2,3-b]pyrazin-2-one;
 8-(1-hydroxymethyl-propylamino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-one;

- 8-(1-ethyl-propylamino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-one;
 8-diethylamino-6-methyl-4-(2,4,6-trimethyl-phenyl)-3,4-dihydro-1H-pyrido-[2,3-b] pyrazin-2-one;
 8-(ethyl-propyl-amino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-one;
 8-(butyl-ethyl-amino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-3,4-dihydro-1H-pyrido [2,3-b]pyrazin-2-one;
 8-(1-hydroxymethyl-propoxy)-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine;
 8-(1-hydroxymethyl-propylamino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4 - tetrahydro-pyrido[2,3-b]pyrazine;
 8-(1-ethyl-propylamino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine;
 8-diethylamino-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine;
 8-(ethyl-propyl-amino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydro - pyrido[2,3-b]pyrazine;
 8-(butyl-ethyl-amino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine;
 4-(1-hydroxymethyl-propoxy)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline;
 4-(1-hydroxymethyl-propylamino)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline;
 4-(1-ethyl-propylamino)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline;
 4-diethylamino-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline;
 4-(ethyl-propyl-amino)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline;
 4-(butyl-ethyl-amino)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline;
 5-(1-hydroxymethyl-propoxy)-7-methyl-1-(2,4,6-trimethyl-phenyl)-1,4-dihydro - 2H-3-oxa-1,8-diaza-naphthalene;
 5-(1-hydroxymethyl-propylamino)-7-methyl-1-(2,4,6-trimethyl-phenyl)-1,4-dihydro-2H-3-oxa-1,8-diaza-naphtha-
 lene;
 5-(1-ethyl-propylamino)-7-methyl-1-(2,4,6-trimethyl-phenyl)-1,4-dihydro-2H-3-oxa-1,8-diaza-naphthalene;
 5-diethylamino-5-methyl-1-(2,4,6-trimethyl-phenyl)-1,4-dihydro-2H-3-oxa-1,8 - diaza-naphthalene;
 5-(ethyl-propyl-amino)-7-methyl-1-(2,4,6-trimethyl-phenyl)-1,4-dihydro-2H-3-oxa-1,8-diaza-naphthalene;
 8-(butyl-ethyl-amino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,4-dihydro-2H-3-oxa-1,8-diaza-naphthalene;
 4-(2,4-dichlorophenyl)-5-methyl-2-[N-(1-(methoxymethyl)-1-(naphth-2-yl) methyl)-N-propylamino]thiazole;
 25 oxalate of 4-(2,4-dichlorophenyl)-5-methyl-2-[N-(6-methoxyisoquinol-5-yl)-N-propylamino]thiazole;
 oxalate of 4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(6-methoxyisoquinol-5 -yl)-N-propylamino]thiazole;
 4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(1-methoxycarbonylmethylindol - 5-yl)-N-propylamino]thiazole;
 oxalate of -(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(6-methoxyisoquinol-5-yl)-N-propylamino]thiazole;
 oxalate of 4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(6-chloroisoquinol-5 -yl)-N- propylamino]thiazole;
 30 oxalate of -(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(6-methoxyisoquinol-5 -yl)-N- propylamino]thiazole;
 4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-1-methoxynaphth-2-yl)-N-propylamino]thiazole;
 oxalate of 4-(2-chloro-4-trifluoromethylphenyl)-5-methyl-2-[N-6-methoxyisoquinol-5-yl)-N-propylamino]thiazole;
 chlorhydrate of 4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(2-ethoxynaphth-1-yl)-N- propylamino]thiazole;
 35 chlorhydrate of 4-(2-chloro-4-methoxyphenyl)-5-methyl-2[N-(2,3-dimethylnaphth-1-yl)-N-propylamino]thiazole;
 chlorhydrate of 4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(6-bromo-2-methoxynaphth-1-yl)-N-propylamino]thi-
 azole;
 chlorhydrate of 4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(2,6-dimethylnaphth-1-yl)-N-propylamino]thiazole;
 chlorhydrate of 4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(1-(methoxymethyl)-1-(naphth-2-yl)methyl)-N-pro-
 pylamino]thiazole;
 40 chlorhydrate of 4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(1-(cyclopropyl)-1-(naphth-2-yl)methyl)-N-pro-
 pylamino]thiazole;
 3-(2,4-dichlorophenyl)-5-methyl-7(N-propyl-N-cyclopropanemethylamino)pyrazolo[2,3-a]pyrimidine;
 3-(2,4-dichlorophenyl)-5-methyl-7-(N-allyl-N-cyclopropanemethylamino)pyrazolo[2,3-a]pyrimidine;
 2-methylthio-3-(2,4-dichlorophenyl)-5-methyl-7-(N,N-diallylamino)pyrazolo[2,3-a]pyrimidine;
 45 2-methylthio-3-(2,4-dichlorophenyl)-5-methyl-7-(N-butyl-N-cyclopropane-methyl-amino)pyrazolo[2,3-a]pyrimi-
 dine;
 2-methylthio-3-(2,4-dichlorophenyl)-5-methyl-7-(N-propyl-N-cyclopropane-methyl-amino)pyrazolo[2,3-a]pyrimi-
 dine;
 2-methyl-3-(4-chlorophenyl)-5-methyl-7-(N,N-dipropylamino)-pyrazolo[2,3-a] pyrimidine;
 50 3-[6-(dimethylamino)-3-pyridinyl-2,5-dimethyl-N,N-dipropylpyrazolo[2,3-a] pyrimidin-7-amine;
 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-N,N-dipropyl-pyrazolo[2,3-a]pyrimidine-7-amine;
 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-7-(N-propyl-N-methoxyethylamino)pyrazolo(2,3-a)pyrimidine;
 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-N-propyl-N-cyclopropylmethyl-pyrazolo[2,3-a]pyrimidin-
 7-amine;
 55 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-N-ethyl-N-cyclopropylmethyl-pyrazolo[2,3-a]pyrimidin-
 7-amine;
 7-(N-diethylamino)-2,5-dimethyl-3-(2-methyl-4-methoxyphenyl)-[1,5-a]-pyrazolopyrimidine;
 7-(N-(3-cyanopropyl)-N-propylamino-2,5,dimethyl-3-(2,4-dimethylphenyl)-[1,5-a]-pyrazolopyrimidine;

[3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-(1-ethyl-propyl)-amine;
 [2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-(1-ethylpropyl)-amine;
 cyclopropylmethyl-[3-(2,4-dimethyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-propyl-amine;
 cyclopropylmethyl-[3-(2-methyl-4-chloro-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-propyl-amine;
 cyclopropylmethyl-[3-(2,4-di-chloro-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-propyl-amine;
 [3-(2-methyl-4-chloro-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-di-propyl-amine;
 [2,5-dimethyl-3-(2,4-dimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-(1-ethyl-propyl)-amine;
 [2,5-dimethyl-3-(2,4-dichloro-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-(1-ethyl-propyl)-amine; and
 4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester.

10

[0035] Even more particularly, specific CRF antagonists useful in the practice of the present invention include, without limitation, the following compounds:

4-(1-ethyl-propoxy)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-pyridine;
 4-(1-ethylpropoxy)-2,5-dimethyl-6-(2,4,6-trimethylphenoxy)-pyrimidine;
 [4-(1-ethyl-propoxy)-3,6-dimethyl-pyridin-2-yl]-(2,4,6-trimethylphenyl)-amine;
 3-{(4-methyl-benzyl)-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amino}-propan-1-ol;
 propyl-ethyl-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
 ethyl-n-propyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;
 2-{N-n-butyl-N-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}-ethanol;
 [3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4,b]pyridin-4-yl]-(1-methoxymethylpropyl)-amine;
 4-(1-ethylpropoxy)-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-b]pyridine;
 2,5,6-trimethyl-7-(1-propylbutyl)-4-(2,4,6-trimethylphenoxy)-7H-pyrrolo[2,3-d]pyrimidine;
 1-(1-ethylpropyl)-6-methyl-4-(2,4,6-trimethylphenoxy)-1,3-dihydro-imidazo[4,5-c]pyridin-2-one;
 1 -(1 -ethyl-propyl)-4,7-dimethyl-5-(2,4,6-trimethyl-phenoxy)-1,4-dihydro-2H-pyrido[3,4-b]pyrazin-3-one;
 1 -(1 -ethyl-propyl)-4,7-dimethyl-5-(2,4,6-trimethyl-phenoxy)-1,2,3,4-tetrahydro-pyrido[3,4-b]pyrazine;
 1-(1-ethyl-propyl)-7-methyl-2-oxo-5-(2,4,6-trimethyl-phenoxy)-1,2,3,4-tetra-hydro-[1,6]naphthyridine-3-carboxylic acid isopropyl ester;
 1 -(1 -ethyl-propyl)-7-methyl-5-(2,4,6-trimethyl-phenoxy)-1,4-dihydro-2H-3-oxa-1,6-diaza-naphthalene;
 (1-ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-amine;
 7-(1-ethyl-propoxy)-2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidine;
 4-(1-ethyl-propoxy)-2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyrimidine;
 4-(butyl-ethyl-amino)-2,6-dimethyl-8-(2,4,6-trimethyl-phenyl)-5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-7-one;
 8-(1-ethyl-propoxy)-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydro-pyrido [2,3-b]pyrazine;
 4-(1-ethyl-propoxy)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline;
 (1-ethyl-propyl)-[2-methyl-8-(2,4,6-trimethyl-phenyl)-quinolin-4-yl]-amine;
 (propyl-ethyl)-[2-methyl-8-(2,4,6-trimethyl-phenyl)-5,6,7,8-tetrahydro-pyrido-[2,3-d] pyrimidin-4-yl]-amine;
 (1-ethyl-propoxy)-2-methyl-8-(2,4,6-trimethyl-phenyl)-5,6,7,8-tetrahydro-pyrido[2,3-d] pyrimidine;
 40 8-(1-hydroxymethyl-propylamino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-3,4-dihydro-1 H-pyrido[2,3-b]pyrazin-2-one;
 4-(1-hydroxymethyl-propylamino)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline;
 5-(1-hydroxymethyl-propylamino)-7-methyl-1-(2,4,6-trimethyl-phenyl)-1,4-dihydro-2H-3-oxa-1,8-diaza-naphthalene;
 45 [3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-(1-ethyl-propyl)-amine;
 cyclopropylmethyl-[3-(2,4-dimethyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-propyl-amine;
 [2,5-dimethyl-3-(2,4-dimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-(1-ethyl-propyl)-amine;
 3-[6-(dimethylamino)-3-pyridinyl-2,5-dimethyl-N,N-dipropylpyrazolo[2,3-a] pyrimidin-7-amine;
 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-N,N-dipropyl-pyrazolo[2,3-a]pyrimidine-7-amine;
 50 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-7-(N-propyl-N-methoxyethylamino)-pyrazolo(2,3-a)pyrimidine;
 7-(N-diethylamino)-2,5-dimethyl-3-(2-methyl-4-methoxyphenyl)-pyrazolopyrimidine; and
 7-(N-(3-cyanopropyl)-N-propylamino-2,5,dimethyl-3-(2,4-dimethylphenyl)-[1,5-a]-pyrazolopyrimidine.

55

[0036] Methods for making the CRF antagonists described above are disclosed in the above-listed patents and published patent applications incorporated by reference herein.


[0037] In one aspect of the present invention, a CRF antagonist may be used in combination with a GR antagonist. The glucocorticoid receptor (GR) is present in glucocorticoid responsive cells where it resides in the cytosol in an inactive state until it is stimulated by an agonist. Upon stimulation the glucocorticoid receptor translocates to the cell

- nucleus where it specifically interacts with DNA and/or protein(s) and regulates transcription in a glucocorticoid responsive manner. Two examples of proteins that interact with the glucocorticoid receptor are the transcription factors, API and NFK-B. Such interactions result in inhibition of API- and NF κ -B- mediated transcription and are believed to be responsible for the antiinflammatory activity of endogenously administered glucocorticoids. In addition, glucocorticoids may also exert physiologic effects independent of nuclear transcription. Biologically relevant glucocorticoid receptor agonists include cortisol and corticosterone. Many synthetic glucocorticoid receptor agonists exist including dexamethasone, prednisone and prednisolone. As defined above, a glucocorticoid receptor (GR) antagonist refers to a compound that binds to the receptor and prevents a glucocorticoid receptor agonist from binding and eliciting GR mediated events, including transcription. RU486 is an example of a non-selective glucocorticoid receptor antagonist.
- [0038] Any GR antagonist can be used to practice the present invention, including those that are described in commonly assigned International patent application, PCT/IB00/00366, filed 27 March 2000; U.S. Patent No. 5,696,127; International patent publications WO 99/41256 and WO 99/41257; U.S. Patent 5,696,127; European patent publication 188396; European patent publication 683172; International patent publication WO 98/26783; International patent publication WO 98/27986; International patent publication WO 98/31702; European patent publication 903146; and International patent publications WO 99/41256 and WO 99/41257. As noted above, the texts of all of these applications and publications are incorporated by reference herein in their entireties.
- [0039] Following are listed particular examples of GR antagonists that may be used in practicing the present invention. It is understood that the variables, e.g., "A", "B", "R₁", "R₂", etc., employed in the generic formula IA below have the meanings attributed to them only with respect to that particular formula.
- [0040] For example, the GR antagonists may be of the following structural formula IA, including the pharmaceutically acceptable salts thereof, as described in commonly assigned International patent application, PCT/IB00/00366, filed 27 March 2000:

25

30

35




40

an isomer thereof, a prodrug of said compound or isomer, or a pharmaceutically acceptable salt of said compound, isomer or prodrug;
wherein m is 1 or 2;

45

... represents an optional bond;
A is selected from the group consisting of


50



and

55

5



A-5

- 10 D is CR₇, CR₇R₁₆, N, NR₇ or O;
 E is C, CR₆ or N;
 F is CR₄, CR₄R₅ or O;
 G, H and I together with 2 carbon atoms from the A-ring or 2 carbon atoms from the B-ring form a 5-membered heterocyclic ring comprising one or more N, O or S atoms; provided that there is at most one of O and S per ring;
 15 J, K, L and M together with 2 carbon atoms from the B-ring forms a 6-membered heterocyclic ring comprising 1 or more N atoms;
 X is a) absent, b) -CH₂-, c) -CH(OH)- or d) -C(O)-;
 R₁ is a) -H, b) -Z-CF₃, c) -(C₁-C₆)alkyl, d) -(C₂-C₆)alkenyl, e) -(C₂-C₆)alkynyl, f) -CHO, g) -CH=N-OR₁₂, h) -Z-C(O)OR₁₂, i) -Z-C(O)-NR₁₂R₁₃, j) -Z-C(O)-NR₁₂-Z-het, k) -Z-NR₁₂R₁₃, l) -Z-NR₁₂het, m) -Z-het, n) -Z-O-het, o) -Z-aryl', p) -Z-O-aryl', q) -CHOH-aryl' or r) -C(O)-aryl' wherein aryl' in substituents o) to r) is substituted independently with 0, 1 or 2 of the following: -Z-OH, -Z-NR₁₂R₁₃, -Z-NR₁₂-het, -C(O)NR₁₂R₁₃, -C(O)O(C₁-C₆)alkyl, -C(O)OH, -C(O)-het, -NR₁₂-C(O)-(C₁-C₆)alkyl, -NR₁₂-C(O)-(C₂-C₆)alkenyl, -NR₁₂-C(O)-(C₂-C₆)alkynyl, -NR₁₂-C(O)-Z-het, -CN, -Z-het, -O-(C₁-C₃)alkyl-C(O)-NR₁₂R₁₃, -O-(C₁-C₃)alkyl-C(O)O(C₁-C₆)alkyl, -NR₁₂-Z-C(O)O(C₁-C₆)alkyl, -N(Z-C(O)O(C₁-C₆)alkyl)₂, -NR₁₂-Z-C(O)-NR₁₂R₁₃, -Z-NR₁₂-SO₂-R₁₃, -NR₁₂-SO₂-het, -C(O)H, -Z-NR₁₂-Z-O(C₁-C₆)alkyl, -Z-NR₁₂-Z-NR₁₂R₁₃, -Z-NR₁₂-(C₃-C₆)cycloalkyl, -Z-N(Z-O(C₁-C₆)alkyl)₂, -SO₂R₁₂, -SOR₁₂, -SR₁₂, -SO₂NR₁₂R₁₃, -O-C(O)-(C₁-C₄)alkyl, -O-SO₂-(C₁-C₄)alkyl, -halo or -CF₃;
 Z for each occurrence is independently a) -(C₀-C₆)alkyl, b) -(C₂-C₆)alkenyl or c) -(C₂-C₆)alkynyl;
 R₂ is a) -H, b) -halo, c) -OH, d) -(C₁-C₆)alkyl substituted with 0 or 1 -OH, e) -NR₁₂R₁₃, f) -Z-C(O)O(C₁-C₆)alkyl, g) -Z-C(O)NR₁₂R₁₃, h) -O-(C₁-C₆)alkyl, i) -Z-O-C(O)-(C₁-C₆)alkyl, j) -Z-O-(C₁-C₃)alkyl-C(O)-NR₁₂R₁₃, k) -Z-O-(C₁-C₃)alkyl-C(O)-O(C₁-C₆)alkyl, l) -O-(C₂-C₆)alkenyl, m) -O-(C₂-C₆)alkynyl, n) -O-Z-het, o) -COOH, p) -C(O)H R₁₂R₁₃ or q) -Z-CN;
 R₃ is a) -H, b) -(C₁-C₁₀)alkyl wherein 1 or 2 carbon atoms, other than the connecting carbon atom, may optionally be replaced with 1 or 2 heteroatoms independently selected from S, O and N and wherein each carbon atom is substituted with 0, 1 or 2 R_y, c) -(C₂-C₁₀)alkenyl substituted with 0, 1 or 2 R_y, d) -(C₂-C₁₀)alkynyl wherein 1 carbon atom, other than the connecting carbon atom, may optionally be replaced with 1 oxygen atom and wherein each carbon atom is substituted with 0, 1 or 2 R_y, e) -CH=C=CH₂, f) -CN, g) -(C₃-C₆)cycloalkyl, h) -Z-aryl, i) -Z-het, j) -C(O)O(C₁-C₆)alkyl, k) -O(C₁-C₆)alkyl, l) -Z-S-R₁₂, m) -Z-S(O)-R₁₂, n) -Z-S(O)₂-R₁₂, o) -CF₃ p) -NR₁₂O-(C₁-C₆)alkyl or q) -CH₂OR_y;
 provided that one of R₂ and R₃ is absent when there is a double bond between CR₂R₃ (the 7 position) and the F moiety (the 8 position) of the C-ring;
 40 R_y for each occurrence is independently a) -OH, b) -halo, c) -Z-CF₃, d) -Z-CF(C₁-C₃ alkyl)₂, e) -CN, f) -NR₁₂R₁₃, g) -(C₃-C₆)cycloalkyl, h) -(C₃-C₆)cycloalkenyl, i) -(C₀-C₃)alkyl-aryl, j) -het or k) -N₃;
 or R₂ and R₃ are taken together to form a) =CHR₁₁, b) =NOR₁₁, c) =O, d) =N-NR₁₂, e) =N-NR₁₂-C(O)-R₁₂, f) oxiranyl or g) 1,3-dioxolan-4-yl;
 45 R₄ and R₅ for each occurrence are independently a) -H, b) -CN, c) -(C₁-C₆)alkyl substituted with 0 to 3 halo, d) -(C₂-C₆)alkenyl substituted with 0 to 3 halo, e) -(C₂-C₆)alkynyl substituted with 0 to 3 halo, f) -O-(C₁-C₆)alkyl substituted with 0 to 3 halo, g) -O-(C₂-C₆)alkenyl substituted with 0 to 3 halo, h) -O-(C₂-C₆)alkynyl substituted with 0 to 3 halo, i) halo, j) -OH, k) (C₃-C₆)cycloalkyl or l) (C₃-C₆)cycloalkenyl;
 or R₄ and R₅ are taken together to form =O;
 50 R₆ is a) -H, b) -CN, c) -(C₁-C₆)alkyl substituted with 0 to 3 halo, d) -(C₂-C₆)alkenyl substituted with 0 to 3 halo, e) -(C₂-C₆)alkynyl substituted with 0 to 3 halo or f) -OH;
 R₇ and R₁₆ for each occurrence are independently a) -H, b) -halo, c) -CN, d) -(C₁-C₆)alkyl substituted with 0 to 3 halo, e) -(C₂-C₆)alkenyl substituted with 0 to 3 halo or f) -(C₂-C₆)alkynyl substituted with 0 to 3 halo; provided that R₇ is other than -CN or -halo when D is NR₇;
 55 or R₇ and R₁₆ are taken together to form =O;
 R₈, R₉, R₁₄ and R₁₅ for each occurrence are independently a) -H, b) -halo, c) (C₁-C₆)alkyl substituted with 0 to 3 halo, d) -(C₂-C₆)alkenyl substituted with 0 to 3 halo, e) -(C₂-C₆)alkynyl substituted with 0 to 3 halo, f) -CN, g) -(C₃-C₆)cycloalkyl, h) -(C₃-C₆)cycloalkenyl, i) -OH, j) -O-(C₁-C₆)alkyl, k) -O-(C₁-C₆)alkenyl, l) -O-(C₁-C₆)alkynyl, m)

-NR₁₂R₁₃, n) -C(O)OR₁₂ or o) -C(O)NR₁₂R₁₃;
 or R₈ and R₉ are taken together on the C-ring to form =O; provided that when m is 2, only one set of R₈ and R₉ are taken together to form =O;
 or R₁₄ and R₁₅ are taken together to form =O; provided that when R₁₄ and R₁₅ are taken together to form =O, D is other than CR₇ and E is other than C;
 5 R₁₀ is a) -(C₁-C₁₀)alkyl substituted with 0 to 3 substituents independently selected from -halo, -OH and -N₃, b) -(C₂-C₁₀)alkenyl substituted with 0 to 3 substituents independently selected from -halo, -OH and -N₃, c) -(C₂-C₁₀)alkynyl substituted with 0 to 3 substituents independently selected from -halo, -OH and -N₃, d) -halo, e) -Z-CN, f) -OH, g) -Z-het, h) -Z-NR₁₂R₁₃, i) -Z-C(O)-het, j) -Z-C(O)-(C₁-C₆)alkyl, k) -Z-C(O)-NR₁₂R₁₃, l) -Z-C(O)-NR₁₂-Z-CN, m) -Z-C(O)-NR₁₂-Z-het, n) -Z-C(O)-NR₁₂-Z-aryl, o) -Z-C(O)-NR₁₂-Z-NR₁₂R₁₃, p) -Z-C(O)-NR₁₂-Z-O(C₁-C₆)alkyl, q) -(C₀-C₆)alkyl-C(O)OH, r) -Z-C(O)O(C₁-C₆)alkyl, s) -Z-O-(C₀-C₆)alkyl-het, t) -Z-O-(C₀-C₆)alkyl-aryl, u) -Z-O-(C₁-C₆)alkyl substituted with 0 to 2 R_x, v) -Z-O-(C₁-C₆)alkyl-CH(O), w) -Z-O-(C₁-C₆)alkyl-NR₁₂-het, x) -Z-O-Z-het-Z-het, y) -Z-O-Z-het-Z-NR₁₂R₁₃, z) -Z-O-Z-het-C(O)-het, a1) -Z-O-Z-C(O)-het, b1) -Z-O-Z-C(O)-het-het, c1) -Z-O-Z-C(O)-(C₁-C₆)alkyl, d1) -Z-O-Z-C(S)-NR₁₂R₁₃, e1) -Z-O-Z-C(O)-NR₁₂R₁₃, f1) -Z-O-Z-(C₁-C₃)alkyl-C(O)-NR₁₂R₁₃, g1) -Z-O-Z-C(O)-O(C₁-C₆)alkyl, h1) -Z-O-Z-C(O)-OH, i1) -Z-O-Z-C(O)-NR₁₂-O(C₁-C₆)alkyl, j1) -Z-O-Z-C(O)-NR₁₂-OH, k1) -Z-O-Z-C(O)-NR₁₂-Z-NR₁₂R₁₃, l1) -Z-O-Z-C(O)-NR₁₂-Z-het, m1) -Z-O-Z-C(O)-NR₁₂-SO₂(C₁-C₆)alkyl, n1) -Z-O-Z-C(=NR₁₂)(NR₁₂R₁₃), o1) -Z-O-Z-C(=NOR₁₂)(NR₁₂R₁₃), p1) -Z-NR₁₂-C(O)-O-Z-NR₁₂R₁₃, q1) -Z-S-C(O)-NR₁₂R₁₃, r1) -Z-O-SO₂(C₁-C₆)alkyl, s1) -Z-O-SO₂-aryl, t1) -Z-O-SO₂-NR₁₂R₁₃, u1) -Z-O-SO₂-CF₃, v1) -Z-NR₁₂C(O)OR₁₃ or w1) -Z-NR₁₂C(O)R₁₃;
 20 or R_g and R₁₀ are taken together on the moiety of formula A-5 to form a) =O or b) =NOR₁₂;
 R₁₁ is a) -H, b) -(C₁-C₅)alkyl, c) -(C₃-C₆)cycloalkyl or d) -(C₀-C₃)alkyl-aryl;
 R₁₂ and R₁₃ for each occurrence are each independently a) -H, b) -(C₁-C₆)alkyl wherein 1 or 2 carbon atoms, other than the connecting carbon atom, may optionally be replaced with 1 or 2 heteroatoms independently selected from S, O and N and wherein each carbon atom is substituted with 0 to 6 halo, c) -(C₂-C₆)alkenyl substituted with 0 to 6 halo or d) -(C₁-C₆)alkynyl wherein 1 carbon atom, other than the connecting carbon atom, may optionally be replaced with 1 oxygen atom and wherein each carbon atom is substituted with 0 to 6 halo;
 25 or R₁₂ and R₁₃ are taken together with N to form het;
 or R₆ and R₁₄ or R₁₅ are taken together to form 1,3-dioxolanyl;
 aryl is a) phenyl substituted with 0 to 3 R_x, b) naphthyl substituted with 0 to 3 R_x or c) biphenyl substituted with 0 to 3 R_x;
 30 het is a 5-, 6- or 7-membered saturated, partially saturated or unsaturated ring containing from one (1) to three (3) heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocycle; and the nitrogen may be in the oxidized state giving the N-oxide form; and substituted with 0 to 3 R_x;
 35 R_x for each occurrence is independently a) -halo, b) -OH, c) -(C₁-C₆)alkyl, d) -(C₂-C₆)alkenyl, e) -(C₂-C₆)alkynyl, f) -O(C₁-C₆)alkyl, g) -O(C₂-C₆)alkenyl, h) -O(C₂-C₆)alkynyl, i) -(C₀-C₆)alkyl-NR₁₂R₁₃, j) -C(O)-NR₁₂R₁₃, k) -Z-SO₂R₁₂, l) -Z-SOR₁₂, m) -Z-SR₁₂, n) -NR₁₂-SO₂R₁₃, o) -NR₁₂-C(O)-R₁₃, p) -NR₁₂-OR₁₃, q) -SO₂-NR₁₂R₁₃, r) -CN, s) -CF₃, t) -C(O)(C₁-C₆)alkyl, u) =O, v) -Z-SO₂-phenyl or w) -Z-SO₂-het';
 aryl' is phenyl, naphthyl or biphenyl;
 40 het' is a 5-, 6- or 7-membered saturated, partially saturated or unsaturated ring containing from one (1) to three (3) heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocycle;
 provided that:
 45 1) X-R₁ is other than hydrogen or methyl;
 2) when R₉ and R₁₀ are substituents on the A-ring, they are other than mono- or di-methoxy;
 3) when R₂ and R₃ are taken together to form =CHR₁₁ or =O wherein R₁₁ is -O(C₁-C₆)alkyl, then -X-R₁ is other than (C₁-C₄)alkyl;
 50 4) when R₂ and R₃ taken together are C=O and R₉ is hydrogen on the A-ring; or when R₂ is hydroxy, R₃ is hydrogen and R₉ is hydrogen on the A-ring, then R₁₀ is other than -O-(C₁-C₆)alkyl or -O-CH₂-phenyl at the 2-position of the A-ring;
 55 5) when X-R₁ is (C₁-C₄)alkyl, (C₂-C₄)alkenyl or (C₂-C₄)alkynyl, R₉ and R₁₀ are other than mono-hydroxy or =O, including the diol form thereof, when taken together; and
 6) when X is absent, R₁ is other than a moiety containing a heteroatom independently selected from N, O or S directly attached to the juncture of the B-ring and the C-ring.

[0041] The compounds of formula IA as described above, their pharmaceutically acceptable salts, and methods of preparing such compounds and salts are disclosed in commonly assigned International patent application PCT/

IB00/00366, filed 27 March 2000. This application, referred to above, is incorporated herein by reference in its entirety.

[0042] Specific GR antagonists useful in the practice of the present invention include, without limitation, the following compounds:

- 5 2-phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-N-(4-pyridinylmethyl)-, [4bS-(4b α ,7 α ,8a β)]-;
- 2-phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-N-(2-pyridinylmethyl)-, [4bS-(4b α ,7 α ,8a β)]-;
- 10 2-phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-N-(3-pyridinylmethyl)-, [4bS-(4b α ,7 α ,8a β)]-;
- carbamic acid, [2-(dimethylamino)ethyl]-, 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester, [4bS-(4b α ,7 α ,8a β)]-;
- 15 2-phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-N-pyrazinyl-, [4bS-(4b α ,7 α ,8a β)]-;
- 2-phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(4-pyridinylmethoxy)-, [2R-(2 α ,4a α ,10a β)];
- 2-phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(2-pyridinylmethoxy)-, [2R-(2 α ,4a α ,10a β)];
- 20 2-phenanthrenecarbonitrile, 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-, [4bS-(4b α ,7 α ,8a β)]-;
- 2-phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-N-[(2-methyl-3-pyridinyl)methyl]-4b-(phenylmethyl)-7-(1-propynyl)-, [4bS-(4b α ,7 α ,8a β)]-;
- 25 2-phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-N-[(2-methyl-3-pyridinyl)methyl]-4b-(phenylmethyl)-7-propyl-, [4bS-(4b α ,7 α ,8a β)]-;
- 2-phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-N-(2-pyridinylmethyl)-, [4bS-(4b α ,7 α ,8a β)]-;
- 2-phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-2-(3,3,3-trifluoropropyl)-, [2S-(2 α ,4a α ,10a β)]-;
- 2-phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-(3,3,3-trifluoropropyl)-, [2S-(2 α ,4a α ,10a β)]-;
- 30 2-phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-N-[(2-methyl-3-pyridinyl)methyl]-4b-(phenylmethyl)-7-(3,3,3-trifluoropropyl)-, (4bS,7S,8aR);
- 2-phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-methyl-N-[(2-methyl-3-pyridinyl)methyl]-4b-(phenylmethyl)-, (4bS,7R,8aR)-;
- 35 2-phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-methyl-4b-(phenylmethyl)-N-3-pyridinyl-, (4bS,7R,8aR)-;
- 2-phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR)-; and
- 2-phenanthrenecarboxamide, 4b, 5, 6, 7, 8, 8a, 9, 10-octahydro-7-hydroxy-N-[(2-methyl-3-pyridinyl)methyl]-4b-(phenylmethyl)-7-(trifluoromethyl)-, (4bS, 7R, 8aR)-.

[0043] Methods for making the GR antagonists described above are available in the art and disclosed in the above listed patents, applications and published patent applications incorporated by reference herein.

[0044] Acid addition salts of the CRF antagonists and GR antagonists employed in the present invention can be prepared in a conventional manner by treating a solution or suspension of the corresponding free base with one chemical equivalent of a pharmaceutically acceptable acid. Conventional concentration or crystallization techniques can be employed to isolate the salts. Illustrative of suitable acids are acetic, lactic, succinic, maleic, tartaric, citric, gluconic, ascorbic, benzoic, cinnamic, fumaric, sulfuric, phosphoric, hydrochloric, hydrobromic, hydroiodic, sulfamic, sulfonic acids such as methanesulfonic, benzene sulfonic, p-toluenesulfonic, and related acids.

[0045] The administration of the CRF antagonist and the GR antagonist, or pharmaceutically acceptable salts thereof, according to the present invention can be sequential in time or simultaneous, with the simultaneous method being generally preferred. For sequential administration, the CRF antagonist and the GR antagonist can be administered in any order. It is generally preferred that such administration be oral. It is even more preferred that the administration be oral and simultaneous. However, if the subject being treated is unable to swallow, or oral absorption is otherwise impaired or undesirable, another route of administration such as suppositories, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), or topical administration will be appropriate. When the CRF antagonist and the GR antagonist are administered sequentially, the administration of each can be by the same method or by different methods.

- [0046] The pharmaceutical compositions of the present invention comprise amounts of a CRF antagonist alone or together with a GR antagonist. One aspect of the present invention provides compositions comprising amounts of a CRF antagonist and a GR antagonist which result in a therapeutic effect. Of such compositions, compositions comprising a CRF antagonist as disclosed in EP 0773023 (which is described above) or a pharmaceutically acceptable salt thereof, and a GR antagonist as disclosed in U.S. Ser. No. 60/132,130 (which is described above) or a pharmaceutically acceptable salt thereof are preferred. It is further preferred that the compositions comprising the CRF antagonist and the GR antagonist be administered in the presence of a pharmaceutically acceptable vehicle, carrier or diluent, in either single or multiple doses.
- [0047] Suitable pharmaceutical vehicles, carriers and diluents include inert solid diluents or fillers, sterile aqueous solutions, and various organic solvents. The pharmaceutical compositions formed by combining the active compound(s) and the pharmaceutically acceptable carriers are then readily administered in a variety of dosage forms such as tablets, powders, lozenges, syrups, injectable solutions, and the like. These pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients, and the like. Thus, for purposes of oral administration, tablets containing various excipients such as sodium citrate, calcium carbonate, and calcium phosphate may be employed along with various disintegrants such as starch, alginic acid, and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin, and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate, and talc are often useful for tabletting purposes. Solid compositions of a similar type can also be employed as fillers in soft and hard filled gelatin capsules. Preferred materials for this include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration, the active ingredient(s) therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin, and combinations thereof.
- [0048] For parenteral administration, solutions of the active compound(s) in sesame or peanut oil, aqueous propylene glycol, or in sterile aqueous solution can be employed. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous, and intraperitoneal administration. The sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.
- [0049] For purposes of transdermal (e.g., topical) administration, dilute, sterile, aqueous or partially aqueous solutions (usually in about 0.1% to 5% concentration), otherwise similar to the above parenteral solutions, are employed.
- [0050] Methods of preparing various pharmaceutical compositions with a certain amount of active ingredient(s) are known, or will be apparent in light of this disclosure, to those skilled in the art. For example, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 19th Edition (1995).
- [0051] A therapeutically effective amount of an active ingredient means an amount that ameliorates, attenuates, or eliminates one or more symptoms of a particular disease or condition or prevents or delays the onset of one or more symptoms of a particular disease or condition. Amount(s) of the CRF antagonist alone or in combination with the GR antagonist necessary to achieve the desired therapeutic effect according to the present invention are within the skill of those who practice in the art of having the benefit of the disclosure herein. Syndrome X-treating or preventing amount(s) of the CRF antagonist alone or in combination with the GR antagonist are preferred.
- [0052] In general, the effective dosage for the CRF antagonist employed in the present invention will depend on the intended route of administration and factors such as the age and weight of the patient, as generally known to a physician. The dosage will also depend on the particular condition to be treated and will generally range from about 0.1 to about 300 mg/kg body weight of the patient per day, with administration carried out in single or divided dosages.
- [0053] In general, the effective dosage for the GR antagonist employed in the present invention will range from about 0.1 μ g/kg of body weight to about 500 mg/kg of body weight, more particularly from about 1 μ g/kg to about 250 mg/kg, and most particularly from about 2 μ g/kg to about 100 mg/kg. More preferably, the GR antagonist will be administered at an amount of about 0.1 mg/kg to about 500 mg/kg of body weight, and most preferably from about 0.1 mg/kg to about 50 mg/kg of body weight. As recognized by those skilled in the art, the particular quantity of the GR antagonist to be administered to a patient according to the present invention will depend upon a number of factors, including, without limitation, the biological activity desired, the condition of the patient, and tolerance for the drug.
- [0054] The methods and compositions of the present invention have utility in the treatment or prevention of Syndrome X in animals, such as dogs, cats, cows, horses, sheep, and humans. Particularly preferred animals are mammals, including both males and females. As such, the methods and compositions of the present invention have utility in the treatment or prevention of Syndrome X in companion animals, such as dogs and cats. The administration of the compositions of this invention may be effected orally or parenterally. An amount of a composition of the invention is administered such that an effective dose is received, usually a daily dose.
- [0055] Conveniently, the medicaments can be carried in the drinking water such that a therapeutic dosage of the agent(s) is ingested with the daily water supply. The agent(s) can be directly metered into drinking water, preferably in the form of a liquid, water-soluble concentrate, such as an aqueous solution of a water-soluble salt. Conveniently,

the active ingredient(s) can also be added directly to the companion animal's feed, as such, or in the form of an animal feed supplement, also referred to as a premix or concentrate. A premix or concentrate of the therapeutic agent(s) in a carrier is more commonly employed for the inclusion of the agent in the feed. Suitable carriers are liquid or solid, as desired, such as water, various meals such as alfalfa meal, soybean meal, cottonseed oil meal, linseed oil meal, corn cob meal and corn meal, molasses, urea, bone meal, and various mineral mixes. A particularly effective carrier is the respective animal feed itself, i.e., a small portion of such feed. The carrier facilitates uniform distribution of the active material(s) in the finished feed with which the premix is blended. It is important that the compound(s) be thoroughly blended into the premix and, subsequently, the feed. In this respect, the agent(s) may be dispersed or dissolved in a suitable oily vehicle such as soybean oil, corn oil, cottonseed oil, and the like, or in a volatile organic solvent and then blended with the carrier. It will be appreciated that the proportions of active material(s) in the concentrate are capable of wide variation since the amount of agent(s) in the finished feed may be adjusted by blending the appropriate proportion of premix with the feed to obtain a desired level of the therapeutic agent(s).

[0056] High potency concentrates may be blended by the feed manufacturer with a proteinaceous carrier such as soybean oil meal and other meals, as described above, to produce concentrated supplements which are suitable for direct feeding to animals. In such instances, the animals are permitted to consume the usual diet. Alternatively, such concentrated supplements may be added directly to the feed to produce a nutritionally balanced, finished feed containing a therapeutically effective amount of the compound(s) according to the present invention. The mixtures are thoroughly blended by standard procedures, such as in a twin shell blender, to insure homogeneity.

[0057] If the supplement is used as a top dressing for the feed, it likewise helps to insure uniformity of distribution of the active ingredient(s) across the top of the dressed feed.

[0058] For veterinary uses, both paste and pellet formulations may also be conveniently employed. Paste formulations can be prepared readily by dispersing the active compound(s) in a pharmaceutically acceptable oil such as peanut oil, sesame oil, corn oil, and the like. Similarly, pellets containing an effective amount of the compound(s) of the present invention can be prepared by admixing the compound(s) of the invention with a suitable diluent such as carbowax, carnauba wax, and the like, and a lubricant, such as magnesium or calcium stearate, can be employed to improve the pelleting process.

[0059] Since one aspect of the present invention relates to the treatment or prevention of Syndrome X with a combination of active ingredients which may be administered separately, the invention also relates to combining separate pharmaceutical compositions in kit form. A kit, according to this invention, comprises two separate pharmaceutical compositions: a first unit dosage form, comprising a therapeutically effective amount of a CRF antagonist and a pharmaceutically acceptable vehicle, carrier or diluent, and a second unit dosage form comprising a therapeutically effective amount of a GR antagonist and a pharmaceutically acceptable vehicle, carrier or diluent. The kit further comprises a container. The container is used to contain the separate compositions and may comprise, for example, a divided bottle or a divided foil packet; however, the separate compositions may also be contained within a single, undivided container. Normally, the kit will also include directions for the administration of the separate components. The kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g., oral and parenteral), are administered at different dosage levels, or when titration of the individual components of the combination is desired by the prescribing physician.

[0060] An example of such a kit is a so-called blister pack. Blister packs are well known in the packaging industry and are being used widely for the packaging of pharmaceutical unit dosage forms (tablets, capsules and the like). Blister packs generally consist of a sheet of relatively rigid material covered with a foil of a preferably transparent plastic material. During the packaging process recesses are formed in the plastic foil. The recesses generally conform to the size and shape of the tablets or capsules to be contained therein. Next, the tablets or capsules are placed in the recesses and the sheet of relatively rigid material is sealed against the plastic foil at the face of the foil which is opposite from the direction in which the recesses were formed. As a result, the tablets or capsules are sealed in the recesses between the plastic foil and the sheet. Preferably, the strength of the sheet is such that the tablets or capsules may be removed from the blister pack by the application of manual pressure on the recesses whereby an opening is formed in the sheet at the place of the recess. The tablet or capsule can then be removed through the formed opening.

[0061] It is further desirable to provide a memory aid on the pack, e.g., in the form of numbers or similar indicia next to the tablets or capsules whereby the indicia correspond with the days of the regimen which the dosage form so specified is to be ingested. An additional example of such a memory aid is a calendar printed on the pack, e.g., as follows "First Week, Monday, Tuesday, ... etc.... Second Week, Monday, Tuesday, ... " etc. Other variations will be readily apparent. A "daily dose" can be a single tablet or capsule or multiple tablets or capsules to be ingested on a given day. Also, a daily dose of a CRF antagonist can consist of one tablet or capsule while a daily dose of a GR antagonist can consist of multiple tablets or capsules, or vice versa. The memory aid should reflect this.

[0062] In another specific embodiment of the invention, a pack designed to dispense the daily doses one at a time in the order of their intended use is provided. Preferably, the pack is equipped with a memory aid, so as to further facilitate compliance with the dosage regimen. An example of such a memory aid is a mechanical counter which indi-

cates the number of daily doses to be dispensed. Another example of such a memory aid is a battery-powered microchip memory coupled with a liquid crystal readout, or audible reminder signal which, for example, reads out the date that the last daily dose has been taken and/or reminds the patient when the next dose is to be taken.

5 [0063] The following references disclose animal models, such as the JCR:LA-corpulent (cp) rat or the obese Zucker rat, that may be used to determine the Syndrome X-treating activity of the compound(s) employed to practice the present invention: J.C. Russell et al., Metabolism, Vol. 48, No. 6 (June), 1999: pp 701-706; Diabetes 46:1958-1964, 1997.

10 [0064] Methods that may be used to determine CRF antagonist activity of the compounds employed to practice the present invention are as described in, e.g., Wynn et al., Endocrinology, 116:1653-1659 (1985), and Grigoriadis et al., Peptides, 10:179-188 (1989). Methods that can be used to determine the CRF binding protein inhibiting activity of compounds employed to practice the present invention are described in Brain Research, (1997), 745(1,2), 248-256. These methods determine the binding affinity of a test compound for a CRF receptor, which is highly related to its expected activity as a CRF antagonist.

15 [0065] Methods that may be used to determine GR antagonist activity of the compounds employed to practice the present invention are described below and in commonly assigned U.S. patent application, Ser. No. 60/132, 130, filed 30 April 1999, which is hereby incorporated by reference herein. These methods determine the binding affinity of a test compound for a GRA receptor, which is highly related to its expected activity as a GR antagonist.

20 [0066] The following is a description of an assay for the identification of glucocorticoid receptor antagonists/agonists: HeLa cells (American Type Culture Collection (ATCC), Rockville, MD) containing endogenous human glucocorticoid receptors are transfected with a 3x pLuxF47-GRE-luciferase plasmid generated by standard procedures and a plasmid conferring neomycin resistance. pLuxF47-GRE was constructed by annealing oligonucleotides 23907-26A and 23907-26B and ligating into the Bg I II and Eag I sites of pLuxF47. Novel glucocorticoid responsive cell lines are generated and characterized. One such cell line designated HeLa-GRE9 is used for determining the activity of compounds at the glucocorticoid receptor. Cells are maintained in charcoal-stripped serum and transferred to 96-well microtiter plates one day prior to treatment with various concentrations (10⁻¹² to 10⁻⁵) of test compounds in the absence and presence of known glucocorticoid receptor agonists (i.e., dexamethasone, hydrocortisone) for up to 24 hours. Treatments are performed in triplicate. Cell lysates are prepared and luciferase activity is determined using a luminometer. Agonist activity is assessed by comparing the luciferase activity from cells treated with test compound to cells treated with the agonist dexamethasone. Antagonist activity is assessed by comparing the luciferase activity of an 25 EC₅₀ concentration of dexamethasone in the absence and presence of test compound. The EC₅₀ (concentration that produced 50% of the maximal response) for dexamethasone is calculated from dose response curves.

30 [0067] The following is a description of an assay for determining the competitive inhibition binding of the Human Type II Glucocorticoid receptor expressed in Sf9 cells:

35 [0068] Binding protocol: Compounds are tested in a binding displacement assay using human glucocorticoid receptor expressed in Sf9 cells with ³H-dexamethasone as the ligand. Human glucocorticoid receptor is expressed in Sf9 cells as described in Mol. Endocrinology 4: 209, 1990. Pellets containing Sf9 cells expressing the human GR receptor from 1L vats are lysed with 40 μ l of 20mM AEBSF stock (Calbiochem, LaJolla, CA) containing 50 mg/ml leupeptin and 40 ml of homogenization buffer is added. The assay is carried out in 96-well polypropylene plates in a final volume of 130 μ l containing 200 ug Sf9 lysate protein, 6.9 nM ³H-dexamethasone (Amersham, Arlington Heights, IL) in presence of test 40 compounds, test compound vehicle (for total counts) or excess dexamethasone (7 μ M non-radioactive, to determine non-specific binding) in an appropriate volume of assay buffer. All compounds are tested at 6 concentrations in duplicate (concentration range 0.1-30 nM or 3-1000 nM). Test compounds are diluted from a 25 mM stock in 100% DMSO with 70%EtOH and added in a volume of 2 μ l. Once all additions are made the plates are shaken, sealed with sealing tape and incubated at 4 °C overnight.

45 [0069] After the overnight incubation, unbound counts are removed with dextran coated charcoal as follows: 75 μ l of dextran coated charcoal (5.0 g activated charcoal, 0.5 g dextran adjusted to volume of 100 ml with assay buffer) is added, plates are shaken and incubated for five minutes at 4 °C. Plates are then centrifuged in a refrigerated benchtop centrifuge at top speed for 15 minutes. 100 μ l of the supernatant from each well is placed into a 96-well PET plate with 200 μ l of scintillation cocktail and counted on a beta counter (1450 MicroBetaTrilux, from Wallac, Turku, Finland).

50 [0070] Data analysis: After subtracting non-specific binding, counts bound are expressed as % of total counts. The concentration response for test compounds are fitted to a sigmoidal curve to determine the IC₅₀ (concentration of compound that displaces 50% of the bound counts).

[0071] Reagents: Assay Buffer: 2.0 ml 1M Tris (pH 7.4), 0.2 ml 0.5mM EDTA (pH 8.0), 77.1 mg DTT, 0.243 g sodium molybdate in a volume of 100 ml water; Homogenization buffer: 2.0 ml 0.5 M K₂HPO₄ (pH 7.6), 20 μ l 0.5 M EDTA (pH 8.0), 77.1 mg DTT, 0.486 g sodium molybdate in a volume of 100 ml water.

55 [0072] The following is a description of an assay for determining receptor selectivity: T47D cells (American Type Culture Collection (ATCC), Rockville, MD) containing endogenous human progesterone and mineralocorticoid receptors are transiently transfected with a 3x pLuxF47-GRE-luciferase using Lipofectamine Plus (GIBCO-DRL, Gaithers-

burg, MD). Twenty-four hours post-transfection cells are maintained in charcoal-stripped serum and transferred to 96-well microtiter plates. The next day cells are treated with various concentrations (10⁻¹² to 10⁻⁵) of test compounds in the absence and presence of a known progesterone receptor agonist (progesterone) and a known mineralocorticoid receptor agonist (aldosterone) for up to 24 hours. Treatments are performed in triplicate. Cell lysates are prepared and luciferase activity is determined using a luminometer. Agonist activity is assessed by comparing the luciferase activity from cells treated with compound alone to cells treated with either the agonist progesterone or aldosterone. Antagonist activity is assessed by comparing the luciferase activity of an EC₅₀ concentration of progesterone or aldosterone in the absence and presence of compound. The EC₅₀ (concentration that produced 50% of maximal response) for progesterone and aldosterone is calculated from dose response curves.

5 [0073] The following is a description of an assay for determining anti-diabetes and anti-obesity activity. The obese, diabetic ob/ob mouse is used to assess the anti-diabetes and anti-obesity activity of the compounds. Six to 10 week old ob/ob male mice (Jackson Labs, Bar Harbor, Maine) are dosed with test compound(s) for 2 to 10 days. Plasma glucose levels are determined by measuring glucose from samples obtained by orbital bleeding. Glucose is quantitated using an Abbott Autoanalyzer (Abbott, Inc., Abbott Park, IL). Food intake is monitored on a daily basis by differential weighing.

10 [0074] The following is a description of an assay for determining the ability of a compound to inhibit glucocorticoid agonist induction of liver tyrosine amino transferase (TAT) activity in conscious rats:

15 [0075] Animals: Male Sprague Dawley rats (from Charles River, Wilmington MA) (adrenal-intact or adrenalectomized at least one week prior to the screen) b.w. 90g are used. The rats are housed under standard conditions for 7-10d prior to use in the screen.

20 [0076] Experimental protocol: Rats (usually 3 per treatment group) are dosed with test compound, vehicle or positive control (RU486) either i.p., p.o., s.c. or i.v. (tail vein). The dosing vehicle for the test compounds is typically one of the following: 100% PEG 400, 0.25% methyl cellulose in water, 70% ethanol or 0.1 N HCl and the compounds are tested at doses ranging from 10 to 125 mg/kg. The compounds are dosed in a volume of 1.0 ml/ 100 g body weight (for p.o.) or 0.1 ml/100g body weight for other routes of administration. Ten minutes after the administration of the test compound, the rats are injected with dexamethasone (0.03 mg/kg i.p. in a volume of 0.1 ml/ 100g) or vehicle. To prepare the dexamethasone dosing solution, dexamethasone (from Sigma, St. Louis, MO) is dissolved in 100% ethanol and diluted with water (final: 10% ethanol:90% water, vol:vol). Groups treated with vehicle-vehicle, vehicle-dexamethasone, and Ru486-dexamethasone are included in each screen. The compounds are tested vs. dexamethasone only. Three hours after the injection of dexamethasone the rats are sacrificed by decapitation. A sample of liver (0.3 g) is excised and placed in 2.7 ml of ice cold buffer and homogenized with a polytron. To obtain cytosol the liver homogenate is centrifuged at 105,000g for 60 min and the supernatant is stored at -80 °C until analysis. TAT is assayed on 100 ul of a 1:20 dilution of the 105,000g supernatant using the methods of D.K. Granner and G.M. Tomkins, "Tyrosine Aminotransferase (Rat Liver)," Methods in Enzymology, 17A: 633-637 (1970)) and a reaction time of 8-10 minutes. TAT activity is expressed as umol product/min/g liver.


25 [0077] Interpretation: Treatment data are analyzed by using analysis of variance (ANOVA) with protected least significant difference (PLSD) post-hoc analysis. Compounds are considered active in this test if the TAT activity in the group pretreated with compound prior to dexamethasone administration is significantly (P < 0.05) decreased relative to the TAT activity in the vehicle-dexamethasone treated group.

30 40

Claims

1. Use of a corticotropin releasing factor antagonist for the manufacture of a medicament for treating or preventing Syndrome X in an animal which comprises administering to said animal an amount of a corticotropin releasing factor antagonist.
2. The use of claim 1 wherein a therapeutically effective amount of a corticotropin releasing factor antagonist is administered.
3. The use of claim 2 wherein the corticotropin releasing factor antagonist is a compound of formula

55



5

10

and the pharmaceutically acceptable acid addition salts thereof, wherein
 A is NR₁R₂, CR₁R₂R₁₁, or C(=CR₁R₁₂)R₂, NHCR₁R₂R₁₁, OCR₁R₂R₁₁, SCR₁R₂R₁₁, NHNR₁R₂, CR₂R₁₁NHR₁, CR₂R₁₁OR₁, CR₂R₁₁SR₁ or C(O)R₂;

15

R₁ is hydrogen, or C₁-C₆ alkyl which may be substituted by one or two substituents R₆ independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, C₁-C₆ alkoxy, O-C(O)-(C₁-C₆ alkyl), O-C(O)-N(C₁-C₄ alkyl)(C₁-C₂ alkyl); amino, NH(C₁-C₄ alkyl), S(C₁-C₆ alkyl), OC(O)NH(C₁-C₄ alkyl), N(C₁-C₂ alkyl)C(O)(C₁-C₄ alkyl), NHC(O)(C₁-C₄ alkyl), COOH, CO(C₁-C₄ alkyl), C(O)NH(C₁-C₄ alkyl), C(O)N(C₁-C₄ alkyl)(C₁-C₂ alkyl), SH, CN, NO₂, SO(C₁-C₄ alkyl); SO₂(C₁-C₄ alkyl), SO₂NH(C₁-C₄ alkyl), SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl), and said C₁-C₆ alkyl may have one or two double or triple bonds;

20

R₂ is C₁-C₁₂ alkyl, aryl or (C₁-C₁₀ alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinolyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, oxazolyl, or benzoxazolyl; 3- to 8-membered cycloalkyl or (C₁-C₆ alkylene) cycloalkyl, wherein said cycloalkyl may have one or two of O, S or N-Z, wherein Z is hydrogen, substituted, independently, for one or two carbons of said cycloalkyl, C₁-C₄ alkyl, benzyl or C₁-C₄ alkanoyl, wherein R² may be substituted independently by from one to three of chloro, fluoro, or C₁-C₄ alkyl, or one of hydroxy, bromo, iodo, C₁-C₆ alkoxy, OC(O)(C₁-C₆ alkyl), O-C-N(C₁-C₄ alkyl)(C₁-C₂ alkyl), S(C₁-C₆ alkyl), NH₂, NH(C₁-C₂ alkyl), N(C₁-C₄ alkyl)C(O)(C₁-C₄ alkyl), NHC(O)(C₁-C₄ alkyl), COOH, C(O)O(C₁-C₄ alkyl), C(O)NH(C₁-C₄ alkyl), C(O)N(C₁-C₄ alkyl)(C₁-C₂ alkyl), SH, CN, NO₂, SO(C₁-C₄ alkyl), SO₂(C₁-C₄ alkyl), SO₂NH(C₁-C₄ alkyl), SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl), and wherein said C₁-C₁₂ alkyl or C₁-C₁₀ alkylene may have one to three double or triple bonds; or

25

NR₁R₂ or CR₁R₂R₁₁ may form a 4- to 8-membered ring optionally having one or two double bonds or one or two of O, S or N-Z wherein Z is hydrogen, C₁-C₄ alkyl, benzyl, or C₁-C₄ alkanoyl;

30

R₃ is hydrogen, C₁-C₆ alkyl, fluoro, chloro, bromo, iodo, hydroxy, amino, O(C₁-C₆ alkyl), NH(C₁-C₆ alkyl), N(C₁-C₄ alkyl)(C₁-C₂ alkyl), SH, S(C₁-C₄ alkyl), SO(C₁-C₄ alkyl), or SO₂(C₁-C₄ alkyl), wherein said C₁-C₄ alkyl and C₁-C₆ alkyl may have one or two double or triple bonds and may be substituted by from 1 to 3 R₇ substituents independently selected from the group consisting of hydroxy, amino, C₁-C₃ alkoxy, dimethylamino, diethylamino, methylamino, ethylamino, NHC(O)CH₃, fluoro, chloro or C₁-C₃ thioalkyl;

35

R₄ is hydrogen, C₁-C₆ alkyl, fluoro, chloro, bromo, iodo, C₁-C₆ alkoxy, amino, NH(C₁-C₆ alkyl), N(C₁-C₆ alkyl)(C₁-C₂ alkyl), SO_n(C₁-C₆ alkyl), wherein n is 0, 1 or 2, cyano, hydroxy, carboxy, or amido, wherein said C₁-C₆ alkyls may be substituted by one to three of hydroxy, amino, carboxy, amido, NHC(O)(C₁-C₄ alkyl), NH(C₁-C₄ alkyl), N(C₁-C₄ alkyl)(C₁-C₂ alkyl), C(O)O(C₁-C₄ alkyl), C₁-C₃ alkoxy, C₁-C₃ thioalkyl, fluoro, bromo, chloro, iodo, cyano or nitro;

40

R₅ is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinolyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzoisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl benzoxazolyl, oxazolyl, pyrrolidinyl, thiazolidinyl, piperazinyl, piperidinyl, or tetrazolyl, wherein each one of the above groups may be substituted independently by from one to three of fluoro, chloro, bromo, formyl, C₁-C₆ alkyl, C₁-C₆ alkoxy or trifluoromethyl, or one of hydroxy, iodo, cyano, nitro, amino, cyclopropyl, NH(C₁-C₄ alkyl), N(C₁-C₄ alkyl)(C₁-C₂ alkyl), COO(C₁-C₄ alkyl), CO(C₁-C₄ alkyl), SO₂NH(C₁-C₄ alkyl), SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl), SO₂NH₂, NHSO₂(C₁-C₄ alkyl), S(C₁-C₆ alkyl), SO₂(C₁-C₆ alkyl), wherein said C₁-C₄ alkyl and C₁-C₆ alkyl may have one double or triple bond and may be substituted by one or two of fluoro, chloro, hydroxy, amino, methylamino, dimethylamino or acetyl; with the proviso that R₅ is not unsubstituted phenyl;

R₁₁ is hydrogen, hydroxy, fluoro, chloro, COO(C₁-C₂ alkyl), cyano, or CO(C₁-C₂ alkyl); and

R₁₂ is hydrogen or C₁-C₄ alkyl;

55

(a) A is not straight chain C₁-C₁₂ alkyl;


(b) when R₃ is hydrogen, A is benzyl or phenethyl, and R₄ is fluoro, chloro, bromo or iodo, then R₅ is not 5'-deoxy-ribofuranosyl or 5'-amino-5'-deoxyribofuranosyl; and

(c) when R^5 is phenyl, said phenyl is substituted by two or three substituents.

4. The use of claim 2 wherein the corticotropin releasing factor antagonist is a compound of formula

5

10



15

and the pharmaceutically acceptable acid addition salts thereof, wherein

B is NR_1R_2 , $CR_1R_2R_{11}$, $C(=CR_2R_{12})R_1$, $NHR_1R_2R_{11}$, $OCR_1R_2R_{11}$, $SCR_1R_2R_{11}$, $NHNR_1R_2$, $CR_2R_{11}NHR_1$, $CR_2R_{11}OR_1$, $CR_2R_{11}SR_1$, or $C(O)R_2$;

20 R_1 is hydrogen, or C_1 - C_6 alkyl which may be substituted by one or two substituents R_7 independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, C_1 - C_8 alkoxy, $O-C(=O)-(C_1$ - C_6 alkyl), $O-C(=O)NH(C_1$ - C_4 alkyl), $O-C(=O)-N(C_1$ - C_4 alkyl)(C_1 - C_2 alkyl), amino, $NH(C_1$ - C_4 alkyl), $N(C_1$ - C_2 alkyl)(C_1 - C_4 alkyl), $S(C_1$ - C_6 alkyl), $N(C_1$ - C_4 alkyl) $C(=O)(C_1$ - C_4 alkyl), $NH(C_1$ - C_4 alkyl), $COOH$, $C(=O)O(C_1$ - C_4 alkyl), $C(=O)NH(C_1$ - C_4 alkyl), $C(=O)N(C_1$ - C_4 alkyl)(C_1 - C_2 alkyl), SH , CN , NO_2 , $SO(C_1$ - C_4 alkyl), $SO_2(C_1$ - C_4 alkyl), $SO_2NH(C_1$ - C_4 alkyl), $SO_2N(C_1$ - C_4 alkyl)(C_1 - C_2 alkyl), and said C_1 - C_6 alkyl may contain one or two double or triple bonds;

25 R_2 is C_1 - C_{12} alkyl, aryl or (C_1 - C_{10} alkylene)aryl wherein said aryl is phenyl, naphthyl, thiienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, oxazolyl, or benzoxazolyl; 3- to 8-membered cycloalkyl or (C_1 - C_6 alkylene) cycloalkyl, wherein said cycloalkyl may contain one or two of O, S or N-Z wherein Z is hydrogen, C_1 - C_4 alkyl, benzyl or C_1 - C_4 alkanoyl, wherein R_2 may be substituted independently by from one to three of chloro, fluoro, or C_1 - C_4 alkyl, or one of hydroxy, bromo, iodo, C_1 - C_6 alkoxy, $O-C(=O)-(C_1$ - C_6 alkyl), $O-C-N(C_1$ - C_4 alkyl)(C_1 - C_2 alkyl), $S(C_1$ - C_6 alkyl), NH_2 , $NH(C_1$ - C_2 alkyl), $N(C_1$ - C_2 alkyl)(C_1 - C_4 alkyl), $N(C_1$ - $C_4)$ - $C(=O)(C_1$ - C_4 alkyl), $NHC(=O)(C_1$ - $C_4)$, $COOH$, $C(=O)O(C_1$ - C_4 alkyl), $C(=O)NH(C_1$ - C_4 alkyl), $C(=O)N(C_1$ - C_4 alkyl)(C_1 - C_2 alkyl), SH , CN , NO_2 , $SO(C_1$ - C_4 alkyl), $SO_2(C_1$ - C_4 alkyl), $SO_2NH(C_1$ - C_4 alkyl), $SO_2N(C_1$ - C_4 alkyl)(C_1 - C_2 alkyl), and wherein said C_1 - C_{12} alkyl or C_1 - C_{10} alkylene may contain one to three double or triple bonds; or

30 NR_1R_2 or $CR_1R_2R_{11}$ may form a saturated 3- to 8 membered carbocyclic ring of which the 5- to 8-membered ring contain one or two double bonds or one or two of O, S or N-Z wherein Z is hydrogen, C_1 - C_4 alkyl, benzyl or C_1 - C_4 alkanoyl;

35 R_3 is hydrogen, C_1 - C_6 alkyl, fluoro, chloro, bromo, iodo, hydroxy, amino, $O(C_1$ - C_6 alkyl), $NH(C_1$ - C_6 alkyl), $N(C_1$ - C_4 alkyl)(C_1 - C_2 alkyl), SH , $S(C_1$ - C_4 alkyl), $SO(C_1$ - C_4 alkyl), or $SO_2(C_1$ - C_4 alkyl), wherein said C_1 - C_4 alkyl and C_1 - C_6 alkyl may contain from one or two double or triple bonds and may be substituted by from 1 to 3 substituents R_5 independently selected from the group consisting of hydroxy, amino, C_1 - C_3 alkoxy, dimethylamino, diethylamino, methylamino, ethylamino, $NHCH_3$, fluoro, chloro or C_1 - C_3 thioalkyl;

40 R_4 and R_6 are each independently hydrogen, C_1 - C_6 alkyl, fluoro, chloro, bromo, iodo, C_1 - C_6 alkoxy, amino, $NH(C_1$ - C_6 alkyl), $N(C_1$ - C_6 alkyl)(C_1 - C_2 alkyl), $SO_n(C_1$ - C_6 alkyl), wherein n is 0, 1 or 2, cyano, hydroxy, carboxy, or amido, wherein said C_1 - C_6 alkyls may be substituted by one to three of hydroxy, amino, carboxy, amido, $NHC(=O)(C_1$ - C_4 alkyl), $NH(C_1$ - C_4 alkyl), $N(C_1$ - C_4 alkyl)(C_1 - C_2 alkyl), $C(=O)O(C_1$ - C_4 alkyl), C_1 - C_3 alkoxy, C_1 - C_3 thioalkyl, fluoro, chloro, iodo, cyano or nitro;

45 R_5 is phenyl, naphthyl, thiienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, benzoxazolyl, oxazolyl, pyrrolidinyl, thiazolidinyl, morpholinyl, piperidinyl, piperazinyl, tetrazolyl, or 3- to 8-membered cycloalkyl or 9- to 12-membered bicycloalkyl, optionally containing one to three of O, S or N-Z wherein Z is hydrogen, C_1 - C_4 alkyl, C_1 - C_4 alkanoyl, phenyl or phenylmethyl, wherein each one of the above groups may be substituted independently by from one to four of fluoro, chloro, C_1 - C_6 alkyl, C_1 - C_6 alkoxy or trifluoromethyl, or one of bromo, iodo, cyano, nitro, amino, $NH(C_1$ - C_4 alkyl), $N(C_1$ - $C_4)(C_1$ - C_2 alkyl), $COO(C_1$ - C_4 alkyl), $CO(C_1$ - C_4 alkyl), $SO_2NH(C_1$ - C_4 alkyl), $SO_2N(C_1$ - C_4 alkyl)(C_1 -

C_2 alkyl), SO_2NH_2 , $NHSO_2(C_1-C_4$ alkyl), $S(C_1-C_6$ alkyl), $SO_2(C_1-C_6$ alkyl), wherein said C_1-C_4 alkyl and C_1-C_6 alkyl may be substituted by one or two of fluoro, chloro, hydroxy, amino, methylamino, dimethylamino or acetyl; with the proviso that R_5 is not unsubstituted phenyl;


R_{11} is hydrogen, hydroxy, fluoro, chloro, $COO(C_1-C_2$ alkyl), cyano, or $CO(C_1-C_2$ alkyl); and

5 R_{12} is hydrogen or C_1-C_4 alkyl; with the proviso that (1) when R_5 is 4-bromophenyl, R_3 is hydrogen, and R_4 and R_6 are methyl, then B is not methylamino or ethyl, and (2) when R_5 is 4-bromophenyl, and R_3 , R_4 and R_6 are methyl, then B is not 2-hydroxyethylamino.

5. The use of claim 2 wherein the corticotropin releasing factor antagonist is a compound of formula

10

15



20

wherein

A is CR_7 or N;

25

B is NR_1R_2 , $CR_1R_2R_{11}$, $C(=CR_2R_{12})R_1$, $NHCHR_1R_2$, $OCHR_1R_2$, $SCHR_1R_2$, CHR_2OR_{12} , CHR_2SR_{12} , $C(S)R_2$ or $C(O)R_2$;

G is oxygen, sulfur, NH, NH_3 , hydrogen, methoxy, ethoxy, trifluoromethoxy, methyl, ethyl, thiomethoxy, NH_2 , $NHCH_3$, $N(CH_3)_2$ or trifluoromethyl;

Y is CH or N;

30

Z is NH, O, S, N (C_1-C_2 alkyl), or $CR_{13}R_{14}$, wherein R_{13} and R_{14} are each independently hydrogen, trifluoromethyl, or C_1-C_4 alkyl, or one of R_{13} and R_{14} may be cyano, chloro, bromo, iodo, fluoro, hydroxy, $O(C_1-C_2$ alkyl), amino, $NH(C_1-C_2$ alkyl), or $CR_{13}R_{14}$ may be $C=O$ or cydopropyl;

35

R_1 is C_1-C_6 alkyl which may be substituted by one or two substituents R_8 independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, C_1-C_4 alkoxy, $O-CO-(C_1-C_4$ alkyl), $O-CO-NH(C_1-C_4$ alkyl), $O-CO-N(C_1-C_4$ alkyl)(C_1-C_2 alkyl), $NH(C_1-C_4$ alkyl), $N(C_1-C_4$ alkyl)(C_1-C_4 alkyl), $S(C_1-C_4$ alkyl), $N(C_1-C_4$ alkyl) $CO(C_1-C_4$ alkyl), $NHCO(C_1-C_4$ alkyl), $COO(C_1-C_4$ alkyl), $CONH(C_1-C_4$ alkyl), $CON(C_1-C_4$ alkyl)(C_1-C_2 alkyl), $S(C_1-C_4$ alkyl), CN, NO_2 , $SO(C_1-C_4$ alkyl), $SO_2(C_1-C_4$ alkyl), and said C_1-C_6 alkyl or C_1-C_4 alkyl may contain one double or triple bond;

40

R_2 is C_1-C_{12} alkyl, aryl or (C_1-C_4 alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, or benzoxazolyl; 3- to 8-membered cycloalkyl or (C_1-C_6 alkylene)cycloalkyl, wherein said cycloalkyl may contain one or two of O, S or N-Rg wherein R_g is hydrogen, or C_1-C_4 alkyl, wherein the above defined R_2 may be substituted independently by from one to three of chloro, fluoro, or C_1-C_4 alkyl, or one of bromo, iodo, C_1-C_6 alkoxy, $O-CO-(C_1-C_6$ alkyl), $O-CO-N(C_1-C_4$ alkyl)(C_1-C_2 alkyl), $S(C_1-C_6$ alkyl), CN, NO_2 , $SO(C_1-C_4$ alkyl), or $SO_2(C_1-C_4$ alkyl), and wherein said C_1-C_{12} alkyl or C_1-C_4 alkylene may contain one double or triple bond; or

45

NR_1R_2 or $CR_1R_2R_{11}$ may form a saturated 5- to 8-membered carbocyclic ring which may contain one or two double bonds or one or two of O or S;

50

R_3 is methyl, ethyl, fluoro, chloro, bromo, iodo, cyano, methoxy, OCF_3 , methylthio, methylsulfonyl, CH_2OH or CH_2OCH_3 ;

R_4 is hydrogen, C_1-C_4 alkyl, fluoro, chloro, bromo, iodo, C_1-C_4 alkoxy, amino, nitro, $NH(C_1-C_4$ alkyl), $N(C_1-C_4$ alkyl)(C_1-C_2 alkyl), $SO_n(C_1-C_4$ alkyl), wherein n is 0, 1 or 2, cyano, hydroxy, $CO(C_1-C_4$ alkyl), CHO, or $COO(C_1-C_4$ alkyl), wherein said C_1-C_4 alkyl may contain one or two double or triple bonds and may be substituted by one or two of hydroxy, amino, carboxy, $NHCOCH_3$, $NH(C_1-C_2$ alkyl), $N(C_1-C_2$ alkyl) $_2$, $COO(C_1-C_4$ alkyl), $CO(C_1-C_4$ alkyl), C_1-C_3 alkoxy, C_1-C_3 thioalkyl, fluoro, chloro, cyano or nitro;

55

R_5 is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, furanyl, benzofuranyl, benzothiazolyl, or indolyl, wherein each one of the above groups R_5 is substituted independently by from one to three of fluoro, chloro, C_1-C_6 alkyl, or C_1-C_6 alkoxy, or one of hydroxy, iodo, bromo, formyl, cyano, nitro, trifluoromethyl, amino, $NH(C_1-C_4$ alkyl), $N(C_1-C_6)(C_1-C_2$ alkyl), $COOH$, $COO(C_1-C_4$ alkyl), $CO(C_1-C_4$ alkyl),

SO₂NH(C₁-C₄ alkyl), SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl), SO₂NH₂, NSO₂(C₁-C₄ alkyl), S(C₁-C₆ alkyl), or SO₂(C₁-C₆ alkyl), wherein said C₁-C₄ alkyl and C₁-C₆ alkyl may be substituted by one or two of fluoro, hydroxy, amino, methylamino, dimethylamino or acetyl;

5 R₆ is hydrogen, or C₁-C₆ alkyl, wherein said C₁-C₆ alkyl may be substituted by one hydroxy, methoxy, ethoxy or fluoro;

R₇ is hydrogen, C₁-C₄ alkyl, fluoro, chloro, bromo, iodo, cyano, hydroxy, O(C₁-C₄ alkyl), C(O)(C₁-C₄ alkyl), or C(O)O(C₁-C₄ alkyl), wherein the C₁-C₄ alkyl groups may be substituted with one hydroxy, chloro or bromo, or one to three fluoro;

10 R₁₁ is hydrogen, hydroxy, fluoro, or methoxy;


R₁₂ is hydrogen or C₁-C₄ alkyl; and

15 R₁₆ and R₁₇ are each independently hydrogen, hydroxy, methyl, ethyl, methoxy, or ethoxy, except that they are not both methoxy or ethoxy, and CR₄R₆ and CR₁₆R₁₇ each independently may be C=O.

6. The use of claim 2 wherein the corticotropin releasing factor antagonist is a compound of formula

15

20



25

and the pharmaceutically acceptable acid addition salts thereof, wherein

30 A is N or -CR₆;

B is -NR₁R₂, -CR₁R₂R₁₁, -C(=CR₂R₁₂)R₁, -NHCHR₁R₂, -OCHR₁R₂, -SCHR₁R₂, -CHR₂OR₁₂, -CHR₂SR₁₂, -C(S)R₁ or -C(O)R₁;

35 R₁ is C₁-C₆ alkyl which may optionally be substituted with one or two substituents independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, C₁-C₄ alkoxy, -O-CO-(C₁-C₄ alkyl), -O-CO-NH(C₁-C₄ alkyl), -O-CO-N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -NH(C₁-C₄ alkyl), -N(C₁-C₂ alkyl)(C₁-C₄ alkyl), -S(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)CO(C₁-C₄ alkyl), -NHCO(C₁-C₄ alkyl), -COO(C₁-C₄ alkyl), -CONH(C₁-C₄ alkyl), -CON(C₁-C₄ alkyl)(C₁-C₂ alkyl), CN, NO₂, -SO(C₁-C₄ alkyl), -SO₂(C₁-C₄ alkyl), and wherein any of the foregoing C₁-C₄ alkyl and C₁-C₆ alkyl groups may optionally contain one carbon-carbon double or triple bond;

40 R₂ is C₁-C₁₂ alkyl, aryl, -(C₁-C₄ alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, oxazolyl, or benzoxazolyl; or 3- to 8-membered cycloalkyl or -(C₁-C₆ alkylene)cycloalkyl, wherein one or two of the ring carbons of said cycloalkyl having at least 4 ring members and the cycloalkyl moiety of said -(C₁-C₆ alkylene)cycloalkyl having at least 4 ring members may optionally be replaced by an oxygen or sulfur atom or by N-Z wherein Z is hydrogen; or C₁-C₄ alkyl, and wherein each of said groups R₂ may optionally be substituted with from one to three substituents independently selected from chloro, fluoro, and C₁-C₄ alkyl, or by one substituent selected from bromo, iodo, C₁-C₆ alkoxy, -O-CO-(C₁-C₆ alkyl), -S(C₁-C₆ alkyl), -COO(C₁-C₄ alkyl), CN, NO₂, -SO(C₁-C₄ alkyl), and -SO₂(C₁-C₄ alkyl), and wherein said C₁-C₁₂ alkyl and the C₁-C₄ alkylene moiety of said -(C₁-C₄ alkylene)aryl may optionally contain one carbon-carbon double or triple bond;

45 50 or -NR₁R₂ may form a saturated 5- to 8-membered heterocyclic ring, or -CHR₁R₂ may form a saturated 5- to 8-membered carbocyclic ring, wherein each of these rings may optionally contain one or two carbon-carbon double bonds and wherein one or two of the carbon atoms of each of these rings may optionally be replaced with a sulfur or oxygen atom;

55 R₃ is C₁-C₄ alkyl, fluoro, chloro, bromo, iodo, -CH₂OH, -CH₂OCH₃, -O(C₁-C₃ alkyl), -S(C₁-C₃ alkyl), or -SO₂(C₁-C₃ alkyl), wherein said C₁-C₃ alkyl may optionally contain one carbon-carbon double or triple bond;

R₄ is hydrogen, C₁-C₆ alkyl, fluoro, chloro, bromo, iodo, C₁-C₄ alkoxy, amino, -NHCH₃, -N(CH₃)₂, -CH₂OH, -CH₂OCH₃, or -SO_n(C₁-C₄ alkyl), wherein n is 0, 1 or 2, cyano, hydroxy, -CO(C₁-C₄ alkyl), -CHO, or -COO(C₁-C₄ alkyl) wherein the C₁-C₄ alkyl moieties in the foregoing R₄ groups may optionally contain one carbon-

carbon double or triple bond;

R₅ is phenyl, naphthyl, thiienyl, benzothienyl, pyridyl, pyrimidyl, benzofuranyl, pyrazinyl or benzothiazolyl, wherein each one of said groups R₅ may optionally be substituted with from one to three substituents independently selected from fluoro, chloro, C₁-C₆ alkyl and C₁-C₆ alkoxy, or by one substituent selected from iodo, hydroxy, bromo, formyl, cyano, nitro, amino, trifluoromethyl, -NH(C₁-C₄ alkyl), -N(C₁-C₆)(C₁-C₂ alkyl), -COO(C₁-C₄ alkyl), -CO(C₁-C₄ alkyl), -COOH, -SO₂NH(C₁-C₄ alkyl), -SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -SO₂NH₂, -NHSO₂(C₁-C₄ alkyl), -S(C₁-C₆ alkyl) and -SO₂(C₁-C₆ alkyl), wherein each of said C₁-C₄ alkyl and C₁-C₆ alkyl moieties in the foregoing R₅ groups may optionally be substituted with one to three fluorine atoms;

R₆ is hydrogen, C₁-C₄ alkyl, fluoro, chloro, bromo, iodo, -CH₂OH, -CH₂OCH₃, or C₁-C₄ alkoxy;

R₇ is hydrogen, C₁-C₄ alkyl, fluoro, chloro, bromo, iodo, -O(C₁-C₄ alkyl), cyano, -CH₂OH, -CH₂O(C₁-C₂ alkyl), -CO(C₁-C₂ alkyl), or -COO(C₁-C₂ alkyl);


R₁₁ is hydrogen, hydroxy, fluoro, or methoxy; and

R₁₂ is hydrogen or C₁-C₄ alkyl;

with the proviso that when A is N, then: (a) B is not unsubstituted alkyl; (b) R₅ is not unsubstituted phenyl or monosubstituted phenyl; and (c) R₃ is not unsubstituted alkyl; or a pharmaceutically acceptable salt of such compound.

7. The use of claim 2 wherein the corticotropin releasing factor antagonist is a compound of formula


20



30

or

35



40

45

or a pharmaceutically acceptable salt thereof, wherein

the dashed lines represent optional double bonds;

A is nitrogen or CR⁷;

B is -NR¹R², -CR¹R²R¹⁰, -C(=CR²R¹¹)R¹, -NHCR¹R²R¹⁰, -OCR¹R²R¹⁰, -SCR¹R²R¹⁰, -CR²R¹⁰NHR¹, -CR²R¹⁰OR¹, -CR²R¹⁰SR¹ or -COR²;

D is nitrogen and is single bonded to all atoms to which it is attached, or D is carbon and is either double bonded to E in formulas I and II or double bonded to the adjacent carbon atom common to both fused rings in formula III, or D is CH and is single bonded to E in formulas I and II;

E is nitrogen, CH or carbon;

F is oxygen, sulfur, CHR⁴ or NR⁴ when it is single bonded to E and F is nitrogen or CR⁴ when it is double bonded to E;

G, when single bonded to E, is hydrogen, C₁-C₄ alkyl, -S(C₁-C₄ alkyl), -O(C₁-C₄ alkyl), NH₂, -NH(C₁-C₄ alkyl) or -N(C₁-C₂ alkyl)(C₁-C₄ alkyl), wherein each of the C₁-C₄ alkyl groups of G may optionally be substituted with

one hydroxy, $-\text{O}(\text{C}_1\text{-C}_2 \text{ alkyl})$ or fluoro group; G, when double bonded to E, is oxygen, sulfur or NH; and G, when E is nitrogen and double bonded to D or F, is absent;

- 5 R¹ is hydrogen, C₁-C₆ alkyl optionally substituted with one or two substituents R⁸ independently selected from hydroxy, fluoro, chloro, bromo, iodo, C₁-C₄ alkoxy, CF₃, $-\text{C}(=\text{O})\text{O}(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{OC}(=\text{O})\text{N}(\text{C}_1\text{-C}_4 \text{ alkyl})(\text{C}_1\text{-C}_2 \text{ alkyl})$, $-\text{NHCO}(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{COOH}$, $-\text{COO}(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{CONH}(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{CON}(\text{C}_1\text{-C}_4 \text{ alkyl})(\text{C}_1\text{-C}_2 \text{ alkyl})$, $-\text{S}(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{CN}$, $-\text{NO}_2$, $-\text{SO}(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{SO}_2(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{SO}_2\text{NH}(\text{C}_1\text{-C}_4 \text{ alkyl})$ and $-\text{SO}_2\text{N}(\text{C}_1\text{-C}_4 \text{ alkyl})(\text{C}_1\text{-C}_2 \text{ alkyl})$, wherein each of the C₁-C₄ alkyl groups in the foregoing R¹ groups may optionally contain one or two double or triple bonds;
- 10 R² is C₁-C₁₂ alkyl which may optionally contain from one to three double or triple bonds, aryl or (C₁-C₄ alkylene)aryl, wherein said aryl and the aryl moiety of said (C₁-C₄ alkylene)aryl is selected from phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidinyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, oxazolyl and benzoxazolyl; C₃-C₈ cycloalkyl or (C₁-C₆ alkylene)(C₃-C₈ cycloalkyl), wherein one or two of the carbon atoms of said cycloalkyl and the 5 to 8 membered cycloalkyl moieties of said (C₁-C₆ alkylene)(C₃-C₈ cycloalkyl) may optionally and independently be replaced by an oxygen or sulfur atom or by NZ² wherein Z² is selected from hydrogen, C₁-C₄ alkyl, benzyl and C₁-C₄ alkanoyl, and wherein each of the foregoing R² groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro, hydroxy and C₁-C₄ alkyl, or with one substituent selected from bromo, iodo, C₁-C₆ alkoxy, $-\text{OC}(=\text{O})(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{OC}(=\text{O})\text{N}(\text{C}_1\text{-C}_4 \text{ alkyl})(\text{C}_1\text{-C}_2 \text{ alkyl})$, $-\text{S}(\text{C}_1\text{-C}_6 \text{ alkyl})$, amino, $-\text{NH}(\text{C}_1\text{-C}_2 \text{ alkyl})$, $-\text{N}(\text{C}_1\text{-C}_2 \text{ alkyl})(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{N}(\text{C}_1\text{-C}_4 \text{ alkyl})\text{-CO}(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{NHCO}(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{COOH}$, $-\text{COO}(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{CONH}(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{CON}(\text{C}_1\text{-C}_4 \text{ alkyl})(\text{C}_1\text{-C}_2 \text{ alkyl})$, $-\text{SH}$, $-\text{CN}$, $-\text{NO}_2$, $-\text{SO}(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{SO}_2(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{SO}_2\text{NH}(\text{C}_1\text{-C}_4 \text{ alkyl})$ and $-\text{SO}_2\text{N}(\text{C}_1\text{-C}_4 \text{ alkyl})(\text{C}_1\text{-C}_2 \text{ alkyl})$;
- 15 -NR¹R² or CR¹R²R¹⁰ may form a saturated 3 to 8 membered carbocyclic ring which may optionally contain from one to three double bonds and wherein one or two of the ring carbon atoms of such 5 to 8 membered rings may optionally and independently be replaced by an oxygen or sulfur atom or by NZ³ wherein Z³ is hydrogen, C₁-C₄ alkyl, benzyl or C₁-C₄ alkanoyl;
- 20 R³ is hydrogen, C₁-C₄ alkyl, $-\text{O}(\text{C}_1\text{-C}_4 \text{ alkyl})$, chloro, fluoro, bromo, iodo, $-\text{CN}$, $-\text{S}(\text{C}_1\text{-C}_4 \text{ alkyl})$ or $-\text{SO}_2(\text{C}_1\text{-C}_4 \text{ alkyl})$ wherein each of the (C₁-C₄ alkyl) moieties in the foregoing R³ groups may optionally be substituted with one substituent R⁹ selected from hydroxy, fluoro and (C₁-C₂ alkoxy);
- 25 each R⁴ is, independently, hydrogen, (C₁-C₆ alkyl), fluoro, chloro, bromo, iodo, hydroxy, cyano, amino, nitro, $-\text{O}(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{N}(\text{C}_1\text{-C}_4 \text{ alkyl})(\text{C}_1\text{-C}_2 \text{ alkyl})$, $-\text{S}(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{SO}(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{SO}_2(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{CO}(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{C}(=\text{O})\text{H}$ or $-\text{C}(=\text{O})\text{O}(\text{C}_1\text{-C}_4 \text{ alkyl})$, wherein each of the (C₁-C₆ alkyl) and (C₁-C₄ alkyl) moieties in the foregoing R⁴ groups may optionally contain one or two double or triple bonds and may optionally be substituted with one or two substituents independently selected from hydroxy, amino, C₁-C₃ alkoxy, dimethylamino, methylamino, ethylamino, $-\text{NHC}(=\text{O})\text{CH}_3$, fluoro, chloro, C₁-C₃ thioalkyl, $-\text{CN}$, $-\text{COOH}$, $-\text{C}(=\text{O})\text{O}(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{C}(=\text{O})(\text{C}_1\text{-C}_4 \text{ alkyl})$ and $-\text{NO}_2$;
- 30 R⁵ is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, furanyl, benzofuranyl, benzothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, benzoxazolyl or C₃-C₈ cycloalkyl wherein one or two of the carbon atoms of said cycloalkyl rings that contain at least 5 ring members may optionally and independently be replaced by an oxygen or sulfur atom or by NZ⁴ wherein Z⁴ is hydrogen, C₁-C₄ alkyl or benzyl; and wherein each of the foregoing R⁵ groups is substituted with from one to four substituents R¹² wherein one to three of said substituents may be selected, independently, from chloro, C₁-C₆ alkyl and $-\text{O}(\text{C}_1\text{-C}_6 \text{ alkyl})$ and one of said substituents may be selected from bromo, iodo, formyl, $-\text{CN}$, $-\text{CF}_3$, $-\text{NO}_2$, $-\text{NH}_2$, $-\text{NH}(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{N}(\text{C}_1\text{-C}_2 \text{ alkyl})(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{C}(=\text{O})\text{O}(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{C}(=\text{O})(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{COOH}$, $-\text{SO}_2\text{NH}(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{SO}_2\text{N}(\text{C}_1\text{-C}_2 \text{ alkyl})(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{SO}_2\text{NH}_2$, $-\text{NHSO}_2(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{S}(\text{C}_1\text{-C}_6 \text{ alkyl})$ and $-\text{SO}_2(\text{C}_1\text{-C}_6 \text{ alkyl})$, and wherein each of the C₁-C₄ alkyl and C₁-C₆ alkyl moieties in the foregoing R⁵ groups may optionally be substituted with one or two substituents independently selected from fluoro, hydroxy, amino, methylamino, dimethylamino and acetyl;
- 35 R⁷ is hydrogen, C₁-C₄ alkyl, halo, cyano, hydroxy, $-\text{O}(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{C}(=\text{O})(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{C}(=\text{O})\text{O}(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{OCF}_3$, $-\text{CF}_3$, $-\text{CH}_2\text{OH}$, $-\text{CH}_2\text{O}(\text{C}_1\text{-C}_4 \text{ alkyl})$;
- 40 R¹⁰ is hydrogen, hydroxy, methoxy or fluoro;
- 45 R¹¹ is hydrogen or C₁-C₄ alkyl; and
- 50 Z is NH, oxygen, sulfur, $-\text{N}(\text{C}_1\text{-C}_4 \text{ alkyl})$, $-\text{NC}(=\text{O})(\text{C}_1\text{-C}_2 \text{ alkyl})$, $-\text{NC}(=\text{O})\text{O}(\text{C}_1\text{-C}_2 \text{ alkyl})$ or CR¹³R¹⁴ wherein R¹³ and R¹⁴ are independently selected from hydrogen, trifluoromethyl and methyl with the exception that one of R¹³ and R¹⁴ can be cyano;
- 55 with the proviso that: (a) in the five membered rings of structures I, II and III, there can not be two double bonds adjacent to each other; and (b) when R⁴ is attached to nitrogen, it is not halo, cyano or nitro;


or a pharmaceutically acceptable salt of such compound.

8. The use of claim 2 wherein the corticotropin releasing factor antagonist is a compound of formula

5

10

15



20

A is nitrogen or CR⁷;

B is -NR¹R², -CR¹R²R¹⁰, -C(=CR²R¹¹)R¹, -NHCR¹R²R¹⁰, -OCR¹R²R¹⁰, -SCR¹R²R¹⁰, -CR²R¹⁰NHR¹, -CR²R¹⁰OR¹, -CR²R¹⁰SR¹ or -COR², and is single bonded to D; or B is -CR¹R², and is double bonded to D and D is carbon;

25

D is nitrogen or CR⁴ and is single bonded to all atoms to which it is attached, or D is carbon and is double bonded to E or double bonded to B;

E is oxygen, nitrogen, sulfur, C=O, C=S, CR⁶R¹², NR⁶ or CR⁶; or E is a two atom spacer, wherein one of the atoms is oxygen, nitrogen, sulfur, C=O, C=S, CR⁶R¹², NR⁶ or CR⁶, and the other is CR⁶R¹² or CR⁹;

30

K and G are each, independently, C=O, C=S, sulfur, oxygen, CHR⁸ or NR⁸ when single bonded to both adjacent ring atoms, or nitrogen or CR⁸ when it is double bonded to an adjacent ring atom;

the 6- or 7-membered ring that contains D, E, K and G may contain from one to three double bonds, from zero to two heteroatoms selected from oxygen, nitrogen and sulfur, and from zero to two C=O or C=S groups, wherein the carbon atoms of such groups are part of the ring and the oxygen and sulfur atoms are substituents on the ring;

35

R¹ is C₁-C₆ alkyl optionally substituted with from one or two substituents independently selected from hydroxy, fluoro, chloro, bromo, iodo, C₁-C₄ alkoxy, CF₃, -C(=O)(C₁-C₄ alkyl), -C(=O)-O-(C₁-C₄)alkyl, -OC(=O)(C₁-C₄ alkyl), -OC(=O)N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -NHCO(C₁-C₄ alkyl), -COOH, -COO(C₁-C₄ alkyl), -CONH(C₁-C₄ alkyl), -CON(C₁-C₄ alkyl)(C₁-C₂ alkyl), -S(C₁-C₄ alkyl), -CN, -NO₂, -SO(C₁-C₄ alkyl), -SO₂(C₁-C₄ alkyl), -SO₂NH(C₁-C₄ alkyl) and -SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl), wherein each of the C₁-C₄ alkyl groups in the foregoing R¹ groups may optionally contain one or two double or triple bonds;

40

R² is C₁-C₁₂ alkyl which may optionally contain from one to three double or triple bonds, aryl or (C₁-C₄ alkylene) aryl, wherein said aryl and the aryl moiety of said (C₁-C₄ alkylene)aryl is selected from phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidinyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, oxazolyl and benzoxazolyl; C₃-C₈ cycloalkyl or (C₁-C₆ alkylene)(C₃-C₈ cycloalkyl), wherein one or two of the carbon atoms of said cycloalkyl and the 5 to 8 membered cycloalkyl moieties of said (C₁-C₆ alkylene)(C₃-C₅ cycloalkyl) may optionally and independently be replaced by an oxygen or sulfur and wherein each of the foregoing R² groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro, hydroxy and C₁-C₄ alkyl, or with one substituent selected from C₁-C₆ alkoxy, -OC(=O)(C₁-C₆ alkyl), -OC(=O)N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -S(C₁-C₆ alkyl), amino, -NH(C₁-C₂ alkyl), -N(C₁-C₂ alkyl)(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)-CO-(C₁-C₄ alkyl), -NHCO(C₁-C₄ alkyl), -COOH, -COO(C₁-C₄ alkyl), -CONH(C₁-C₄ alkyl), -CON(C₁-C₄ alkyl)(C₁-C₂ alkyl), -SH, -CN, -NO₂, -SO(C₁-C₄ alkyl), -SO₂(C₁-C₄ alkyl), -SO₂NH(C₁-C₄ alkyl) and -SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl);

45

-NR¹R² or CR¹R²R¹⁰ may form a ring selected from saturated 3 to 8 membered rings, the 5 to 8 membered rings of which may optionally contain one or two double bonds, and wherein one or two of the ring carbon atoms of such 5 to 8 membered rings may optionally and independently be replaced by an oxygen or sulfur atom or by NZ³ wherein Z³ is hydrogen or C₁-C₄ alkyl;

50

R³ is hydrogen, C₁-C₄ alkyl, -O(C₁-C₄ alkyl), chloro, fluoro, bromo, iodo, -S(C₁-C₄ alkyl) or -SO₂(C₁-C₄ alkyl);

55

R⁴ is hydrogen, C₁-C₂ alkyl, hydroxy or fluoro;

each R⁶, R⁸ and R⁹ that is attached to a carbon atom is selected, independently, from hydrogen, C₁-C₂ alkyl, fluoro, chloro, bromo, iodo, hydroxy, hydroxymethyl, formyl, trifluoromethyl, cyano, amino, nitro, -O(C₁-C₂ alkyl), -N(C₁-C₂ alkyl)(C₁-C₂ alkyl), -S(C₁-C₂ alkyl), -CO(C₁-C₂ alkyl), -C(=O)H or -C(=O)O(C₁-C₂ alkyl), wherein each of the C₁-C₂ alkyl moieties in the foregoing R⁶, R⁸, and R⁹ groups may optionally contain one double or triple bond; and each R⁶, R⁸, and R⁹ that is attached to a nitrogen atom is selected, independently, from hydrogen and C₁-C₄ alkyl;

5 R⁵ is substituted phenyl, naphthyl, pyridyl or pyrimidyl, wherein each of the foregoing R⁵ groups is substituted with from two to four substituents R¹⁵, wherein from one to three of said substituents may be selected, independently, from chloro, C₁-C₆ alkyl, -O(C₁-C₆ alkyl) and -(C₁-C₆ alkylene)O(C₁-C₆ alkyl), and wherein one of said substituents may be selected, independently, from bromo, iodo, formyl, cyano, trifluoromethyl, nitro, amino, -NH(C₁-C₄ alkyl), -N(C₁-C₂ alkyl)(C₁-C₆ alkyl), -C(=O)O(C₁-C₄ alkyl), -C(=O)(C₁-C₄ alkyl), -COOH, -SO₂NH(C₁-C₄ alkyl), -SO₂N(C₁-C₂ alkyl)(C₁-C₄ alkyl), -SO₂NH₂, -NSO₂(C₁-C₄ alkyl), -S(C₁-C₆ alkyl) and -SO₂(C₁-C₆ alkyl), and wherein each of the C₁-C₄ alkyl and C₁-C₆ alkyl moieties in the foregoing R⁵ groups may optionally be substituted with one or two substituents independently selected from fluoro, hydroxy, amino, methylamino, dimethylamino and acetyl;

10 R⁷ is hydrogen, methyl, halo, hydroxy, methoxy, -C(=O)(C₁-C₂ alkyl), -C(=O)O(C₁-C₂ alkyl), trifluoromethoxy, hydroxymethyl, trifluoromethyl or formyl;


15 R¹⁰ is hydrogen, hydroxy, methoxy or fluoro;

R¹¹ is hydrogen or C₁-C₄ alkyl;

20 R¹² is hydrogen or methyl; and

Z is NH, oxygen, sulfur, -N(C₁-C₄ alkyl), or CR¹³R¹⁴ wherein R¹³ and R¹⁴ are independently selected from hydrogen, and methyl with the exception that one of R¹³ and R¹⁴ may optionally be cyano; with the proviso that: (a) in the six or seven membered rings of structures in formula I, there can not be two double bonds adjacent to each other; and (b) when D is carbon and is double bonded to B, then B is CR¹R²; 25 or a pharmaceutically acceptable salt of such compound.

9. The use of claim 2 wherein the corticotropin releasing factor antagonist is a compound of formula



or a pharmaceutically acceptable salt thereof, wherein

the dashed lines represent optional double bonds;

A is nitrogen or CR⁷;

45 B is -NR¹R², -CR¹R²R¹⁰, -C(=CR²R¹¹)R¹, -NHCR¹R²R¹⁰, -OCR¹R²R¹⁰, -SCR¹R²R¹⁰, -CR²R¹⁰NHR¹, -CR²R¹⁰OR¹, -CR²R¹⁰SR¹ or -COR²;

J and K are each independently nitrogen or carbon and both J and K are not nitrogens;

D and E are each selected, independently, from nitrogen, CR⁴, C=O, C=S, sulfur, oxygen, CR⁴R⁶ and NR⁸;

G is nitrogen or carbon;

50 the ring containing D, E, G, K, and J in formula I may be a saturated or unsaturated 5-membered ring and may optionally contain one or two double bonds and may optionally contain from one to three heteroatoms in the ring and may optionally have one or two C=O or C=S groups;

R¹ is C₁-C₆ alkyl optionally substituted with one or two substituents independently selected from hydroxy, fluoro, chloro, bromo, iodo, -O-(C₁-C₄ alkyl), CF₃, -C(=O)O-(C₁-C₄ alkyl), -OC(=O)(C₁-C₄ alkyl), -OC(=O)N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -NHCO(C₁-C₄ alkyl), -COOH, -COO(C₁-C₄ alkyl), -CONH(C₁-C₄ alkyl), -CON(C₁-C₄ alkyl)(C₁-C₂ alkyl), -S(C₁-C₄ alkyl), -CN, -NO₂, -SO(C₁-C₄ alkyl), -SO₂(C₁-C₄ alkyl), -SO₂NH(C₁-C₄ alkyl) and -SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl), wherein each of the C₁-C₄ alkyl groups in the foregoing R¹ groups may optionally contain one or two double or triple bonds;

55

R² is C₁-C₁₂ alkyl which may optionally contain from one to three double or triple bonds, aryl or (C₁-C₄ alkylene) aryl, wherein said aryl and the aryl moiety of said (C₁-C₄ alkylene)aryl is selected from phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidinyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, oxazolyl and benzoxazolyl; C₃-C₈ cycloalkyl or (C₁-C₆ alkylene)(C₃-C₈ cycloalkyl), wherein one or two of the carbon atoms of said cycloalkyl and the 5 to 8 membered cycloalkyl moieties of said (C₁-C₆ alkylene)(C₃-C₈ cycloalkyl) may optionally and independently be replaced by an oxygen or sulfur atom or by NZ² wherein Z² is selected from hydrogen, C₁-C₄ alkyl, benzyl and C₁-C₄ alkanoyl, and wherein each of the foregoing R² groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro, hydroxy and C₁-C₄ alkyl, or with one substituent selected from bromo, iodo, C₁-C₆ alkoxy, -OC(=O)(C₁-C₆ alkyl), -OC(=O)N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -S(C₁-C₆ alkyl), amino, -NH(C₁-C₂ alkyl), -N(C₁-C₂ alkyl)(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)-CO-(C₁-C₄ alkyl), -NHCO(C₁-C₄ alkyl), -COOH, -COO(C₁-C₄ alkyl), -CONH(C₁-C₄ alkyl), -CON(C₁-C₄ alkyl)(C₁-C₂ alkyl), -SH, -CN, -NO₂, -SO(C₁-C₄ alkyl), -SO₂(C₁-C₄ alkyl), -SO₂NH(C₁-C₄ alkyl) and -SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl);

-NR¹R² or CR¹R²R¹⁰ may form a saturated 3 to 8 membered carbocyclic ring which may optionally contain from one to three double bonds and wherein one or two of the ring carbon atoms of such 5 to 8 membered rings may optionally and independently be replaced by an oxygen or sulfur atom or by NZ³ wherein Z³ is hydrogen, C₁-C₄ alkyl, benzyl or C₁-C₄ alkanoyl;

R³ is hydrogen, C₁-C₄ alkyl, -O(C₁-C₄ alkyl), chloro, fluoro, bromo, iodo, (C₁-C₂ alkylene)-O-(C₁-C₂ alkyl), (C₁-C₂ alkylene)-OH, or -S(C₁-C₄ alkyl);

each R⁴ is, independently, hydrogen, (C₁-C₆ alkyl), fluoro, chloro, bromo, iodo, hydroxy, cyano, amino, (C₁-C₂ alkylene)-OH, CF₃, CH₂SCH₃, nitro, -O(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -S(C₁-C₄ alkyl), -CO(C₁-C₄ alkyl), -C(=O)H or -C(=O)O(C₁-C₄ alkyl);

R⁶ is hydrogen, methyl or ethyl;

R⁸ is hydrogen or C₁-C₄ alkyl;

R⁵ is phenyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl and wherein each of the foregoing R⁵ groups is substituted with from one to four substituents R¹³ wherein one to three of said substituents may be selected, independently, from fluoro, chloro, C₁-C₆ alkyl and -O(C₁-C₆ alkyl) and one of said substituents may be selected from bromo, iodo, formyl, OH, (C₁-C₄ alkylene)-OH, (C₁-C₄ alkylene)-O-(C₁-C₂ alkyl), -CN, -CF₃, -NO₂, -NH₂, -NH(C₁-C₄ alkyl), -N(C₁-C₂ alkyl)(C₁-C₆ alkyl), -OCO(C₁-C₄ alkyl), (C₁-C₄ alkylene)-O-(C₁-C₄ alkyl), -S(C₁-C₆ alkyl), (C₁-C₄ alkylene)-S-(C₁-C₄ alkyl), -C(=O)O(C₁-C₄ alkyl), -C(=O)(C₁-C₄ alkyl), -COOH, -SO₂NH(C₁-C₄ alkyl), -SO₂N(C₁-C₂ alkyl)(C₁-C₄ alkyl), -SO₂NH₂, -NSO₂(C₁-C₄ alkyl), -S(C₁-C₆ alkyl) and -SO₂(C₁-C₆ alkyl), and wherein each of the C₁-C₄ alkyl and C₁-C₆ alkyl moieties in the foregoing R⁵ groups may optionally have one or two double bonds;

R⁷ is hydrogen, C₁-C₄ alkyl, halo (e.g., chloro, fluoro, iodo or bromo), hydroxy, -O(C₁-C₄ alkyl), -C(=O)(C₁-C₄ alkyl), -C(=O)O(C₁-C₄ alkyl), -OCF₃, -CF₃, -CH₂OH or -CH₂O(C₁-C₂ alkyl);


R¹⁰ is hydrogen, hydroxy, methoxy or fluoro;

R¹¹ is hydrogen or C₁-C₄ alkyl; and

with the proviso that: a) when both J and K are carbons and D is CR⁴ and E is nitrogen, then G can not be nitrogen; (b) when both J and K are carbons and D and G are nitrogens, then E can not be CR⁴ or C=O or C=S; (c) when both J and K are carbons and D and E are carbons, then G can not be nitrogen; (d) when G is carbon, it must be double banded to E; and (e) in the ring containing J, K, D, E and G, there can not be two double bonds adjacent to each other;

and the pharmaceutically acceptable salts of such compounds.

45 10. The use of claim 2 wherein the corticotropin releasing factor antagonist is a compound of formula



wherein the dashed lines represent optional double bonds;

A is nitrogen or CR⁷;

5 B is -NR¹R², -CR¹R²R¹⁰, -C(=CR²R¹¹)R¹, -NHCR¹R²R¹⁰, -OCR¹R²R¹⁰, -SCR¹R²R¹⁰, -CR²R¹⁰NHR¹, -CR²R¹⁰OR¹, -CR²R¹⁰SR¹ or -COR²;

G is nitrogen or CR⁴ and is single bonded to all atoms to which it is attached, or G is carbon and is double bonded to K;

10 K is nitrogen or CR⁶ when double bonded to G or E, or K is oxygen, sulfur, C=O, C=S, CR⁶R¹² or NR⁸ when single bonded to both adjacent ring atoms, or K is a two atom spacer, wherein one of the two ring atoms of the spacer is oxygen, nitrogen, sulfur, C=O, C=S, CR⁶R¹², NR⁶ or CR⁶, and the other is CR⁶R¹² or CR⁹;

D and E are each, independently, C=O, C=S, sulfur, oxygen, CR⁴R⁶ or NR⁸ when single bonded to both adjacent ring atoms, or nitrogen or CR⁴ when it is double bonded to an adjacent ring atom;

15 the 6- or 7-membered ring that contains D, E, K and G may contain from one to three double bonds, from zero to two heteroatoms selected from oxygen, nitrogen and sulfur, and from zero to two C=O or C=S groups, wherein the carbon atoms of such groups are part of the ring and the oxygen and sulfur atoms are substituents on the ring;

20 R¹ is C₁-C₆ alkyl optionally substituted with from one or two substituents independently selected from hydroxy, fluoro, chloro, bromo, iodo, C₁-C₄ alkoxy, CF₃, -C(=O)(C₁-C₄ alkyl), -C(=O)-O-(C₁-C₄)alkyl, -OC(=O)(C₁-C₄ alkyl), -OC(=O)N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -NHCO(C₁-C₄ alkyl), -COOH, -COO(C₁-C₄ alkyl), -CONH(C₁-C₄ alkyl), -CON(C₁-C₄ alkyl)(C₁-C₂ alkyl), -S(C₁-C₄ alkyl), -CN, -NO₂, -SO(C₁-C₄ alkyl), -SO₂(C₁-C₄ alkyl), -SO₂NH(C₁-C₄ alkyl) and -SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl), wherein each of the C₁-C₄ alkyl groups in the foregoing R¹ groups may optionally contain one or two double or triple bonds;

25 R² is C₁-C₁₂ alkyl which may optionally contain from one to three double or triple bonds, aryl or (C₁-C₄ alkylene) aryl, wherein said aryl and the aryl moiety of said (C₁-C₄ alkylene)aryl is selected from phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidinyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, oxazolyl and benzoxazolyl; C₃-C₈ cycloalkyl or (C₁-C₆ alkylene)(C₃-C₈ cycloalkyl), wherein one or two of the carbon atoms of said cycloalkyl and the 5 to 8 membered cycloalkyl moieties of said (C₁-C₆ alkylene)(C₃-C₈ cycloalkyl) may optionally and independently be replaced by an oxygen or sulfur atom or by NZ where Z is hydrogen, C₁-C₄ alkyl or benzyl, and wherein each of the foregoing R² groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro, hydroxy and C₁-C₄ alkyl, or with one substituent selected from C₁-C₆ alkoxy, -OC(=O)(C₁-C₆ alkyl), -OC(=O)N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -S(C₁-C₆ alkyl), amino, -NH(C₁-C₂ alkyl), -N(C₁-C₂ alkyl)(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)-CO-(C₁-C₄ alkyl), -NHCO(C₁-C₄ alkyl), -COOH, -COO(C₁-C₄ alkyl), -CONH(C₁-C₄ alkyl), -CON(C₁-C₄ alkyl)(C₁-C₂ alkyl), -SH, -CN, -NO₂, -SO(C₁-C₄ alkyl), -SO₂(C₁-C₄ alkyl), -SO₂NH(C₁-C₄ alkyl) and -SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl);

30 35 -NR¹R² or CR¹R²R¹⁰ may form a ring selected from saturated 3 to 8 membered rings, the 5 to 8 membered rings of which may optionally contain one or two double bonds, and wherein one or two of the ring carbon atoms of such 5 to 8 membered rings may optionally and independently be replaced by an oxygen or sulfur atom or by NZ² where Z² is hydrogen, benzyl or C₁-C₄ alkyl;

40 R³ is hydrogen, C₁-C₄ alkyl, -O(C₁-C₄ alkyl), chloro, fluoro, bromo, iodo, -S(C₁-C₄ alkyl) or -SO₂(C₁-C₄ alkyl); each R⁸, R⁹ and R¹² is selected, independently, from hydrogen and C₁-C₂ alkyl;

45 each R⁴ and R⁶ that is attached to a carbon atom is selected, independently, from hydrogen and C₁-C₆ alkyl, fluoro, chloro, bromo, iodo, hydroxy, hydroxy (C₁-C₂ alkyl), trifluoromethyl, cyano, amino, nitro, -O(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -CH₂SCH₃, -S(C₁-C₄ alkyl), -CO(C₁-C₄ alkyl), -C(=O)H or -C(=O)O(C₁-C₄ alkyl), wherein each of the C₁-C₂ alkyl moieties in the foregoing R⁴ and R⁶ groups may optionally contain one double or triple bond; and R⁶, when attached to a nitrogen atom, is selected from hydrogen and C₁-C₄ alkyl;

50 R⁵ is substituted phenyl, naphthyl, pyridyl or pyrimidyl, wherein each of the foregoing R⁵ groups is substituted with from two to four substituents R¹³, wherein up to three of said substituents may be selected, independently, from chloro, C₁-C₆ alkyl, -O(C₁-C₆ alkyl) and -(C₁-C₆ alkylene)O(C₁-C₆ alkyl), and wherein one of said substituents may be selected, independently, from bromo, iodo, formyl, cyano, trifluoromethyl, nitro, amino, -NH(C₁-C₄ alkyl), -N(C₁-C₂ alkyl)(C₁-C₆ alkyl), -C(=O)O(C₁-C₄ alkyl), -C(=O)(C₁-C₄ alkyl), -COOH, -SO₂NH(C₁-C₄ alkyl), -SO₂N(C₁-C₂ alkyl)(C₁-C₄ alkyl), -SO₂NH₂, -NHSO₂(C₁-C₄ alkyl), -(C₀-C₁alkylene)-S-(C₁-C₂alkyl), -(C₀-C₁alkylene)-SO-(C₁-C₂alkyl), -(C₀-C₁alkylene)-SO₂-(C₁-C₂alkyl) and -(C₁-C₄alkylene)-OH, and wherein each of the C₁-C₄ alkyl and C₁-C₆ alkyl moieties in the foregoing R⁵ groups may optionally be substituted with one or two substituents independently selected from fluoro, hydroxy, amino, methylamino, dimethylamino and acetyl;

55 R⁷ is hydrogen, methyl, halo (e.g., chloro, fluoro, iodo or bromo), hydroxy, methoxy, -C(=O)(C₁-C₂ alkyl), -C(=O)O(C₁-C₂ alkyl), hydroxymethyl, trifluoromethyl or formyl;


R¹⁰ is hydrogen, hydroxy, methoxy or fluoro; and
 R¹¹ is hydrogen or C₁-C₄ alkyl;
 with the proviso that in the ring containing D, E, K and G of formula I, there can not be two double bonds
 adjacent to each other;
 and the pharmaceutically acceptable salt of such compound.

5

11. The use of claim 2 wherein the corticotropin releasing factor antagonist is a compound of formula

10

15



20


wherein each of R¹ and R² is independently a halogen atom; a C₁-C₅ hydroxyalkyl radical; C₁-C₅ alkyl; C₇-C₁₀ aralkyl; C₁-C₅ alkoxy; trifluoromethyl; nitro; nitrile; a group -SR where R is hydrogen, a C₁-C₅ alkyl radical or a C₇-C₁₀ aralkyl radical; a group S-CO-R where R is a C₁-C₅ alkyl radical or aralkyl in which the aryl portion is C₆-C₈ and the alkyl portion is C₁-C₄; a group -COOR' where R' is hydrogen or C₁-C₅ alkyl; a group -CONR'R" where R' and R" are as defined above for R'; a group -NR'R" where R' and R" are as previously defined for R'; a group -CONRaRb or NRaRb, where Ra and Rb, taken together with the nitrogen atom to which they are attached, form a 5- to 7-membered heterocyclic ring; or a group -NHCO-NR'R", where R' and R" are as defined above for R'; R³ is hydrogen or as defined for R¹ and R² is a hydrogen atom; C₁₋₅ alkyl; halogen; a hydroxymethyl group; or a formyl group; R⁵ is C₁-C₂ alkyl; a C₃-C₇ cycloalkyl group; a cycloalkylalkyl group in which the cycloalkyl portion is C₃-C₇ and the alkyl portion is C₁-C₅; or C₅-C₆ alkenyl; n is 0 or 1; R⁶ is C₁₋₅ alkyl; alkoxyalkyl in which the alkyl portions are C₁-C₅; C₃-C₇ cycloalkyl; a cycloalkylalkyl group in which the cycloalkyl portion is C₃-C₇ and the alkyl portion is C₁-C₅; a cycloalkyloxyalkyl radical in which the cycloalkyl is C₃-C₇ and the alkyl is C₁-C₄; a hydroxyalkyloxyalkyl radical in which the alkyls are C₂-C₁₀; or an alkoxyalkyloxyalkyl radical in which the alkyls are C₃-C₁₂; and Z is an optionally substituted bi- or tricyclic aromatic or heteroaromatic group; and stereoisomers and/or addition salts thereof.

35

12. The use of claim 2 wherein the corticotropin releasing factor antagonist is a compound of formula

40

45



including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein

50

R¹ is NR⁴R⁵ or OR⁵;
 R² is C₁-C₆alkyl, C₁-C₆alkyloxy or C₁-C₆alkylthio,
 R³ is hydrogen, C₁-C₆alkyl, C₁-C₆alkylsulfonyl, C₁-C₆alkylsulfoxy or C₁-C₆alkylthio;
 R⁴ is hydrogen, C₁-C₆alkyl, mono- or di(C₃-C₆cycloalkyl)methyl, C₃-C₆cycloalkyl, C₃-C₆alkenyl, hydroxyC₁-C₆alkyl, C₁-C₆alkylcarbonyloxyC₁-C₆alkyl or C₁-C₆alkyloxyC₁-C₆alkyl;
 R⁵ is C₁-C₈alkyl, mono- or di(C₃-C₆cycloalkyl)methyl, Ar¹CH₂, C₃-C₆alkenyl, C₁-C₆alkyloxyC₁-C₆alkyl, hydroxyC₁-C₆alkyl, thienylmethyl, furanylmethyl, C₁-C₆alkylthioC₁-C₆alkyl, morpholinyl, mono- or di(C₁-C₆alkyl)aminoC₁-C₆alkyl, di(C₁-C₆alkyl)amino, C₁-C₆alkylcarbonylC₁-C₆alkyl, C₁-C₆alkyl substituted with imidazolyl; or a radical of formula -Alk-O-CO-Ar¹;

or R⁴ and R⁵ taken together with the nitrogen atom to which they are attached may form a pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group, optionally substituted with C₁-C₆alkyl or C₁-C₆alkyloxyC₁-C₆alkyl; and

5 Ar is phenyl; phenyl substituted with 1, 2 or 3 substituents independently selected from halo, C₁-C₆alkyl, trifluoromethyl, hydroxy, cyano, C₁-C₆alkyloxy, benzyloxy, C₁-C₆alkylthio, nitro, amino and mono- or di(C₁-C₆alkyl)amino; pyridinyl; pyridinyl substituted with 1 ~ 2 or 3 substituents independently selected from halo, C₁-C₆alkyl, trifluoromethyl, hydroxy, cyano, C₁-C₆alkyloxy, benzyloxy, C₁-C₆alkylthio, nitro, amino, mono- or di(C₁-C₆alkyl)amino and piperidinyl; and wherein said substituted phenyl may optionally be further substituted with one or more halogens;

10 Ar¹ is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, C₁-C₆alkyl, C₁-C₆alkyloxy, di(C₁-C₆alkyl)aminoC₁-C₆alkyl, trifluoromethyl and C₁-C₆alkyl substituted with morpholinyl; or pyridinyl; and Alk is C₁-C₆alkanediyl;


with the proviso that

15 5-methyl-3-phenyl-7-(phenylmethoxy)-pyrazolo[1,5-a]-pyrimidine and 2,5-dimethyl-7-(methylamino)-3-phenyl-pyrazolo[1,5-a]pyrimidine are not included.

13. The use of claim 2 wherein the corticotropin releasing factor antagonist is a compound of formula

20

25



30

including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein

X is S, SO or S0₂;

R¹ is NR⁴R⁵ or OR⁵;

35 R² is C₁-C₆alkyl, C₁-C₆alkyloxy or C₁-C₆alkylthio;

R³ is hydrogen, C₁-C₆alkyl, C₁-C₆alkylsulfonyl, C₁-C₆alkylsulfoxy or C₁-C₆alkylthio;

R⁴ is hydrogen, C₁-C₆alkyl, mono- or di(C₃-C₆cycloalkyl)methyl, C₃-C₆cycloalkyl, C₃-C₆alkenyl, hydroxyC₁-C₆alkyl, C₁-C₆alkylcarbonyloxyC₁-C₆alkyl or C₁-C₆alkyloxyC₁-C₆alkyl;

40 R⁵ is C₁-C₆alkyl, mono- or di(C₃-C₆cycloalkyl)methyl, Ar¹CH₂, C₃-C₆alkenyl, C₁-C₆alkyloxyC₁-C₆alkyl, hydroxyC₁-C₆alkyl, thiethylmethyl, furanylmethyl, C₁-C₆alkylthioC₁-C₆alkyl, morpholinyl, mono- or di(C₁-C₆alkyl)aminoC₁-C₆alkyl, di(C₁-C₆alkyl)amino, C₁-C₆alkylcarbonylC₁-C₆alkyl, C₁-C₆alkyl substituted with imidazolyl; or a radical of formula -Alk-O-CO-Ar;

45 or R⁴ and R⁵ taken together with the nitrogen atom to which they are attached may form a pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group, optionally substituted with C₁-C₆alkyl or C₁-C₆alkyloxyC₁-C₆alkyl;

Ar is phenyl; phenyl substituted with 1, 2 or 3 substituents independently selected from halo, C₁-C₆alkyl, trifluoromethyl, hydroxy, cyano, C₁-C₆alkyloxy, benzyloxy, C₁-C₆alkylthio, nitro, amino and mono- or di(C₁-C₆alkyl)amino; pyridinyl; pyridinyl substituted with 1, 2 or 3 substituents independently selected from halo, C₁-C₆alkyl, trifluoromethyl, hydroxy, cyano, C₁-C₆alkyloxy, benzyloxy, C₁-C₆alkylthio, nitro, amino, mono- or di(C₁-C₆alkyl)amino and piperidinyl; and wherein said substituted phenyl may optionally be further substituted with one or more halogens;

50 Ar¹ is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, C₁-C₆alkyl, C₁-C₆alkyloxy, di(C₁-C₆alkyl)aminoC₁-C₆alkyl trifluoromethyl, and C₁-C₆alkyl substituted with morpholinyl; or pyridinyl; and

55 Alk is C₁-C₆alkanediyl.

14. The use of claim 2 wherein the corticotropin releasing factor antagonist is a compound selected from the group consisting of:

4-(1-ethyl-propoxy)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-pyridine;
 butyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-ethyl-amine;
 4-(butyl-ethylamino)-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one;
 4-(1-ethylpropoxy)-2,5-dimethyl-6-(2,4,6-trimethylphenoxy)-pyrimidine;
 5 N-butyl-N-ethyl-2,5-dimethyl-NN-(2,4,6-trimethylphenyl)-pyrimidine-4,6-diamine;
 [4-(1-ethyl-propoxy)-3,6-dimethyl-pyridin-2-yl]-(2,4,6-trimethylphenyl)-amine;
 6-(ethyl-propyl-amino)-2,7-dimethyl-9-(2,4,6-trimethylphenyl)-7,9-dihydro-purin-8-one;
 3-[(4-methyl-benzyl)-{3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amino}-propan-1-ol;
 10 diethyl-[6-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
 2-{butyl-[6-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amino}-ethanol;
 dibutyl-[6-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
 butyl-ethyl-[6-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
 15 butyl-ethyl-[6-methyl-3-methylsulfonyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
 butyl-cyclopropylmethyl-[6-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
 di-1-propyl-[6-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
 diallyl-[6-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
 20 butyl-ethyl-[6-chloro-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
 butyl-ethyl-[6-methoxy-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
 propyl-ethyl-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
 4-(1-ethyl-propyl)-6-methyl-3-methylsulfanyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidine;
 n-butyl-ethyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;
 25 di-n-propyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;
 ethyl-n-propyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;
 diethyl-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;
 n-butyl-ethyl-[2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;
 30 2-[N-n-butyl-N-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-ethanol;
 4-(1-ethyl-propyl)-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine;
 n-butyl-ethyl-[2,5-dimethyl-7-(2,4-dimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;
 2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidyl-4-yl)-(1-ethyl-propyl)amine;
 butyl-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-ethylamine;
 [3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-(1-methoxymethylpropyl)-amine;
 35 4-(1-methoxymethylpropoxy)-3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridine;
 (1-ethylpropyl)-[3,5,6-trimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-amine;
 4-(1-ethylpropoxy)-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-b]pyridine;
 4-(1-ethylpropoxy)-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-b]pyridine;
 4-(1-ethylpropoxy)-2,5-dimethyl-7-(2,6-dimethyl-4-bromophenyl)-7H-pyrrolo[2,3-b]pyridine;
 40 2,5,6-trimethyl-7-(1-propylbutyl)-4-(2,4,6-trimethylphenoxy)-7H-pyrrolo[2,3-d]pyrimidine;
 1-(1-ethylpropyl)-6-methyl-4-(2,4,6-trimethylphenylamino)-1,3-dihydro-imidazo[4,5-c]pyridin-2-one;
 9-(1-ethylpropyl)-2-methyl-6-(2,4,6-trimethylphenylamino)-7,9-dihydro-purin-8-one;
 1-(1-ethylpropyl)-6-methyl-4-(2,4,6-trimethylphenoxy)-1,3-dihydro-imidazo[4,5-c]pyridin-2-one;
 45 1-(1-ethylpropyl)-6-methyl-4-(2,4,6-trimethylphenoxy)-1H-imidazo[4,5-c]pyridine;
 1-(1-ethylpropyl)-3,6-dimethyl-4-(2,4,6-trimethylphenoxy)-1,3-dihydro-imidazo[4,5-c]pyridin-2-one;
 1-(1-ethylpropyl)-3,6-dimethyl-4-(2,4,6-trimethylphenylamino)-1,3-dihydro-imidazo[4,5-c]pyridin-2-one;
 1-(1-ethyl-propyl)-4,7-dimethyl-5-(2,4,6-trimethyl-phenoxy)-1,4-dihydro-2H-pyrido[3,4-b]pyrazin-3-one;
 50 1-(1-ethyl-propyl)-4,7-dimethyl-5-(2,4,6-trimethyl-phenoxy)-1,2,3,4-tetrahydro-pyrido[3,4-b]pyrazine;
 1-(1-ethyl-propyl)-7-methyl-5-(2,4,6-trimethyl-phenoxy)-1,2,3,4-tetrahydro-pyrido[3,4-b]pyrazine;
 1-(1-ethyl-propyl)-7-methyl-2-oxo-5-(2,4,6-trimethyl-phenoxy)-1,2,3,4-tetra-hydro-[1,6]naphthyridine-3-carboxylic acid methyl ester;
 1-(1-ethyl-propyl)-7-methyl-2-oxo-5-(2,4,6-trimethyl-phenoxy)-1,2,3,4-tetra-hydro-[1,6]naphthyridine-3-carboxylic acid isopropyl ester;
 55 1-(1-ethyl-propyl)-7-methyl-5-(2,4,6-trimethyl-phenoxy)-3,4-dihydro-1H-[1,6]naphthyridin-2-one;
 1-(1-ethyl-propyl)-7-methyl-5-(2,4,6-trimethyl-phenoxy)-1,2,3,4-tetrahydro-[1,6]naphthyridine;
 1-(1-ethyl-propyl)-7-methyl-5-(2,4,6-trimethyl-phenoxy)-1,4-dihydro-2H-3-oxa-1,6-diaza-naphthalene;
 1-(1-ethyl-propyl)-4,7-dimethyl-5-(2,4,6-trimethyl-phenoxy)-1,4-dihydro-2H-3-oxa-1,6-diaza-naphthalene;
 1-(1-ethyl-propyl)-3,7-dimethyl-5-(2,4,6-trimethyl-phenoxy)-3,4-dihydro-1H-3-oxa-[1,6]-naphthyridin-2-one;

1-(1-ethyl-propyl)-3,3,6-trimethyl-4-(2,4,6-trimethyl-phenoxy)-2,3-dihydro-1 H-pyrrolo[3,2-c]pyridine;
 7-(1-ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidine;
 [2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]- (1-ethyl-propyl)-amine;
 (1-ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-amine;
 5 7-(1-ethyl-propoxy)-2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidine;
 [2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-ethylpropyl-amine;
 [6-bromo-5-bromomethyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl]- (1-ethyl-propyl)-
 amine;
 (1-ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl]-amine;
 10 [6-bromo-5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl]- (1-ethyl-propyl)-methyl-
 amine;
 7-(1-ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridine;
 4-(1-ethyl-propoxy)-2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyrimidine;
 15 (\pm)-2,5-dimethyl-4-(tetrahydro-furan-3-yloxy)-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo-[3,2-d]pyrimidine;
 2,5-dimethyl-4-(S)-(tetrahydro-furan-3-yloxy)-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo-[3,2-d]pyrimidine;
 2,5-dimethyl-4-(1-propyl-butoxy)-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyrimidine;
 4-sec-butylsulfanyl-2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyrimidine;
 4-(butyl-ethyl-amino)-2,6-dimethyl-8-(2,4,6-trimethyl-phenyl)-5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-7-one;
 8-(1-ethyl-propoxy)-6-methyl-4-(2,4,6-trimethyl-phenyl)-3,4-dihydro-1H-pyrido[2,3-b] pyrazin-2-one;
 20 8-(1-ethyl-propoxy)-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydro-pyrido [2,3-b]pyrazine;
 4-(1-ethyl-propoxy)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline;
 5-(1-ethyl-propoxy)-7-methyl-1-(2,4,6-trimethyl-phenyl)-1,4-dihydro-2H-3-oxa-1,8-diaza-naphthalene;
 5-(1-ethyl-propoxy)-7-methyl-1-(2,4,6-trimethyl-phenyl)-1,2-dihydro-3-oxa-1, 8-diaza-naphthalen-4-one;
 25 8-(1-ethyl-propoxy)-1,6-dimethyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine;
 (1-ethyl-propyl)-[2-methyl-8-(2,4,6-trimethyl-phenyl)-quinolin-4-yl]-amine;
 4-(butyl-ethyl-amino)-2,6-dimethyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-
 7-one;
 30 4-(butyl-ethyl-amino)-2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,8-dihydro-6 H- pyrido[2,3-d]pyrimidin-
 7-one;
 4-(1-ethyl-propoxy)-2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,8-dihydro-6 H- pyrido[2,3-d]pyrimidin-
 7-one;
 (butyl-ethyl)-[2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-4-yl]-
 35 amine;
 (propyl-ethyl)-[2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-4-yl]-
 amine;
 (diethyl)-[2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,6,7,8-tetrahydro-pyrido [2,3-d]pyrimidin-4-yl]-amine;
 (1-ethyl-propyl)-[2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,6,7,8-tetrahydro- pyrido[2,3-d]pyrimidin-4-yl]-
 40 amine;
 (1-ethyl-propoxy)-2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidine;
 4-(butyl-ethyl-amino)-2-methyl-8-(2,4,6-trimethyl-phenyl)-5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-7-one;
 4-(1-ethyl-propoxy)-2-methyl-8-(2,4,6-trimethyl-phenyl)-5,8-dihydro-6H-pyrido [2,3-d]pyrimidin-7-one;
 (butyl-ethyl)-[2-methyl-8-(2,4,6-trimethyl-phenyl)-5,6,7,8-tetrahydro-pyrido[2, 3-d] pyrimidin-4-yl]-amine;
 (propyl-ethyl)-[2-methyl-8-(2,4,6-trimethyl-phenyl)-5,6,7,8-tetrahydro-pyrido-[2,3-d] pyrimidin-4-yl]-amine;
 (diethyl)-[2-methyl-8-(2,4,6-trimethyl-phenyl)-5,6,7,8-tetrahydro-pyrido[2,3-d] pyrimidin-4-yl]-amine;
 45 (1-ethyl-propyl)-[2-methyl-8-(2,4,6-trimethyl-phenyl)-5,6,7,8-tetrahydropyrido[2,3-d] pyrimidin-4-yl]-amine;
 (1-ethyl-propoxy)-2-methyl-8-(2,4,6-trimethyl-phenyl)-5,6,7,8-tetrahydropyrido[2,3-d] pyrimidine;
 8-(1-ethyl-propoxy)-6-methyl-4-(2,6-dimethyl-4-bromo-phenyl)-3,4-dihydro-1H-pyrido [2,3-b]pyrazin-2-one;
 8-(1-ethyl-propoxy)-6-methyl-4-(2,6-dimethyl-4-bromo-phenyl)-1,2,3,4-tetrahydro- pyrido[2,3-b]pyrazine;
 50 4-(1-ethyl-propoxy)-2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-quinoline;
 5-(1-ethyl-propoxy)-7-methyl-1-(2,6-dimethyl-4-bromo-phenyl)-1,4-dihydro-2 H- 3-oxa-1,8-diaza-naphtha-
 lene;
 5-(1-ethyl-propoxy)-7-methyl-1-(2,6-dimethyl-4-bromo-phenyl)-1,2-dihydro-3 - oxa-1,8-diaza-naphthalen-
 4-one;
 8-(1-ethyl-propoxy)-1,6-dimethyl-4-(2,6-dimethyl-4-bromo-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine;
 55 (1-ethyl-propyl)-[2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-quinolin-4-yl]-amine;
 4-(butyl-ethyl-amino)-2,6-dimethyl-8-(2,6-dimethyl-4-chloro-phenyl)-5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-
 7-one;
 8-(1-ethyl-propoxy)-6-methyl-4-(2,6-dimethyl-4-chloro-phenyl)-3,4-dihydro-1 H- pyrido[2,3-b]pyrazin-2-one;

8-(1-ethyl-propoxy)-6-methyl-4-(2,6-dimethyl-4-chloro-phenyl)-1,2,3,4-tetrahydro- pyrido[2,3-b]pyrazine;
 4-(1-ethyl-propoxy)-2-methyl-8-(2,6-dimethyl-4-chloro-phenyl)-quinoline; 5-(1-ethyl-propoxy)-7-methyl-1-(2,6-dimethyl-4-chloro-phenyl)-1,4-dihydro-2H-3-oxa-1,8-diaza-naphthalene;
 5-(1-ethyl-propoxy)-7-methyl-1-(2,6-dimethyl-4-chloro-phenyl)-1,2-dihydro-3-oxa-1,8-diaza-naphthalen-
 5
 4-one;
 8-(1-ethyl-propoxy)-1,6-dimethyl-4-(2,6-dimethyl-4-chloro-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine;
 (1-ethyl-propyl)-[2-methyl-8-(2,6-dimethyl-4-chloro-phenyl)-quinolin-4-yl]-amine;
 8-(1-hydroxymethyl-propoxy)-6-methyl-4-(2,4,6-trimethyl-phenyl)-3,4-dihydro - 1H-pyrido[2,3-b]pyrazin-
 10
 2-one;
 8-(1-hydroxymethyl-propylamino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-3,4-dihydro-1H-pyrido[2,3-b]pyrazin-
 2-one;
 8-(1-ethyl-propylamino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-one;
 8-diethylamino-6-methyl-4-(2,4,6-trimethyl-phenyl)-3,4-dihydro-1H-pyrido-[2,3-b] pyrazin-2-one;
 8-(ethyl-propyl-amino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-one;
 15
 8-(butyl-ethyl-amino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-3,4-dihydro-1H-pyrido [2,3-b]pyrazin-2-one;
 8-(1-hydroxymethyl-propoxy)-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine;
 8-(1-hydroxymethyl-propylamino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4 - tetrahydro-pyrido[2,3-b]pyra-
 20
 25
 30
 35
 40
 45
 50
 55
 zine;
 8-(1-ethyl-propylamino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine;
 8-diethylamino-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine;
 8-(ethyl-propyl-amino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydro - pyrido[2,3-b]pyrazine;
 8-(butyl-ethyl-amino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine;
 4-(1-hydroxymethyl-propoxy)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline;
 4-(1-hydroxymethyl-propylamino)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline;
 4-(1-ethyl-propylamino)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline;
 4-diethylamino-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline;
 4-(ethyl-propyl-amino)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline;
 4-(butyl-ethyl-amino)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline;
 5-(1-hydroxymethyl-propoxy)-7-methyl-1-(2,4,6-trimethyl-phenyl)-1,4-dihydro - 2H-3-oxa-1,8-diaza-naphtha-
 2
 7
 12
 17
 22
 27
 32
 37
 42
 47
 52
 57
 62
 67
 72
 77
 82
 87
 92
 97
 102
 107
 112
 117
 122
 127
 132
 137
 142
 147
 152
 157
 162
 167
 172
 177
 182
 187
 192
 197
 202
 207
 212
 217
 222
 227
 232
 237
 242
 247
 252
 257
 262
 267
 272
 277
 282
 287
 292
 297
 302
 307
 312
 317
 322
 327
 332
 337
 342
 347
 352
 357
 362
 367
 372
 377
 382
 387
 392
 397
 402
 407
 412
 417
 422
 427
 432
 437
 442
 447
 452
 457
 462
 467
 472
 477
 482
 487
 492
 497
 502
 507
 512
 517
 522
 527
 532
 537
 542
 547
 552
 557
 562
 567
 572
 577
 582
 587
 592
 597
 602
 607
 612
 617
 622
 627
 632
 637
 642
 647
 652
 657
 662
 667
 672
 677
 682
 687
 692
 697
 702
 707
 712
 717
 722
 727
 732
 737
 742
 747
 752
 757
 762
 767
 772
 777
 782
 787
 792
 797
 802
 807
 812
 817
 822
 827
 832
 837
 842
 847
 852
 857
 862
 867
 872
 877
 882
 887
 892
 897
 902
 907
 912
 917
 922
 927
 932
 937
 942
 947
 952
 957
 962
 967
 972
 977
 982
 987
 992
 997
 1002
 1007
 1012
 1017
 1022
 1027
 1032
 1037
 1042
 1047
 1052
 1057
 1062
 1067
 1072
 1077
 1082
 1087
 1092
 1097
 1102
 1107
 1112
 1117
 1122
 1127
 1132
 1137
 1142
 1147
 1152
 1157
 1162
 1167
 1172
 1177
 1182
 1187
 1192
 1197
 1202
 1207
 1212
 1217
 1222
 1227
 1232
 1237
 1242
 1247
 1252
 1257
 1262
 1267
 1272
 1277
 1282
 1287
 1292
 1297
 1302
 1307
 1312
 1317
 1322
 1327
 1332
 1337
 1342
 1347
 1352
 1357
 1362
 1367
 1372
 1377
 1382
 1387
 1392
 1397
 1402
 1407
 1412
 1417
 1422
 1427
 1432
 1437
 1442
 1447
 1452
 1457
 1462
 1467
 1472
 1477
 1482
 1487
 1492
 1497
 1502
 1507
 1512
 1517
 1522
 1527
 1532
 1537
 1542
 1547
 1552
 1557
 1562
 1567
 1572
 1577
 1582
 1587
 1592
 1597
 1602
 1607
 1612
 1617
 1622
 1627
 1632
 1637
 1642
 1647
 1652
 1657
 1662
 1667
 1672
 1677
 1682
 1687
 1692
 1697
 1702
 1707
 1712
 1717
 1722
 1727
 1732
 1737
 1742
 1747
 1752
 1757
 1762
 1767
 1772
 1777
 1782
 1787
 1792
 1797
 1802
 1807
 1812
 1817
 1822
 1827
 1832
 1837
 1842
 1847
 1852
 1857
 1862
 1867
 1872
 1877
 1882
 1887
 1892
 1897
 1902
 1907
 1912
 1917
 1922
 1927
 1932
 1937
 1942
 1947
 1952
 1957
 1962
 1967
 1972
 1977
 1982
 1987
 1992
 1997
 2002
 2007
 2012
 2017
 2022
 2027
 2032
 2037
 2042
 2047
 2052
 2057
 2062
 2067
 2072
 2077
 2082
 2087
 2092
 2097
 2102
 2107
 2112
 2117
 2122
 2127
 2132
 2137
 2142
 2147
 2152
 2157
 2162
 2167
 2172
 2177
 2182
 2187
 2192
 2197
 2202
 2207
 2212
 2217
 2222
 2227
 2232
 2237
 2242
 2247
 2252
 2257
 2262
 2267
 2272
 2277
 2282
 2287
 2292
 2297
 2302
 2307
 2312
 2317
 2322
 2327
 2332
 2337
 2342
 2347
 2352
 2357
 2362
 2367
 2372
 2377
 2382
 2387
 2392
 2397
 2402
 2407
 2412
 2417
 2422
 2427
 2432
 2437
 2442
 2447
 2452
 2457
 2462
 2467
 2472
 2477
 2482
 2487
 2492
 2497
 2502
 2507
 2512
 2517
 2522
 2527
 2532
 2537
 2542
 2547
 2552
 2557
 2562
 2567
 2572
 2577
 2582
 2587
 2592
 2597
 2602
 2607
 2612
 2617
 2622
 2627
 2632
 2637
 2642
 2647
 2652
 2657
 2662
 2667
 2672
 2677
 2682
 2687
 2692
 2697
 2702
 2707
 2712
 2717
 2722
 2727
 2732
 2737
 2742
 2747
 2752
 2757
 2762
 2767
 2772
 2777
 2782
 2787
 2792
 2797
 2802
 2807
 2812
 2817
 2822
 2827
 2832
 2837
 2842
 2847
 2852
 2857
 2862
 2867
 2872
 2877
 2882
 2887
 2892
 2897
 2902
 2907
 2912
 2917
 2922
 2927
 2932
 2937
 2942
 2947
 2952
 2957
 2962
 2967
 2972
 2977
 2982
 2987
 2992
 2997
 3002
 3007
 3012
 3017
 3022
 3027
 3032
 3037
 3042
 3047
 3052
 3057
 3062
 3067
 3072
 3077
 3082
 3087
 3092
 3097
 3102
 3107
 3112
 3117
 3122
 3127
 3132
 3137
 3142
 3147
 3152
 3157
 3162
 3167
 3172
 3177
 3182
 3187
 3192
 3197
 3202
 3207
 3212
 3217
 3222
 3227
 3232
 3237
 3242
 3247
 3252
 3257
 3262
 3267
 3272
 3277
 3282
 3287
 3292
 3297
 3302
 3307
 3312
 3317
 3322
 3327
 3332
 3337
 3342
 3347
 3352
 3357
 3362
 3367
 3372
 3377
 3382
 3387
 3392
 3397
 3402
 3407
 3412
 3417
 3422
 3427
 3432
 3437
 3442
 3447
 3452
 3457
 3462
 3467
 3472
 3477
 3482
 3487
 3492
 3497
 3502
 3507
 3512
 3517
 3522
 3527
 3532
 3537
 3542
 3547
 3552
 3557
 3562
 3567
 3572
 3577
 3582
 3587
 3592
 3597
 3602
 3607
 3612
 3617
 3622
 3627
 3632
 3637
 3642
 3647
 3652
 3657
 3662
 3667
 3672
 3677
 3682
 3687
 3692
 3697
 3702
 3707
 3712
 3717
 3722
 3727
 3732
 3737
 3742
 3747
 3752
 3757
 3762
 3767
 3772
 3777
 3782
 3787
 3792
 3797
 3802
 3807
 3812
 3817
 3822
 3827
 3832
 3837
 3842
 3847
 3852
 3857
 3862
 3867
 3872
 3877
 3882
 3887
 3892
 3897
 3902
 3907
 3912
 3917
 3922
 3927
 3932
 3937
 3942
 3947
 3952
 3957
 3962
 3967
 3972
 3977
 3982
 3987
 3992
 3997
 4002
 4007
 4012
 4017
 4022
 4027
 4032
 4037
 4042
 4047
 4052
 4057
 4062
 4067
 4072
 4077
 4082
 4087
 4092
 4097
 4102
 4107
 4112
 4117
 4122
 4

3-(2,4-dichlorophenyl)-5-methyl-7-(N-allyl-N-cyclopropanemethylamino)-pyrazolo[2,3-a]pyrimidine;
 2-methylthio-3-(2,4-dichlorophenyl)-5-methyl-7-(N,N-diallylamino)pyrazolo[2,3-a]pyrimidine;
 2-methylthio-3-(2,4-dichlorophenyl)-5-methyl-7-(N-butyl-N-cyclopropanemethyl-amino)pyrazolo[2,3-a]pyrimidine;
 5 2-methylthio-3-(2,4-dichlorophenyl)-5-methyl-7-(N-propyl-N-cyclopropanemethyl-amino)pyrazolo[2,3-a]pyrimidine;
 2-methyl-3-(4-chlorophenyl)-5-methyl-7-(N,N-dipropylamino)-pyrazolo[2,3-a] pyrimidine;
 3-[6-(dimethylamino)-3-pyridinyl-2,5-dimethyl-N,N-dipropylpyrazolo[2,3-a] pyrimidin-7-amine;
 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-N,N-dipropyl-pyrazolo[2,3-a]pyrimidine-7-amine;
 10 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-7-(N-propyl-N-methyloxyethylamino)pyrazolo(2,3-a)pyrimidine;
 7-(N-diethylamino)-2,5-dimethyl-3-(2-methyl-4-methoxyphenyl)-[1,5-a]-pyrazolopyrimidine;
 7-(N-(3-cyanopropyl)-N-propylamino-2,5,dimethyl-3-(2,4-dimethylphenyl)-[1,5-a]-pyrazolopyrimidine;
 [3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-(-ethyl-propyl)-amine;
 [2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-(1-ethylpropyl)-amine;
 15 cyclopropylmethyl-[3-(2,4-dimethyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-propyl-amine;
 cyclopropylmethyl-[3-(2-methyl-4-chloro-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-propyl-amine;
 cyclopropylmethyl-[3-(2,4-di-chloro-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-propyl-amine;
 [3-(2-methyl-4-chloro-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-di-propyl-amine;
 [2,5-dimethyl-3-(2,4-dimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-(1-ethylpropyl)-amine;
 20 [2,5-dimethyl-3-(2,4-dichloro-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-(1-ethylpropyl)-amine;
 4-(1-ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester;
 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-N-propyl-N-cyclopropylmethyl-pyrazolo[2,3-a]pyrimidin-7-amine; and
 25 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-N-ethyl-N-cyclopropylmethyl-pyrazolo[2,3-a]pyrimidin-7-amine.

15. The use of claim 2 wherein the corticotropin releasing factor antagonist is a compound selected from the group consisting of:

30 4-(1-ethyl-propoxy)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-pyridine;
 4-(1-ethylpropoxy)-2,5-dimethyl-6-(2,4,6-trimethylphenoxy)-pyrimidine;
 [4-(1-ethyl-propoxy)-3,6-dimethyl-pyridin-2-yl]-(2,4,6-trimethylphenyl)-amine;
 3-[(4-methyl-benzyl)-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amino]-propan-1-ol;
 35 propyl-ethyl-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
 ethyl-n-propyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;
 2-{N-n-butyl-N-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}-ethanol;
 [3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4,b]pyridin-4-yl]-(1-methoxymethylpropyl)-amine;
 40 4-(1-ethylpropoxy)-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2, 3-b]pyridine;
 2,5,6-trimethyl-7-(1-propylbutyl)-4-(2,4,6-trimethylphenoxy)-7H-pyrrolo[2,3-d]pyrimidine;
 1-(1-ethylpropyl)-6-methyl-4-(2,4,6-trimethylphenoxy)-1,3-dihydroimidazo[4,5-c]pyridin-2-one;
 1-(1-ethyl-propyl)-4,7-dimethyl-5-(2,4,6-trimethyl-phenoxy)-1,4-dihydro-2H-pyrido[3,4-b]pyrazin-3-one;
 1-(1-ethyl-propyl)-4,7-dimethyl-5-(2,4,6-trimethyl-phenoxy)-1,2,3,4-tetrahydro-pyrido[3,4-b]pyrazine;
 45 1-(1-ethyl-propyl)-7-methyl-2-oxo-5-(2,4,6-trimethyl-phenoxy)-1,2,3,4-tetrahydro-[1,6]naphthyridine-3-carboxylic acid isopropyl ester;
 1-(1-ethyl-propyl)-7-methyl-5-(2,4,6-trimethyl-phenoxy)-1,4-dihydro-2H-3-oxa-1,6-diaza-naphthalene;
 (1-ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-amine;
 7-(1-ethyl-propoxy)-2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidine;
 50 4-(1-ethyl-propoxy)-2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyrimidine;
 4-(butyl-ethyl-amino)-2,6-dimethyl-8-(2,4,6-trimethyl-phenyl)-5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-7-one;
 8-(1-ethyl-propoxy)-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydropyrido [2,3-b]pyrazine;
 4-(1-ethyl-propoxy)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline;
 (1-ethyl-propyl)-[2-methyl-8-(2,4,6-trimethyl-phenyl)-quinolin-4-yl]-amine;
 55 (propyl-ethyl)-[2-methyl-8-(2,4,6-trimethyl-phenyl)-5,6,7,8-tetrahydro-pyrido-[2,3-d] pyrimidin-4-yl]-amine;
 (1-ethyl-propoxy)-2-methyl-8-(2,4,6-trimethyl-phenyl)-5,6,7,8-tetrahydropyrido[2,3-d] pyrimidine;
 8-(1-hydroxymethyl-propylamino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-one;

4-(1-hydroxymethyl-propylamino)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline;
 5-1-hydroxymethyl-propylamino)-7-methyl-1-(2,4,6-trimethyl-phenyl)-1,4-dihydro-2H-3-oxa-1,8-diaza-naphthalene;
 5 [3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-1-ethyl-propyl-amine;
 cyclopropylmethyl-[3-(2,4-dimethyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-propyl-amine;
 [2,5-dimethyl-3-(2,4-dimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-1-ethylpropyl-amine;
 10 3-[6-(dimethylamino)-3-pyridinyl-2,5-dimethyl-N,N-dipropylpyrazolo[2,3-a] pyrimidin-7-amine;
 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-N,N-dipropylpyrazolo[2,3-a]pyrimidine-7-amine;
 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-7-(N-propyl-N-methoxyethylamino)-pyrazolo(2,3-a)pyrimidine;
 15 7-(N-diethylamino)-2,5-dimethyl-3-(2-methyl-4-methoxyphenyl-[1,5-a]-pyrazolopyrimidine; and
 7-(N-(3-cyanopropyl)-N-propylamino-2,5,dimethyl-3-(2,4-dimethylphenyl)-[1,5-a]-pyrazolopyrimidine.

16. The use of claim 1 which further comprises administering to said animal an amount of a glucocorticoid receptor antagonist;


15 wherein the amount of the corticotropin releasing factor antagonist and the amount of the glucocorticoid receptor antagonist result in a therapeutic effect.

17. The use of claim 16 wherein the glucocorticoid receptor antagonist is a compound of formula IA

20

25

30




35 an isomer thereof, a prodrug of said compound or isomer, or a pharmaceutically acceptable salt of said compound, isomer or prodrug; wherein m is 1 or 2;

--- represents an optional bond;

A is selected from the group consisting of

40

45




and

50

55

5



A-5

10

D is CR₇, CR₇R₁₆, N, NR₇ or O;E is C, CR₆ or N;F is CR₄, CR₄R₅ or O;

15

G, H and I together with 2 carbon atoms from the A-ring or 2 carbon atoms from the B-ring form a 5-membered heterocyclic ring comprising one or more N, O or S atoms; provided that there is at most one of O and S per ring; J, K, L and M together with 2 carbon atoms from the B-ring forms a 6-membered heterocyclic ring comprising 1 or more N atoms;

20

X is a) absent, b) -CH₂-, c) -CH(OH)- or d) -C(O)-;R₁ is a) -H, b) -Z-CF₃, c) -(C₁-C₆)alkyl, d) -(C₂-C₆)alkenyl, e) -(C₂-C₆)alkynyl, f) -CHO, g) -CH=N-OR₁₂, h) -Z-C(O)OR₁₂, i) -Z-C(O)-NR₁₂R₁₃, j) -Z-C(O)-NR₁₂-Z-het, k) -Z-NR₁₂R₁₃, l) -Z-NR₁₂het, m) -Z-het, n) -Z-O-het, o) -Z-aryl', p) -Z-O-aryl', q) -CHOH-aryl' or r) -C(O)-aryl' wherein aryl' in substituents o) to r) is substituted independently with 0, 1 or 2 of the following: -Z-OH, -Z-NR₁₂R₁₃, -Z-NR₁₂-het, -C(O)NR₁₂R₁₃, -C(O)O(C₁-C₆)alkyl, -C(O)OH, -C(O)-het, -NR₁₂-C(O)-(C₁-C₆)alkyl, -NR₁₂-C(O)-(C₂-C₆)alkenyl, -NR₁₂-C(O)-(C₂-C₆)alkynyl, -NR₁₂-C(O)-Z-het, -CN, -Z-het, -O-(C₁-C₃)alkyl-C(O)-NR₁₂R₁₃, -O-(C₁-C₃)alkyl-C(O)O(C₁-C₆)alkyl, -NR₁₂-Z-C(O)O(C₁-C₆)alkyl, -N(Z-C(O)O(C₁-C₆)alkyl)₂, -NR₁₂-Z-C(O)-NR₁₂R₁₃, -Z-NR₁₂-SO₂-R₁₃, -NR₁₂-SO₂-het, -C(O)H, -Z-NR₁₂-Z-O(C₁-C₆)alkyl, -Z-NR₁₂-Z-NR₁₂R₁₃, -Z-NR₁₂-(C₃-C₆)cycloalkyl, -Z-N(Z-O(C₁-C₆)alkyl)₂, -SO₂R₁₂, -SOR₁₂, -SR₁₂, -SO₂NR₁₂R₁₃, -O-C(O)-(C₁-C₄)alkyl, -O-SO₂-(C₁-C₄)alkyl, -halo or -CF₃;

25

Z for each occurrence is independently a) -(C₀-C₆)alkyl, b) -(C₂-C₆)alkenyl or c) -(C₂-C₆)alkynyl;

30

R₂ is a) -H, b) -halo, c) -OH, d) -(C₁-C₆)alkyl substituted with 0 or 1 -OH, e) -NR₁₂R₁₃, f) -Z-C(O)O(C₁-C₆)alkyl, g) -Z-C(O)NR₁₂R₁₃, h) -O-(C₁-C₆)alkyl, i) -Z-O-C(O)-(C₁-C₆)alkyl, j) -Z-O-(C₁-C₃)alkyl-C(O)-NR₁₂R₁₃, k) -Z-O-(C₁-C₃)alkyl-C(O)-O(C₁-C₆)alkyl, l) -O-(C₂-C₆)alkenyl, m) -O-(C₂-C₆)alkynyl, n) -O-Z-het, o) -COOH, p) -C(OH)R₁₂R₁₃ or q) -Z-CN;

35

R₃ is a) -H, b) -(C₁-C₁₀)alkyl wherein 1 or 2 carbon atoms, other than the connecting carbon atom, may optionally be replaced with 1 or 2 heteroatoms independently selected from S, O and N and wherein each carbon atom is substituted with 0, 1 or 2 R_y, c) -(C₂-C₁₀)alkenyl substituted with 0, 1 or 2 R_y, d) -(C₂-C₁₀)alkynyl wherein 1 carbon atom, other than the connecting carbon atom, may optionally be replaced with 1 oxygen atom and wherein each carbon atom is substituted with 0, 1 or 2 R_y, e) -CH=C=CH₂, f) -CN, g) -(C₃-C₆)cycloalkyl, h) -Z-aryl, i) -Z-het, j) -C(O)O(C₁-C₆)alkyl, k) -O(C₁-C₆)alkyl, l) -Z-S-R₁₂, m) -Z-S(O)-R₁₂, n) -Z-S(O)₂-R₁₂, o) -CF₃ p) -NR₁₂O-(C₁-C₆)alkyl or q) -CH₂OR_y;

40

provided that one of R₂ and R₃ is absent when there is a double bond between CR₂R₃ (the 7 position) and the F moiety (the 8 position) of the C-ring;

45

R_y for each occurrence is independently a) -OH, b) -halo, c) -Z-CF₃, d) -Z-CF(C₁-C₃ alkyl)₂, e) -CN, f) -NR₁₂R₁₃, g) -(C₃-C₆)cycloalkyl, h) -(C₃-C₆)cycloalkenyl, i) -(C₀-C₃)alkyl-aryl, j) -het or k) -N₃;or R₂ and R₃ are taken together to form a) =CHR₁₁, b) =NOR₁₁, c) =O, d) =N-NR₁₂, e) =N-NR₁₂-C(O)-R₁₂, f) oxiranyl or g) 1,3-dioxolan-4-yl;

50

R₄ and R₅ for each occurrence are independently a) -H, b) -CN, c) -(C₁-C₆)alkyl substituted with 0 to 3 halo, d) -(C₂-C₆)alkenyl substituted with 0 to 3 halo, e) -(C₂-C₆)alkynyl substituted with 0 to 3 halo, f) -O-(C₁-C₆)alkyl substituted with 0 to 3 halo, g) -O-(C₂-C₆)alkenyl substituted with 0 to 3 halo, h) -O-(C₂-C₆)alkynyl substituted with 0 to 3 halo, i) halo, j) -OH, k) (C₃-C₆)cycloalkyl or l) (C₃-C₆)cycloalkenyl;or R₄ and R₅ are taken together to form =O;

55

R₆ is a) -H, b) -CN, c) -(C₁-C₆)alkyl substituted with 0 to 3 halo, d) -(C₂-C₆)alkenyl substituted with 0 to 3 halo, e) -(C₂-C₆)alkynyl substituted with 0 to 3 halo or f) -OH;R₇ and R₁₆ for each occurrence are independently a) -H, b) -halo, c) -CN, d) -(C₁-C₆)alkyl substituted with 0 to 3 halo, e) -(C₂-C₆)alkenyl substituted with 0 to 3 halo or f) -(C₂-C₆)alkynyl substituted with 0 to 3 halo; provided that R₇ is other than -CN or -halo when D is NR₇;or R₇ and R₁₆ are taken together to form =O;R₈, R₉, R₁₄ and R₁₅ for each occurrence are independently a) -H, b) -halo, c) (C₁-C₆)alkyl substituted with 0 to 3 halo, d) -(C₂-C₆)alkenyl substituted with 0 to 3 halo, e) -(C₂-C₆)alkynyl substituted with 0 to 3 halo, f) -CN,

g) $-(C_3-C_6)cycloalkyl$, h) $-(C_3-C_6)cycloalkenyl$, i) $-OH$, j) $-O-(C_1-C_6)alkyl$, k) $-O-(C_1-C_6)alkenyl$, l) $-O-(C_1-C_6)alkynyl$, m) $-NR_{12}R_{13}$, n) $-C(O)OR_{12}$ or o) $-C(O)NR_{12}R_{13}$;

or R_8 and R_9 are taken together on the C-ring to form $=O$; provided that when m is 2, only one set of R_8 and R_9 are taken together to form $=O$;

5 or R_{14} and R_{15} are taken together to form $=O$; provided that when R_{14} and R_{15} are taken together to form $=O$, D is other than CR_7 and E is other than C;

R_{10} is a) $-(C_1-C_{10})alkyl$ substituted with 0 to 3 substituents independently selected from -halo, -OH and $-N_3$, b) $-(C_2-C_{10})alkenyl$ substituted with 0 to 3 substituents independently selected from -halo, -OH and $-N_3$, c) $-(C_2-C_{10})alkynyl$ substituted with 0 to 3 substituents independently selected from -halo, -OH and $-N_3$, d) -halo, e) $-Z-CN$, f) $-OH$, g) $-Z-het$, h) $-Z-NR_{12}R_{13}$, i) $-Z-C(O)-het$, j) $-Z-C(O)-(C_1-C_6)alkyl$, k) $-Z-C(O)-NR_{12}R_{13}$, l) $-Z-C(O)-NR_{12}Z-CN$, m) $-Z-C(O)-NR_{12}Z-het$, n) $-Z-C(O)-NR_{12}Z-aryl$, o) $-Z-C(O)-NR_{12}Z-NR_{12}R_{13}$, p) $-Z-C(O)-NR_{12}Z-O(C_1-C_6)alkyl$, q) $-(C_0-C_6)alkyl-C(O)OH$, r) $-Z-C(O)O(C_1-C_6)alkyl$, s) $-Z-O-(C_0-C_6)alkyl-het$, t) $-Z-O-(C_0-C_6)alkyl-aryl$, u) $-Z-O-(C_1-C_6)alkyl$ substituted with 0 to 2 R_x , v) $-Z-O-(C_1-C_6)alkyl-CH(O)$, w) $-Z-O-(C_1-C_6)alkyl-NR_{12}het$, x) $-Z-O-Z-het-Z-het$, y) $-Z-O-Z-het-Z-NR_{12}R_{13}$, z) $-Z-O-Z-het-C(O)-het$, a1) $-Z-O-Z-C(O)-het$, b1) $-Z-O-Z-C(O)-het-het$, c1) $-Z-O-Z-C(O)-(C_1-C_6)alkyl$, d1) $-Z-O-Z-C(S)-NR_{12}R_{13}$, e1) $-Z-O-Z-C(O)-NR_{12}R_{13}$, f1) $-Z-O-Z-(C_1-C_3)alkyl-C(O)-NR_{12}R_{13}$, g1) $-Z-O-Z-C(O)-O(C_1-C_6)alkyl$, h1) $-Z-O-Z-C(O)-OH$, i1) $-Z-O-Z-C(O)-NR_{12}O(C_1-C_6)alkyl$, j1) $-Z-O-Z-C(O)-NR_{12}OH$, k1) $-Z-O-Z-C(O)-NR_{12}Z-NR_{12}R_{13}$, l1) $-Z-O-Z-C(O)-NR_{12}Z-het$, m1) $-Z-O-Z-C(O)-NR_{12}SO_2-(C_1-C_6)alkyl$, n1) $-Z-O-Z-C(=NR_{12})(NR_{12}R_{13})$, o1) $-Z-O-Z-C(=NOR_{12})(NR_{12}R_{13})$, p1) $-Z-NR_{12}C(O)-O-Z-NR_{12}R_{13}$, q1) $-Z-S-C(O)-NR_{12}R_{13}$, r1) $-Z-O-SO_2-(C_1-C_6)alkyl$, s1) $-Z-O-SO_2-aryl$, t1) $-Z-O-SO_2-NR_{12}R_{13}$, u1) $-Z-O-SO_2-CF_3$, v1) $-Z-NR_{12}C(O)OR_{13}$ or w1) $-Z-NR_{12}C(O)R_{13}$;

15 or R_9 and R_{10} are taken together on the moiety of formula A-5 to form a) $=O$ or b) $=NOR_{12}$;

R_{11} is a) $-H$, b) $-(C_1-C_5)alkyl$, c) $-(C_3-C_6)cycloalkyl$ or d) $-(C_0-C_3)alkyl-aryl$;

R_{12} and R_{13} for each occurrence are each independently a) $-H$, b) $-(C_1-C_6)alkyl$ wherein 1 or 2 carbon atoms, other than the connecting carbon atom, may optionally be replaced with 1 or 2 heteroatoms independently selected from S, O and N and wherein each carbon atom is substituted with 0 to 6 halo, c) $-(C_2-C_6)alkenyl$ substituted with 0 to 6 halo or d) $-(C_1-C_6)alkynyl$ wherein 1 carbon atom, other than the connecting carbon atom, may optionally be replaced with 1 oxygen atom and wherein each carbon atom is substituted with 0 to 6 halo;

20 or R_{12} and R_{13} are taken together with N to form het;

25 or R_6 and R_{14} or R_{15} are taken together to form 1,3-dioxolanyl;

30 aryl is a) phenyl substituted with 0 to 3 R_x , b) naphthyl substituted with 0 to 3 R_x or c) biphenyl substituted with 0 to 3 R_x ;

35 het is a 5-, 6- or 7-membered saturated, partially saturated or unsaturated ring containing from one (1) to three (3) heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocycle; and the nitrogen may be in the oxidized state giving the N-oxide form; and substituted with 0 to 3 R_x ;

40 R_x for each occurrence is independently a) -halo, b) $-OH$, c) $-(C_1-C_6)alkyl$, d) $-(C_2-C_6)alkenyl$, e) $-(C_2-C_6)alkynyl$, f) $-O(C_1-C_6)alkyl$, g) $-O(C_2-C_6)alkenyl$, h) $-O(C_2-C_6)alkynyl$, i) $-(C_0-C_6)alkyl-NR_{12}R_{13}$, j) $-C(O)-NR_{12}R_{13}$, k) $-Z-SO_2R_{12}$, l) $-Z-SOR_{12}$, m) $-Z-SR_{12}$, n) $-NR_{12}SO_2R_{13}$, o) $-NR_{12}C(O)-R_{13}$, p) $-NR_{12}OR_{13}$, q) $-SO_2-NR_{12}R_{13}$, r) $-CN$, s) $-CF_3$, t) $-C(O)(C_1-C_6)alkyl$, u) $=O$, v) $-Z-SO_2-phenyl$ or w) $-Z-SO_2-het'$;

45 aryl' is phenyl, naphthyl or biphenyl;

45 het' is a 5-, 6- or 7-membered saturated, partially saturated or unsaturated ring containing from one (1) to three (3) heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocycle; provided that:

50 1) $X-R_1$ is other than hydrogen or methyl;

2) when R_9 and R_{10} are substituents on the A-ring, they are other than mono- or di-methoxy;

55 3) when R_2 and R_3 are taken together to form $=CHR_{11}$ or $=O$ wherein R_{11} is $-O(C_1-C_6)alkyl$, then $-X-R_1$ is other than $(C_1-C_4)alkyl$;

4) when R_2 and R_3 taken together are $C=O$ and R_9 is hydrogen on the A-ring; or when R_2 is hydroxy, R_3 is hydrogen and R_9 is hydrogen on the A-ring, then R_{10} is other than $-O-(C_1-C_6)alkyl$ or $-O-CH_2-phenyl$ at the 2-position of the A-ring;

5) when $X-R_1$ is $(C_1-C_4)alkyl$, $(C_2-C_4)alkenyl$ or $(C_2-C_4)alkynyl$, R_9 and R_{10} are other than mono-hydroxy or $=O$, including the diol form thereof, when taken together; and

55 6) when X is absent, R_1 is other than a moiety containing a heteroatom independently selected from N, O or S directly attached to the juncture of the B-ring and the C-ring.

18. The use of claim 17 wherein the glucocorticoid receptor antagonist is a compound selected from the group consisting of:

5 2-phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-N-(4-pyridinylmethyl)-, [4bS-(4b α , 7 α , 8a β)]-;
 2-phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-N-(2-pyridinylmethyl)-, [4bS-(4b α , 7 α , 8a β)]-;
 2-phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-N-(3-pyridinylmethyl)-, [4bS-(4b α , 7 α , 8a β)]-;
 10 carbamic acid, [2-(dimethylamino)ethyl]-, 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester, [4bS-(4b α , 7 α , 8a β)]-;
 2-phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-N-pyrazinyl-, [4bS-(4b α , 7 α , 8a β)]-;
 15 2-phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(4-pyridinylmethoxy)-, [2R-(2 α , 4a α , 10a β)]-;
 2-phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(2-pyridinylmethoxy)-, [2R-(2 α , 4a α , 10a β)]-;
 20 2-phenanthrenecarbonitrile, 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-, [4bS-(4b α , 7 α , 8a β)]-;
 2-phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-N-[(2-methyl-3-pyridinyl)methyl]-4b-(phenylmethyl)-7-(1-propynyl)-, [4bS-(4b α , 7 α , 8a β)]-;
 25 2-phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-N-[(2-methyl-3-pyridinyl)methyl]-4b-(phenylmethyl)-7-propyl-, [4bS-(4b α , 7 α , 8a β)]-;
 2-phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-N-(2-pyridinylmethyl)-, [4bS-(4b α , 7 α , 8a β)]-;
 2-phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-2-(3,3,3-trifluoropropyl)-, [2S-(2 α , 4a α , 10a β)]-;
 2-phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-(3,3,3-trifluoropropyl)-, [2S-(2 α , 4a α , 10a β)]-;
 30 2-phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-N-[(2-methyl-3-pyridinyl)methyl]-4b-(phenylmethyl)-7-(3,3,3-trifluoropropyl)-, (4bS, 7S, 8aR);
 2-phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-methyl-N-[(2-methyl-3-pyridinyl)methyl]-4b-(phenylmethyl)-4b-(phenylmethyl)-, (4bS, 7R, 8aR);
 35 2-phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-methyl-4b-(phenylmethyl)-N-3-pyridinyl-, (4bS, 7R, 8aR);
 2-phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R, 4aS, 10aR); and
 2-phenanthrenecarboxamide, 4b, 5, 6, 7, 8, 8a, 9, 10-octahydro-7-hydroxy-N-[(2-methyl-3-pyridinyl)methyl]-4b-(phenylmethyl)-7-(trifluoromethyl)-, (4bS, 7R, 8aR).-.

- 40 19. A pharmaceutical composition which comprises a corticotropin releasing factor antagonist and a pharmaceutically acceptable vehicle, carrier or diluent.
- 45 20. The composition of claim 19 which comprises a therapeutically effective amount of a corticotropin releasing factor antagonist.
- 50 21. The composition of claim 20 wherein the corticotropin releasing factor antagonist is a compound selected from the group consisting of the compounds defined in claim 14.
- 55 22. The composition of claim 20 wherein the corticotropin releasing factor antagonist is a compound selected from the group consisting of the compounds defined in claim 15.
23. The composition of claim 19 which further comprises an amount of a glucocorticoid receptor antagonist and a pharmaceutically acceptable vehicle, carrier or diluent.
24. The composition of claim 23 wherein the glucocorticoid receptor antagonist is a compound defined in claim 17.
25. The composition of claim 24 wherein the glucocorticoid receptor antagonist is a compound selected from the group

consisting of compounds defined in claim 18.

5

10

15

20

25

30

35

40

45

50

55